var title_f31_36_32320="Nissen fundoplication";
var content_f31_36_32320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Nissen fundoplication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Nissen fundoplication provides a 360&deg; \"wrap\" or collar around the esophagus. Mobilization of the fundus is generally accomplished by dividing the short gastric vessels to the spleen. A variant of this procedure, the Nissen Rosati fundoplication, does not divide the short gastric vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32320=[""].join("\n");
var outline_f31_36_32320=null;
var title_f31_36_32321="Porcelain gallbladder CT";
var content_f31_36_32321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Porcelain gallbladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Porcelain gallbladder seen on computed tomography (arrow). Note the characteristic calcific gallbladder wall with the bile filled gallbladder lumen appearing dark.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32321=[""].join("\n");
var outline_f31_36_32321=null;
var title_f31_36_32322="Incremental response with RNS";
var content_f31_36_32322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repetitive nerve stimulation: Incremental response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 257px; background-image: url(data:image/gif;base64,R0lGODlhtAEBAfcAAJGLjpiUl52aoK+vsm1pb5OTmNnU12hiZru1tQAAAHNqbXNwdVpRVry4u3lzdWReYcfBwbu2uK+qrLCsr83Iy9/a3c3LzaOdna+pqYyGiKSeoCsmKMG+wZ6ancG8vlBKTJGRkdPR046Ii3x2eb+/v25nabu7vs/Lx7Kxrc/Pz6Sgo93Z2cnKyGFbXRwYHFJRV0tJSqmkpr2+uoWAhcfEx9PNzZSOkXZ2fP///4+Pj11WW4uIjry9wraytV9fX6OgprWwsomFhc7R1dPO0WVhZJmdl7W1u87Oya+vr29vcNvd2sjLznx8gampqmdnas3N0bi4uNTRzZORjlRPUUNAQTcyN9nZ3T03OrOxs0tDRZ6foaagnYF8f0VDSdTX2q+xtoR/gamqsLOzt765vJmZm4WFi05HSpqWmKSlqkM+QN/f37W0sUxMUkE6PH9/fz8/P56YmoV/f5iRlJ2Xl8fCxKmmqf39/amjo4B5f8G7u/f39+nm6dfT083Hx/Hx8ePg4/by9uXl5YuBhbWvr/Hs8Onl5XRtc+Pf3+vr6/z4/NnX2fDs6//+//z49//+/fby8cHBxMnEwv///uvr8IeFgpiTkd/g4+Xm6YF7ev38+Ofj4NPT1+zp5oyHhvHy9sfHzb64tf3+//Lw7HZwb/j28aymo+zw8pGOlLiyr7GsqdvZ1MS+u/f4/OHf2u/v73p5ddrd4CAdIJ+amMPEwcLDyJeYny4tMObp7J+gnfL2+Pj8/tfX0/7//6Wmo+Hj3+Dj5ra4vvj89/7//p6am395fN/f3t/e3fL28djY2I+KjOzw693d3bOvsVhYXrizs8PDw6uvqdfT17CrqcXDvp6Zmebp42pqZt3e311bV768vmJjXt/e38rGxIaJhF9cYd3c2bm3s7/BvsXGw4WAf4CAhTArMNPX07W1tZWZlIuMiYWBhI6Mkc7SzcPFx5mbn6ejpd7f35GOkdnc3o+QlLm8vsnMzj09QaenpzgyNKmno1hWVhEPEIqKiqGhod7f3oiDgyH5BAAAAAAALAAAAAC0AQEBAAj/AHEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1Kwk3YMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPqNVvRzZu9gAMLHky4sOHDiBMjTtDXTdfHkCOLZEwRrOTLmDNLpDzRsubPoEPj4CzRs+jTqLmSjmg6tevXUldDbA27tm2ksh/Svs27t8/cDnf7Hk6cJvCGwosrX67yOMPkzKNLB+l8IfTp2LNbrK7wuvbv4Bly/0/oPbz58wLHIyyPvr129QfZu58fHb5B+fTzE7dfEL/+/7fxR5B/ABbomoADEWjggqEhKJCCDEaImYM4QCjhhY9R6EYSanTo4YcghijiiCSWaOKJKKao4oostujiizDGKOOMNNZo440hasghjjz26OOPQAYp5JBEFjmkho5hqGRqSC7ppGhNPillZlFOaSVkVV6ppVZZbullVV1+KSZUYY5p5lJlnqmmUWmu6WZQbb4pJ09xzmnnTXXeqadMee7pZ0t9/ikoSoEOauhIhR6qqEeJLupoRo0+KilFkU6aVSlxiBKUHna4VKmlPHGSCUKjEiRJIwNBUMpAgbQAAyi26f9o5Ky01mrrrSiewwAXI6YzjYfRKEDEN2qEQ0U5sqgBTwbqiEHMILhG66Ks0lZr7bXSFvNhMgC0Ao8aLNyxgocYSNPhCkEwMMqvILJwQBaofEsGFQycUQwZbHChwAnI+BBDMTckg+3AIn4KakeLlIBJqXMooIpAFLQwxSoCAfDBFgKFkEUWK+AQgSCfGAFrQRPE4YQNOOgiggQ8UALIAALocgoqgexwCA5hVCIJbAYfXJAKBdVBUAYj0DAQHRAcPUULBuAwiQgHzLHzAFBocQcOioggABw3T8AEHhEQIscFOFgggUFyAECBCKpcAsAjpshBRww14CzIIELj4AEAfvD/3JjPGAFRwtk4hFLLCHsIRMgDCgwhUA1TlNAHDnZgQIcHSQORxyVy1OBHBHpYccEhEpRiBwUGIHLHLn+UEsEESuCwiQakEOQHE3cAEsYcQAANCAiUwJEIDpC0EEcIAgkBwM2v9Qz4IzOUcIcjOOzhQAkaCBRDHBbMQQgOAQQggQhYz5FJDXDQAMAJOGgggQd54OAHHBDE4AEONUQAQQQ45CJCHD3oVAjkkLiBWGIEk/uEDuLQNDvMIAuEs8QLRjCQPQAAec37G+AgwggaOM5jCIRA3TQABzXM4AR6iAMfcNABBPwhU3oAgCogMAEcqAEAGZgDqjwgBzlEQiATUEEJ/3EwhAzE4YehcMAHeiCQP1ygEAQJQRw4UbYrUFAgZbDFCnHAixtQYiCmEITRMliZJG2QICz4oUDqkAFN4aAHkfsDDiQABxxUoAetEMHkAnCBIQgCEDjggA04QDY72KASGNjiHRQwiCY6QAEdm6MDYrAzPTCBARYQSBLSUDccqA6KHVhVCMiGgxDAYA4DkUAJqCcQKNRQILzIQAP8VsZF+aFvDGEBDD7guFZdYVV6mEEGItADJbjPkxroARwSF4ERzAEDAlGDA+BAMRa2oBKAxEEMSvBBPbRAAXoQiAZa0EkcxAEPwwOfIaCIg0DYIAIcUEAGakCDLVbAAWokIimBCP8EgtjglQfSoKEAoYBR1A4HEBBBJw8hLoFkAA87iAEgJjACDdiAD7/IQAVwMIdnbrQRABgB0Ij4gQdssRA6KMFGcUAHGOxzAgBAlUBGUEeBDGAEVMRBIjIQg4GEQALZ1IMIPjCKQOzBEA4o4B9EEMlAkk8gl2jBUwWiguyRsTNmfFMfmCeQRQykAR84AB1wcAgH6CAAAhkqylYggj/8Qgs8rGEpNEAHFVDPBiXgn0AckIX44YAQKR0IIRjwAJ+2oJ8C8UAMGDGQVCRNIFaQwPcEIgEEDMQAQB3IDmIxAxzoIQ0fkOkQFLBFHEBtID2oQhwIIoEAlIpJAjXTELyKAxr/6AAPmhAIBkrQSThMwANAAIQK5ECBGAzBA3CAhATyQEIcsCIAIugAFOlgg3cKpAMPKOdQc0tVxApEAPv0QwDGKpA82PWrk4MYBmSKAxXoFQclK2B7W7DRSTzgijgwAQyq6QcntCCcegBBEqQ7EB5cgL2ocZ6BQqADQQjkAhKQQAZwAIgSlIBsFYBDKAgBhL1RAAdAgIMI4kcDPMSBvKfQATRL6QBB0LYHkBwIJEYwWUbc4bEZwzEgMNA0gQRgBNkE3/0EQokDIEIgfigBWgXSiQOwU29woJ4u4NBIqn5AFk1MQoxrIAIeDKCcVlABbWFbSy9xIg+dmiMABDEEsSUi/5h/qIEcLBGDHiDglRKYwRzCSQcHjKBphDDxZAuQBsviwAAXHoganijjmEbzA6hM5YqJOIKHCWQULaCtEkrARE1+IJI0gMFqPTuCBzQVCnDolB1UYOhAxCEJABCIBV4BAKMRUhl18CsOYJGBpiY4tlcaKv8QcQFC0EADDaipBIBwASbSwAEi+KAGICjrB9iAeoyAQ6fhuwA1QBUPVW5nDHLKiBGUIM0RSAPKkBxYIH5AjYQYwSiYBwUdiIB6t5iBAjpZh0TbsAxsFggj5LBuZHzgqRQA4IFxwEYgNNID/APCtm+RgShctTRZtVIeRiC+QiAge4kgOAcgds5M7uEBM/9gLPjSQF4DHIBwb+xxKSUQThwwQgLkZfgDPjjYD+Q0AApYN9a6cABUMQIAU1jxE9bMPhxcwAEz+F5xL9D0CAwCAVQ0AQAuQN5JLGDCOICCainXgzpUwAa5PYUKaFCHQMSgaT2YNAtZcHHWZHxJktgZDgAwB0bkYQ422IRAZvAA5hmAARlgrB14OhAO4FYggBCBXiWhgXxa4AK4fIQNZimQOKQhvX8QxAMotgcbjK8VAulBBlTwiLLFYWwCiUAM5HC/CnSgtd/rQR88cL9ASGAIdfhwA1QwgB5QzxIEiAP1JGDtv86BAmVdgR065/sGaCCcEugAQQKA41+X+UmN6IT/g/fOvzwwINI4yEALsqkGBngXAR9sJwJqjgMMPDYQB7iaQOBwgEAk9gNW5QcZoAAWhwN/pwBY1gcXsAgaED+IAAcUUAcdUwcaMASLlQh3kD9jFQFAUAEYUAiIMAGFQAOD0AgNIAGBoAJohjqKgAGtRwNxIAKcQAp3YAMaQAiFIAeFEHI18AeVoAeXQAkigFgm0AF6Bz7v5X1YpSSPcAKslAcHYAOHcAgB0DQUMAVDhgMUYFU48AgAYAWQdweWhgMNMAfptAhxgFh9kAXrZgdM0ALehgNw8AGvBAFwgAF1wwgYkAcBAAd60GEeM0s9cAGJUAd90AhzYAB7sF5DcAGk/1ADELAINjBWPUABs8A/QyAuPaAI8JUHd7QHamADVAQEdaACdEAHcIAAKhACfdBT2tQANIAyl3ADDvBhOMADcnBQDIcCdTcbd6cfFxAHzGMDDHA2ibAyvBABmHABnUIIcMBdOBAJ3uUHNrBSfMAAqDAQI3AA2cQBABh7LbBuigAAALBRniAHeqRTyGYB9yMKGDAJn9ABQwAHcgQEqLAHIzBWNNAHK3BtiUA3GNBTmzAIeSAC3hYBpeBDOGAFARADQNApg5AKQDAHiGAFM7ACeyABBoCKctADh6ACg9ADVtUBczAIq8IKnSAHacYDIjBmE6B/ZLaE+hEMescHhuAEKv+QCBWAB3KgAQhAByKQOBrAAI/1j9zFCCXgAJc1BbbYAxswan6gAA/QY3NAbdo0AiLwPa60XIemARzgAYVwCBrwB1agAR5nA4ywCYJwAXJAPXXwfDvQKX1wBxhASjGgARcwOZYQAIKgATtDA5hAWjplAy8nEJCgAbfXP8EHAQ9pBZiAB5xICwGgAXrVANBWN6HABEsmOyDAVWFgAwgGJcDWHmrQAqMQTnlQB5bwksdkABkgeRCjAZ4gEAbwAI8lClnAADJFB2ngih2gAymnhXHgALACCOrXSHwQAyqwPJNwARSgTIWQBwhQCMsVCfzzB3CwN2RTCA9wAFVmmVwHMSX/EAcfhAEjIAdUtFM64FeW0AIHUEBxkAXkZQXVBWqlYAMfZgEtIAidcgkjMAIrZQC3pXIgUFPtBADxBwktGVDfNx8TwDgI4AuJpIUPgAeJ0wilxk7JmU13kAV6tQuGoAA9dgctMGGE0IcB0AjCAAAdQGU4wAcdAAAxcAj2owgXwAcUMAeaQAGnwAESsEIxIAIXgDyBAAcxMAcrBAhTcAWdFAJpAE4CMQRElWYT8AFCp0SRBAtXoJSaZAg1h2iJRzkS0GJe5QEwoH048Af6oAC0tQT6AHPEVEGUMAsDAQvLxKCdsSMEs6c40gDE4Aw0MAJEYAPXoAbZwABg0CHGgGmF/6oGI9AGY6AGy1ACZhAAHTIMNjACHaAGHOAAYMArY2ADUNAB0cABI0AC2WcBKoABzICXYPAMagACHUANGqAGIZAMQRAAyBCrDxAE0aAGyKAOBBAA2nIND6ADqtAh7XAFo+AhHGBt2qIGAdAGd+AhJfAAv6oG7WAGAqMG17AANuAhJGAGxOAhOzAFw9AhWEAEzKAtzkAFxLAMHTIADxCpHYKYHrIM5KACHvIJ8/QtfHot1BKwBCsjyZCoanAGxdghfMAF0NIhZ9CtxtAC+ACr5sAFxBCuoUgBw5CuKlAHFhAAfMAMzqAGY9AAFxADahABRSABw/CrMTAKANAhHeAAQf9AB2pQDBpAABhwr/qwqWqwDQ5ABRLgIUGgsTlLDMnSIXTABaDgIQGgAzjbIUHQCR6yDVzQsx1iA9XaIU9AAEhbADrQAB2SDVzAAR0CDDpwBh5CA0HADWrgD0rABWzrIepwAR5CAX9asNaiYKhhfweBASOXpirAPHwwArYIUpG2AiXQAitEB3WAao9oA4/QAxOgCZ2AA5pgA4MAADVACgggCIzkCD3QCXGACQJxAFiZVgugD5y3AIYwECWwAAegd5iwAAShACVAECMwfu0lCK6IA2gAoAOBARhwhDFgi2SYhYDQATjGAXHATuMYSZYwA/l0dtylCElwAXrHCBkATcf/kAmIkAFAwAs48Fqg4bcmwUo3wTytEAWroAqLcAiCQAAjgLo4MAqFhQMOkAEoAAp49VQlYAjjd7tTcGktwAC7mwUtgAOYEAeGgL86cAD4e7uxiwOwi7+jYMECAbt4IBC3mwYDYb8DsQAEoAMlvL+pq8I4cAWZu0bfi1oZ4H9phX6B4AA5R5ADAQh0MxC7UAfZBAEOEEl/4LlHs04CwQFXgL8C8QNRJhBClYSi2aC+QUqqWwYWjAk2EACGIDEtsAMtcMI3QIv2WwY4MAL228A48AKGoAOx9gAiIAJl3MH2ewoCQcJ0vAMdrKnXBbsDcQAE8AkCsQMEUAADUQZmLBC1/1ACUDAQYfBKrHAJBYABnpALuTAAV8BEjEUBI5BJAkFdbmQHOsDEKlAFhmYHI7BPkohjlRAHB1UAWbBFiCAH6YUDWvABvtDE+8ClAgEEAEB/AcB5SohxxTEAF2AClnAKH7ADJjwCZeAFt6AFTtADpwALO6ADwJALkzBjAaAFkwAEGSAAgYcDBIcGZCsHAmEIhtBPmWkIPyAQlqADZRAKPrYArCAQS1dAe2C/6cQBEaB3atABchSl5WQANjDQjKABkxYIOoB+HDAF2/bQTcdRLcBdiNACX1QxG+CKiDAF+BUCB8B5f5AGWdB66ZcFarQHnTMQTBALahQAttAJrxUGcf9g0nMUbqcRJex7G4NQi2/UU4iwxb8Axec0m5GgAWlWAxcQzJnQBxSwiIfQCG+nCBxwAjFAz3hgCFTaApYgEI4gAPFngQPxBzc4EHWwbXmQjQIRCBrAVQiwbTHLPIEwCgZKB7Gwu5QDBw4AUAOQBVk4A1fwQWoQB2/jUL0pEBc9AipHASVAXn/ABjpQcypgCHo1BA5QgDiwA7ZgWXYgAoYgAQN9izswZoOYZjk9mrahChkQBoNwATZQQKmQN3n9SqkQB7msTfYTA6mQCn7gCHJwB8BlR+ioV5M5EBYgAtnkCBLAVTVgaNEoCJOlN2PkwHFQKhTgAOmFyi+cfgwQSYf/oAB1nQYlsDOKEAcS0ACsVAdL5NWCMAWPVQM4hHqhAAAL4IqBgAciUCpDEAcj8wczIAhQlAgqIAiIRQEPMDJ+UAtMMFasYAMd0AAyNwl3AI1L0AE2PcUyaRsnoNZxEAY4gABpYKA2YKB/MAorNgcPMEuiYAMWQI15tX8PIAdyNASj0AmT1QelBQF9JxD4aIuSIAixpj14kGaPQOCQ9wE6gEsx8AFDVpqj5kA6sEVDcABTFQmEHU40IAIhMAg51W+pIBCK8FB+5QEdcFHONQEBoEM40AedAAdBPE1RKmIUAwgBMAMr5gEPsGKKwEf95AeIJAETPQk2gEFOEwNjhuHE/2wbrWBuDRAJGXBkh/AAY6QHCoAJNZcHVxBrhRADAPDPeSAH9BwHLTDQQDAFVmUACkA4gGADI3PG4y0QEHAFVUYIaYDC++cAORUJafBUFbA07AQAacB5DaAPcYAq8XYA6UUDB+AAfZMJqAAHbg5iKjsHHUMINVjgKqACar1sMWBxgRABdWADtQMEIjAHVCQMKrAAcCAM8KUCAmBZiJDtMTAqKlCYtVUJMVAJC0kJtACIApFvypsLAnDbp03FqUEKc2ACVhADdwCGOCAKRfM4GTBPAiEHZ6oJg8ABFQABqKABgqxNdgwxMyB4TpMBgzsEaYC/SsoAuCQBV2BVKGUImv+SCDZgCLYYAVfwwVqIVCsFBw9QZRNQAjMARf24eSRnCI5zdhMAB6iHbHpwAT80BHPQAIjFAUAQAVfjBxMQAnVgNBAAfxfQemUnAj8UCCIgB0BACnqgAhxAAxHQCD/FASpQCLwQA6mcxGtXAIBAn4twXAPBC1qQc6EQA7EzzHbnGq1QCRY3fI9jhgIRCQ/QU6RwAUsQYQ8vBz8gASkJSAgwOEcDCQNRAYNQc4lAV5/8pAKxkzOwRREwrLAuAgHQMUUsCGN+X5qSBxPfMcoAU9AkCSrQkDfDATFA9aiyCh0wA/dTAxkwBCoQiRekTZbVA9U49+3TAyGwXoqAAKJQB5b/NQiR4Acz6gc98AQ/0E+KYAM9gAqHgAigrQaDgAhD0AMWuAKAAAW1sG4mEAF/EACKABAhNOCwMAHHQRy9BiHEIaEPQ4gRJU6kWNHiRYwZKSbQGNGNm44hRY4kKbKQoAUXEACZdLCBIUQ4Gt2ZYcPRiRg4KHR41CeCrkEtgByMYCjEQUCCFh7MY+PRQU5xEBxMZSiDHhwRMMSYKglDBhEy4QDRAIGghAkSDnoAIOiQpB4T4AzBcQKIhBiN9gTgAGmIowgRQsTg5GcOkDoecGyqQ0gCAkUZYmoY2AGOJzk1EomAcAlDIQ6DGEW4s2jQCjsdKKhpsIdDDxwhMFhwaGCC/x5Cpy1Y2AOkDx8URuA0whHDAyE5fVhgwEELDsMYpRjCYV7S+nXsITmS/Jjd+3fvhSBIwiELgKchguggnFPCAI4+PYRcGKQBFg5FAC5ciEkHgKmD+tCAkIMoSCMDhDD5IBCmPljIDxvkUAERSeDIQwI5cGglAxUySCQQOCyRIAIcEKCBArUKAaKBCyooZAAL7uCgkUEQoGMOTdTQwAA6PAAkDwsumSMKRWxQxIo8HKFAMQ+AoEADYXDoAQ5HVBgKjlX2kOMQVgbhQwLmaLgAAhtakZIDCDhIBBIMRMkDgUUgyAOCBnDQA4g3V0ikji3SGkILUfyY4aEYQPEgDxyeEP9hEYR6uIO8g36AA1LwKrVUpO1G6u5STjuN6CQCYqAhhltwsKMTunBQBYM6KHhkjqMwOOCHg/aYYQRIDqqBxIMGEWSPg3qYAgBHZHLgg/dw0GAKEg+xAYo7DAAEAAoGwcMOBACwwAZODBiIjkEcW8EACRq58I8JKOAghgowyKMQG/L4Y0dyA6EDgwrkTQSOBvpQwQ5AEDhkEETVqKOHqXTqwDELikPAADgAwYGGPC6ok5AI6ojjEBw+kQsUHJZQYQUJELUgFQk4wAEzGy5YAQdgKAEhgj868CUEQ9TAoQEbKjGLBgdUQQiSOZ46aAAbsPJ0aaZxyFSkTZuWOrtM4Aj/4AkNZkh2kRFIlKSTEBKJoC2J8yjBioOEmaODUA6CoxJI8fhAEZliAEAFRoeIwwHFcOgADzrsgOCCP2Kgo5AAAhmC2zsGmQQOCiLIKQQV+ojhkQpGvqPOCEqBQ4JELICADwBqYKQBChqYwA4D5iCYOAQGkR0HQAbow0IcJhFhhqF0smGICf6QEoMG4GAEBwgqkYOPYDMAAKtNAhAEUS8CgCCGhjexIQOzEpHjFRuEt8IBQ+gARIUaLPAQBw8UiIMCHGApg/mDFAmgkKGdmnp/8J4OKWr+BRAjoKADKVYRgLZB4AEVOAgE4hCAR0AAD6xQlg5gg4MK5AQhMVALDjhR/wJDEMgODmAA3fxFgbngYBAAGAsONDGHCNAhBCvCARAwICA76KEHfIAcI+6AARWQqAJz6FnuNIAADTCvDzZQD+0iIAE4xEQrFsMBIQQxggvWQANziMTKJjCIANRgZQrQQd/UYIPPZWJilbCBBouysYN04AADwQEiKGEIMSICDhe4A7Au4YASiBEHddABJp5SgQcc4D0RWIWYDsKCA4ggJqGoA/1yFwAlIEQNcgCWAD05Ev91BICfJCVC4KCDDkBBA5Y4iAoOQBdVXEAgeMjAJw5CE10cJBJyOJ5M4kDHSOBBEDorBABGwLwYREAPNhjKBKBAh3J5AA6uqRHHKBCAC/9oEAETAADHehAHEaxnD4J4wByCJYdKaAIHfxCEA1IVA0PIoVg9AAtdGCGID6TiICEYgQPoBogYBAAOjNJDCVrAiYPYIQAMoKMiRlACROmEAQpgFA4wUAJeeUIBBxCeshyggeNd4gEP6OQAruCAg1hCHy0QBQ44MAEgaHATH0DpQRKDED9koGEHIQQAGFhKoFoklBoZZVAFeIISfMEUssgQDvLQAR7QoRUXGAAGHxAAhFSiAwgZAQMYpCoGZCgTg4gAEBgIPBVwYIjw++IherAHS2hgBdtUoSAk8BRC2CAOfRuEAyiBFQt8oAQv08UIstA7D5RAEATSAx4UeRAJTAH/QRNzQBy+moEs1AkHQ2DAA2KSCBXg4Q4HYQQeZsCQAlShd5N4wBQ6qogqHKBYNSxBqibBAEPY4SAaYEB1DEBThJggCzY4iCde8AHyQCEDcEjYE2xRAoTcYbQHSQQAIko7EOzCqNuNyFAzUlTueqoRGJiDAcZaVRyMAqWHkAODPGCDMOQCB46YA91wQIoHnNaDBziAIGfxAOL+AQh/sMAQEAEBA1ihBzGYA8cMsJKpAAIOPUAFXS7AgK0epBPuWQsDJhuILJQgEQfBJ/3ykIY4HE8PhsCDxHamg+lWQAGC0C0OMqCDnxqAAXhACG+ni4MB0DFSMOgoDnSgA02mQb8u/8WDzmjnhEog5As6WA8GnWDOg2xiBH3DwQ0OQB4LHOB9KX1BUxuCVYR0oDo4CEUHBBle7noXI+CF86Xm8IAMxCAGBnFqCQDQAAnsNARw6OgKRNDRPjgAD35AngouoBZJYEgFe+ADB0JRg8f0QGIIcEAAsIKIAODBLH4bwYAakoUM4wAPOvgqBT6gAtLeAAAIAcIMlEaDNBDXTnjQIPvwQD9LXLXHIyAQDixhCCH/wBZC3sSamaw0HDBhyZ7YK0IK10kc/KB3OLBCGX6qhzusAiGWgIMlgYDmSzgBjjjgBRx4hQNIwCEYCJHABSilAi7XOahyvgid9f2dIeABErywhP8DYDOtCExiDhfEQQ200LZBluAhjagDDeBghUbAIRB9QNAhLjCECPQACGJUhAjs2qssTNYOI5jCUfyWBiwPQQd8xoEcHKA0PjyABo3atiLWHIIDbPuICBnCHPBXxwOkmgbcQkoAaN6ANCRMJ0LGQSCAoMaDcEDqJbIkIIAQkwBplnZAOLpTu8jTGLw5BHxGhCE6MVuHIQQWHcA2B4aDEBVI59/7Lom/906SQmhArRjomx+qDYHnkCIDP8UBHBzA6EfIQQR18pYdesABOsTBDvCyRANy0oc42OA9dgCAUHqVhucc5MadjMEVOriI3yGEAxeYLSIucAmERM7aExgxDg7/oS1aSx0RMeCYqUDQQQyWplHvrsAMdooDFcSBIYTwQI1xoIYTMAQIVcaBH0pR9rggBBAYeBkOWKGBpXS/Dtk/CBBmjQNTvGAUDBGAPg/ihw4kK1EAQOjRZIH1v/skfrMIvwvAjuAESsADOMCDDBMFODAOQGOlOyiBTqoAAMADBkKADsiDcJkA2Bg0ANA1BMAQxVgBB4iYgwAABoCfhhuzYLEBCtIJQ0gVR/CAr/I9IJgtO/CAihokLMOB1im2R8AA/YuBbSMEuUKICVCZfZqDTrKDGEi/PZiDNzMEHSCOg7CAOMA2MGEIOUi/CrCB4sOBMjCzP4gD9kOEBQiLg7iE/wDgPgL4gGJjAwVACDtgAqq7A/bDgV8QBKE5CC+Yg5YyQE8awIpwAx8gAUVcREZsREd8REiMREmcREqERAcggHMggw9QB0V0ACKAgniYAhsggTU4AALQAkUEg3gAAC0YA0M4AyBQh38gAA0ggTFgADMAAUXsAB0gggkggSY4AABYRDAIOkVcAzB4h0XUABFYxAgAgyZQxDH4h2hUxDMAg0U8h1HogEXUAW9YxE74gDpQxB5wAG5URG0ogUW8ByIgg0V0gH9YxCD4gFokASTQASdYxA6YAjlQxHPIgjbIB3lMA2VUxF5cRBOYAgdYRH6YgkpYRH3QARlQRDkwgxxQRP8JoIIpyAZFfIcpGAFFhAJ7iIVzPIAkWEQtwId8XER1GEZFNIESCIBFHIADKMhKvEmczEmd3MlJNESKKEBCnAhEkIAngA8VGDG28JFWkAUGGgQGEJ4RRAQg2AM9wABA2EEggIMRy4MREAEsxIMHKDZFkCyeugAWrAsgqLFCCCeEsJzeO4Y7yDEF4D45mIEaOwQdgDUcKIQDwINOmoM0eIhEaQE+Y4QDYLWDoIEW0Cw/KAHp262oO4gKmII6JIor0MsKWAAHEEzoeyXqwgPNa8MWmKxsY4AL4KoSKL4YYAANQgQnKIGW4oUQgIGaQoQkmII64YU6WDMaqIL5U0IhYwT/G0AFhPAESuC+oNwfn5wIoExOhniEGXAAHuiQlliBOwiEeZGATrIBBlADSWgRHJgDh+gbODAEzfIAHagDhJAmhOBLOmIEBEiVnbEBsKODB+i1C1AAsOOABxDMBrgCLEsEPCiBjqqAlCsQB5iBiJqBD0iYBqgCQbg/Q5iCncOBCcgCDSKED2CDYpuDLDhNq7q5rLuCx7QAANAA4uw+vZIA8vgDANjMg1ADB8CEipIAPFgUO8kAQ1AMRtAABbAB3QoEAMgA+oEEmlIjAxCBjzoID0QIGoCBA+jBmBnExgPR3Uo/55Sa5ZSI5gxKSTi6CMgAU9CDI0sER4gBuiAFB+ig/xXoADUjq155ILQJTwI9CD5wgE1ACC1CiEaYg755Fe4LgClgwQY4ADnoPXzK08a7gguSgDSI0Coa0CqjAR2AVLK4AHOqANDkMzr4SOL4Azkogd6pgw9oqj3QgS6wJzl4gNRThDgQhGQxgRaIA/KIAMGDA0YLhDuYgABgHgsIABHQIAsogDigC0L4Iht4GTWIARCANT2YgA4IAGAhl6GrIQXAUYsLAKwShiCityQAgChACCtggnA9CCOwASzMCtrL0qnZUo8ACXaVCFLoBCeIgBWABE8okQPYATqAABaMhAOAApmYgyGwgzigwINYhBMlOjlgNBx4BMLJqgNwWK5ZCv+ZQzMcsIE06CAEyIBkNZU4aNCDkAMAvSVDqAQCqYAMyAD19JtREASsUAEaoANBYAQr6ADJARbSEQQGWgEgyAAskwA/GzELMIQHqBM9mIM4UAHi4AA0Wo9Q6BBOwoE7GDAbyD6fK4QYUBnJsYAOYLQFswHFMICPQ9Od6QEoEAE/GEoamA3B4QAo6IUR64E5yIwaioFPuIBHmAQFiLI4CgCRQ4hEAAEu8wJKKLIhqASjidelcVeI6NIAzCkm+IQGEIQ8pQlYWIFRQLNA6AQAiIBFWAUss4GaYooKvb5KABAcWARM4L4SmIJUCYEs0C8I+MiWKI4DeA49iIEw6ACVWYH/DBCtg7CBFhABibmDPaMLCFABOtCARICQDhCEFWCE5RmnQqiABviDOaCAHfQAOViPPkidhq3KlQWWHgiAAjCIP7ABDAACAokBFWiAqVgEEZAACRgCSYgBRAmA0WqKrECUxxBOtsqDCZiKJygNE7AARggiS+gAPggBCZgEDyC/HggBRYADTQCEAo6BBvADFUAADV6BQPiAV2g6DqCAdYUshjM8cTsIUBtDxu0Ux2UIyP07OCiDttkCQ4AEA+iBlqhdXbsDG/CEBsAEObCvQUg1HAAFgT2IGHiA4lOFKaCjQojO6uAAHRgBYMmDGdApF6oDONAAP9iDGAiBCLgAUaCD/xiAgA5QAwlTARXQGTQNgTzQoQZohAk4BE2Iy8PQEgYaEw6oEwyoYOJbiaE0AEJgF9awOAOAwgZQY0KwgPKiAAMYLzqwgssJBDnYBDrIg0eog/XgGRxo3lGOAR9ClDqIAD+YgAoAuUaoFvzgADUIgC6iAQ/oAdhQg82JAEJABBvogz+ogyiotF3ogIe45f8aAcjCgxXwBBXoPxyAAnRNszWzA/SJ4cbtO3iN10IAhVVogC/IpUH4ATrok4NQhQCQgAbQYzg4CkRKParVNVPp4jQrgb6JhBLIsOuZgGkGAjmwARqQhEGwX5XxAA1o2xowgEEAhD2AA62jAz9IpoIIhP8G4IA9CJdJuAM+QADmgQAI8IDR8oD8AwJGowNMrRMauIOMAYRDsBE4YCAPCAEK6AMNzoNFiAEKQJcVADQ98AAJUANWTgQJqAE60Eq3UgRWBkJB9AASCYHSwWn86AEIsMreOIQIqBMNrgM5wB8r0AAAmAprxoTR4oV0HoIGAAQ/sKEYwB8L6AQRYAI5aKkJEASEmgBLcqhyJYhtw4FZuC5svpQZRogaDi8EKIESOAB/wgET+AFWWMsLOJ4YgA0/uIM54L4O6BtJsIEWO4hHGFDhyYQJUAEN0K0YgAMnxIEL6AGVrYDvpIMewIAhKGMLAIJF4AAT8IMeyYMc3BnJg5//IdAA5t2szVGMZZqDGJhWZtyqQIjChKG2EoCfm22hUb6AqaUBIBiTncEAPriDFdCDg7kpDqCEwCCQeuPd7psADMCAEQMEDUiFC9g5VggAG7gD/PEE6RmtUOAKLwmWGZADrDCFGbDngziFNJCFgzAB/hW3UAiAUWjZdGMAFRhqgoAD3aqDbbODUxA7T+iBxa2ADjiGv+aUwD6IwQ4qO2iEFfgBWqiDGTACIJiDoiSFVICETYAAIAAC+VIWG+g9SRCB6VqiOkiVFdCAAlCZQsCATZCACkDnTYiBPqBeE2g8OmCvQAiEOpiDiEGEzWmAl8mNTqgOReAvBkqEDBiFLpeD/04QTA1ogaYyBR0lEUaQAAf4sTgEFupVAM2igEgqFpWF0T9I7zmIiQAYgTlAmz0AgDkQTBNwABtgHkaIgSU98ELqqAs1s1OYgumaABEwuiwsARvopRl4ACcTgCvonT/IgBGIqFpIgx9jgg+ggR5YCCgA0QEAAUqBAvszlQvYQ08AARYIccDW5uQEhRHQAQYQgUtQgw7I0wszoQuKATyYU6oVMk5ogQU4CIG6NGDxAEi4BA94hEiIATuwgBi4gK0yACAIARtoGDq4AwS4g7bhgAPQta+4zoMQgQ/oHT14gBZwWBE4ALADgAegH1d7v1DIAAfAveLId4SoBR7bLR1IFv8auAJIxYE4mIKdgnQKTxQxczENiINkCYQDeICjqwNDOEtLSIPKxAEe6IJeC4ONBURD0OKDgIUWEDIBmAEs/IQbSBZTsMJUoYUpsFIjYAJNoAB9ioHq2AQmKD8cMFwzsamWPZrqoBRgx44Rx4ESDyBHIA86YAICIIBa6AEPGIJ8bQUVEIAJAAUfJgpBuF1SmINOcLI+EIEAMABG6IAorxZRGIT3mGAqsgOlbZhEiAFBAAACkbAR4LMaYKgCUQA5wMIR+ABFhb6rIIoCUBogSM2D+ANDQL5/RggoOAD7WicuC4HFa0MCQL450AH62UcN0gXTQghSbeFQcIAWKDYPiAP/hz2IHTAzT6CWoXmBwjsAu0woAciVfRqAXlruIgMAAii2UPiBd1OECziGS+gBHRm1g08/U3CAFA2ZCyAFhPACFSB/67v668j6rZcI66xj8ACEOxgB97FtALCl1tEZThCBXAEIDww04CjoIQ6Ngq0wdABScMITPxMuBLiEo4IgDQMI4QgkQoWegnRm7CkY4YCRgjiA6PBQcE8GDgUT4bGhsgMTjgVXBXhUMIQEOwUDXSiJI5GGPCp7wFFZQU4hlSsmSCrYCI4FlRGGqNwE50/BHgwiqBxAsCCtFhBU1gGgUpENsCqBzFGJY6tKUyPW4mDFRILdCUoLVgha0AClGiqH/8BZVJBRDFAq6cR5BOhOjwhRC/KwkaksBpWIKilRqauXKruqV7Nu7fo17NiyZ9tNQHu1Gze3XUNg8AJPhqy7VTvC4ahGhgABkjiIESIUjjxwLCkbNGMC4RFQCorCICcGIBwIoFzqMWRFnZARGDQtOOfAp7lkCxKCE6jgn4qL8VQo6EgCVwVp0IFKHMzhWEFwPMCHSZ0YRcgdm9lhQydVieeAHwUVAgCDBSGgwAr0jSCLSjaEVtAQIoSIgxoZdIgDDXd8hoMlAAiHAwVn4YDcIXaJwECPAvKFAyIK9FBgHyoxMkIciRQUgwObQcLAFiqxgIliOCiiwyiNFDTAB1HFEP8HHXZ5kkEkKl0yR5B2nNKAXR6kMhydddp5p0q21ZkbnpIgIMITBdEwx4vDpRKHDSUQYIkfF5gQgiB34LCIHELg8IgCZUCHwx9vFtRHHX+EEMIfcpiAwxBzwAFJQYvMkBBhM1ihUiAuFaSKAjLhYAcQcuFwCBxGaeIAYALa4GV0cWSJAwBZtBeDAoMUtEIcaeJACB4KBNjBFIOpUsJ8OKjwwAVDMTFKiHscMIJPONShw5w4+KHBiuICgOwKgiRZUB4zaPIQiKJlUIJkOHiCh6Q/lVCXSauoZMcNB6hR0A5TIPDQAQCIUpAELaCCIgGjdPjFCxdzMMXHdgXA8FEZSFv/0BNbkNKVCJzgeTPOOddmJ592HhIHJZ7Y9Qcc+8rWSHGJoPKKCAssUEcDdTxRQwNQ3JFHHgY8lgGBD8mhgSI4NHCkMBjAAcQkBWXgwC0qaRBfQXbMUeZOcoSEgwRTiBCSKILI4BRCBdUwhQIZ2iHCAXQ3MMIcHD0iBx7KLqIBHBlwBYEDnfi0ggoTxJCIHXDgMUdIfRjiUEcdSCAHgxao4IBDFWQwgq1AOBBHK5zSHncGhqxIxwPF4jCIIWc1YMgFM4sHABAqbGyBISOsOAEeM1CAgx4PUEIrHCOQ5UcBBNggCSCdT5AmIxfgocLMQHQQAV91BNCJI5Y4YatKTwSw/3FBWsxhISvmcAKV/AIP1tIZAhN4Gz3RqWd04kMc5MCayQUqNqAowQgukAEB5AEEWhiCDWyxg2pcADuZkICurnW7khjABoo4RAc0MIGJ4YAOcvCV7SzRqoyopAYjsJtxZlCCJDmiAx2Qg0sCoQBBGMWHNuBIDQRhCLIs4gKCwE4jUNABPFzMAHKwQARigAEgEEIDcwDEBGQxB7JQIA/HiAEd1KABCsTgehiYgwS0ZgEAJGIQMXiEBGogAQ00og89kEAHHJEIIPRABA6xwAPO4gcbjKISn5mAAyphsz3EoAM2OAQjgAAEAdgqBpVQRgcS0gMbyOFIOJBhDGKwKx0cAP9BEaBDHeoyhAB8IQBDoAAcODEEWSLiAh4AAgT8UIcehCAGorhFACwgAsVIoF4qicGyaAAC/uHACK4sCAjKpcBxkrM1DByOA28TiABkIGysoYADHJC2SekEexWwRCAiUAImxHNgDlhBIQJwSzlUAlY4uEMH7tYADXBAAjSgA6twAIES1EElfujA9ThmCDggIjo2qAPq7mCDHiTEDxnARQwQkQgVICIEcPBDM/EgSxxcAAMAiEEjPECBCASFDzQoTA36cAcDSEAFiaADQewAOa0pQhCDGIQvAgE2DySJBnAwGyMoMIE/dGAFHgAMHepCA+ZpABAVCAAFMGABRNRhBQb/0EAh6KCZCMxABBPjgwokkIFd2KEDdcAAYKwABys0wAMWkMMePiFBcV2sDgSZQAT2YCsVBEINFwBEIuYwA8WwQg6aUEMHEMEBDPghAhmwAVkOcYFFrAADjRhCB0IgAz4EYg59oAAu9ICBHvgBAA5TjQpmioNcdCBIOHjCBWYktjkIpZzOLec5d5NO2TiiBw6QAytYA8EX3EAOdaCB7WbwiULsIgNpsAUb0kCACFzCFz0IgAYg4AGtrQQPGbqIDQIgk0VgoCR/iEMGhJYg4SICAHDwUiLkIIFDBmICFnDV9VQQAmFoYBOKSA+o6IAdHMBBEAC4RAQckIhCKCAEFijh/wUIAQgM5KEOIcDBBEQABwkwYhEToMCCCxIHHdyHwyNwpQYAcIGoFCIOCqhoIS5AORwoAQCAiAB2ABEAPGzYpiLokYYD0JQnT0AFkJiAB+wQAQQ8YgIN+EMd1EC0P+SIUyrQAEEOgYdCJAIAXOHAE3vAIARUwA845UUdLECBPgCBIIjoCYxCQFUcACJ6PkEEHOmglD1cQAV36BEU3nyxJ8wBAzM4kV2A0AnliSuFapiDzQpiCQy067muRmB0bzNd2PABD3iY1WpIIQsHhIERBelELA4gBGhOoQU3GMEBCECAA3BAGBMYQEEeYAiVQCC2BSlhIvjQAAerRAIlyKgj5v+AB131QQMNoEMjNBGDDDWgAxFtgApYAB4ccOAUcqBbolBngCwwQCgOgEAk8FASE7RABAXBwLq0togMjMJWeRCB5a7tAJ3QQQF8AQIDbFIQAHwAVuM6SwwGMccnfQBOOLAAA0YQkkIgDnW2y4AeKpCKIaggITnyQAQYARkVwEEpvfVeQQLQBwsg2hOVHoRPPIeADUdABZ/8wxwqEALU7UECMdiMllVi1QvQrQcKsEEwTp6EEnzMFA5gdg+WVZBbzCF3X7qAheyggmXpQQVReDXecxZr2szaNQ04cmsiAQDsFoQCdZCBBAwxNznsAAAzEEAnrbCCToiAvprAQwDAUoj/OnAADnRQRQQEDAdD0BAHPdgBHBJSgRgYQQVGsEQDtHYIRMKqETaAmyMAoABbMcIGhrBIDb+tEgcYwtcNyIAINjwEBsy0Auu6rwpG0J+TM8ABd+t82HGwBxG8GAcGKME3I9CC6dOhBfOpwAhsMM/yw8oSDFisHfAQpYJMKQ44CIUEAqCFjiJCBIG7SwsYQo8wgiDoQEbRAXzhzw8wwMt4gQMowL48wQI4gE9QAAIAwYoEQgnYgFCEAFrRyghIT1g8wMVwCgOkgQj4xAyMgh3AggYoF8fgzyZUQj0ZwWCojY7knQ7Syd7NRt+xRiSIgKWsxgnYAB7ASg2IwAxwQCPU/8ADpMEGtEAF0UEMZNdBRZwkoJAdWEAI0EGg6AEQ2IAMNBcHPAAA1EAj8EFK+YEKXEAdPYQhCJcEKIA7OYIgBMBkMEAKUYAIOMmlyELpxYBbqM0B4NoeCIJBAYHw1MAgKI+6aNwrOUBHMdoH4kAhCEL3XQQAGEUhVML06UEJLBYOTIIcZKLnuQ2oKQK5fEkLFEsoOMAHdMjyzYBKqAAe3M0lPMDEqYQRpEEJ4oADYIKF5OJibQKT9IFj1EEsPAAH1AEICECAXEv0IAsHzEC9BMAM0JcJxAs2qcYTmByjzUG9hEAqWMhKBEBx7KA6LhDP6EZsqIIKzJNd1EAcjIIr9f9BAAjCqWjCHd6CEjzAB0wAIWhCCNzNIwCBJYSABmSACmgFEPjatQDATf3BQf4VANjACASArzXCCDBAgDRC5NxNDXAIYYgAJQxGowlXHuABfQUCJdANDgTACNxXA8RBeEwKlc2FBkDkIfTXY3TAhmVCBihAhxCCDexLDejAN/lQgIjCICAIDojALwaCIERjB7wMjuDPvHTIExCA0cBBLRXEJEFbQTQAAKQjDkSOXVjCCEQjEICjMAAABhxCDThALHyACOzAcqSBEwSABASCJfQAguhBBrQHi6iAcfUATGpAwnhAwdCKQeHNAVkWVE6CBKTaOmYmbPSgbPygXUSCDWz/gmpIwgUcwCncDRy0ABp8ChOgzgTQwh5gXCzoQx1IwG5tygSkwQhYACD4QQDYQANAAAt0Aq95wBB0wgHYCgckgQ1QgK/lQQtUFA5kggpUggc4SST0wHzdxQAoghyQhQEEQA+siGZ9Dr05wEtdimahTg88AH3VgCFkQKoJQgmsCAQcYdyIwGJBQAxMgAQUhwEAgK0MwgF0zSuxR+HFQb0AAFaKRcH4wQF0gkrIQQbcZH3QlxqMgEE1ErIAggbgzwwcQKutjF1swiaWiHDpQRyMAAAEgCF8gAZ4wSb8wSZwQOmhCoLsAQCECyHkwd3QQBooQCTcAQs4wImYQlvtwSrU/0EHVIIIICMnqIEsgBorXMAAxU0dZJRm5owkZIIasMCNDgdnxoZneogD0IJqiIIIMAGuPUIM/MA8pYIIeIFICAcgyIETVEEspMEVXAFl6UEkSADiTUAcZMEBHIAOOMEIZMB3hgAuAEAdDIEd5IEG7EEkdIABqMEnmAAHKAICNIAeqEEIBAIFIIIf9AAEUECG/MFI9QAsBMMEVEAwIMAeHMIfMAIdWIEpFEcFbIJoFQTGAQZpSoAEZEUFXEDyhcUMxIBQIIIDjEAjhM4Q6EEMlAQQ3FIFaIJ5NEDYrMAFAIAgOEkMxOFLjMBZeKgDMEyIZUBJTEIJHMD0DUEJ6IoBlP8BrNhBBuCB8oxElgwBo+oEISiAcOFABwjCTVLADYBjCBiCCIBFCPRAc+GIDZyAJNiBHhCCB1gLIkjA9AUDNMgCHXjVCFTBB4yUHMxCHpSEIhzqDDjBA8RBAeiiCCSBIRzAKOTBjGDAL9IbC2wpnXCCL2iCKhwBCoiACBSBCGACE0BDxIopzySBGkSt1KpBMSADFsTBDZDA1KqBNCwAAFxD1E7DCHRA1BYDAOwAMqjBLoDBBHDAARCDjapBNpCDDuDDPsTCFbTBG4xAOLDAGRzAApwBGRCAN0jAMqQVF5ABPBTDJ9RBEMStM4CBBEStBVCDDURD1HprNkStBsTA1Ib/QM1F7TIwgwh0wDbQnA1kAAlQABTQwQVgQQ1gwAqowTIQqxpYbdQOATJwwDJcAwdYAQWsrgRQgBpwQBM0AQdQAA1ELR3QARaIwDNIABfEwDaoAR+kQghwQDRcgw1IwB1oAAasw+wyQxM4gxrAAwI4gxAMQx+MAQCMQQxYgBo8gwYMQxypwRhwwQWAig0MAzPMbghgQQzwwTawgAZgQQgYAx2MwTLQQNwywzDErRo4QzbEwDQUMBaYgwxsAQY4Aws4AzVww+1yw+wWgwocQAtkQD8kQwaUZhtwQS/EQACIgDTUwRS4QCxsABWUgBT8wyvYaNqeQTIwQweoAwg8Azts/0LUSkAEiwEwGAE/BMDsaurmRi08oECabe3UFsPU+oMSrAAXb8MucHHU7sIuTC0f8IExcPEJOIMM7II4SMMgiMMaTwM4NMA0cHEU1AAZq4ExcAMKgMAoKIA2EMEojIAbkIMDqAM6oEMT1IM8aLEkT7IajClsuEEScEEnLAAD6MADeIM3EIET7IAQbO0Z3AAGwEPUYsAIhEHUcgAANEHU9oEDJAPVfkAzPIHUGgMzaIA7FEALdAEM2EILqMM6vAMwcLEEEAExQIEaDMEZDMMYRC0FdEAVq4EEIIAqcy0KqPIKrEHIyAAyRAE7sAALMIMz+MMYhEDUfsMIUME6QAIPxP8AEbzAASjADbwAFXiDOhDACNQBCwhwH0gDOCzDNGxBAPTCMqiBOKhAB9TABF/AJjdBHehiOOyCNCgAFZQDA4iAAzyACvDBNHSCNQzCN6jBClDDMJgv/obDNEgDC6ACCdSACnBADSQDNcCRGsiADIBDE0QDB1wAH5xAAIwCETygG3CBNYxAEECBOdiANXSDDTgDHYiADWABDRjDBZiBAxRBMpyBNZTAOBDBAUDBGehDPAVBB1BBAiTAFJxBCbQBA4BBEdwADOjDAmRAENwAMbgBEUwBEcCAC1yBN5SAYJfDFDRDEjgBA9zAGVDDCExBEZxA1HbDCHhwODjDLixD2u7/dCUcwTYUgzGogDRQ7QoAcgwUQQec8BTAMAg4QAscgFqfQToowCicwR1IgRuEoAMcciHbQBG4wRRMQSVAQw44gA9kTg6MgzUowAg4gDVYw26PQDdAtwPkRjekgzXowzhsATpUtz5MATa8Qg64QxiQAOYWQx9TMntvrSW/Rm4EgBFYwRNAghB4gRDAwqaoRCY0AA/sNyAMwC8UBCIIgSkUBClAwoCjShgsOA5oAq4VhBAIjQH8ABMUAElB5a6wxjHcAh1kbA04QisYNiWIQBZswBWkAQw8wBVswAG8gj6UgAjY1AFcQRXoQwu8QhwwQR1QRCUoQAGoQB2ogC0kwD4M/8gGpAE2tAAU7sMGFHlbc8kV3G2S28IGwEAapMEMEMM+7MMDHMAGtHUCwABsf8ADTEGY78OLY0MaPEAdRMEKHOuXz8ADxIKRh/eTH0DPXUAL6OkVjEAW7EMWtAAMVMGVo3CYt7WSt/UVzEAAOMAGZIEsVA4MtLUT3IA+7EMC4O0DvEKlXwETLMAOLEBb20IX5PALlEEBLICdV0Ed2IAOdEEJ0DkBMMEIqIAFfMEMMEEYAJ8aNIAFQMEOMMELCDMoUIItwMAcqAATYENG1sEsqAAB6AOus4AKtIACdAAlLICOz0AGVAKzH8AN4MIpXDoTUEIlgAAu1PUMqAAIUAI0AP9BAIAAk97ADYBAL4BAGdSB/BTBAMzCLEBBETBBL7DAAEC7L2yCCbAADfRCEeBCAYBAJVxBAqTBK2DCjleCEGSfc723a/DJIZxAK6xAH5yAJpACKXDCKpRCD9QBJlRC7ohCKpRCJJy8JkQCKLQCKazCKzgAKOwCKiCAIphjK4AqDkhCFLSCMBSEJuRBCOxBD4xCFezDFMwBKGwBJfTAzJBCKbTACFTCA0z9PjCAPog5AVRBAlCBE+ABcmp6W7uAl7eA27d1LFDCAbR1l2/6FWQBlCfAFZA63bt9OYh5AujDCxA+4S/ABADBBIT6D4TBKdwAG9zAJ3iBBCwAHgjADCz/QDPQfSzEAgxkPhCcAgHcwKqj/T4wwQ04gQNgvgPcwAMk+QskehrgwQ6UAQFUTzOwwRXEwj6UAwzEQhU8/AgUQBk8gAiAlAA8AAHEgAD8QMQEAC28VxncwBIAwhDUQA/svgBAghXQwgAQ7yasOhoYgCJwwA4UgS9gljIs2N2ohCNEgRwYQhxo2QAwQRc84RTYwhUABIgGn2ppCbFrwg4mlIBgqFTkxoIAP6DwkFCjAo0nMnoM8aOGhq9qMnpB2RUs2KZZKKDNYsHH164oLHpA4YSjEQsLqpQdiwTlxCxQMo7IAFUtUzBfsypRElGg0qgPG64keQUCSpRgOLh29foV/2xYsVwTjDXL1Y0bHBQI6HDCZIcCBh+y2NqwwdaHEi2m1L2i74GODzoY6JiyYd8GBjDyOohTYkqaKwwMlcjSRQEeTJA/KOjUwlasBPtiSd6378qGBKudMPZ2Q3SCB06chJEAIsOoOD9o4dpQpcCCKk5q1dpB4MW+F0xexNrgJM3q1adXbyAQ3bqDLguAdXjxgg0eKLRo1WrGpFaVWEkAUAoAoNMEDlYI8YEwhE8MQak0saBT54UFTPAijFMaMICPABQAIA9FhAhDCEL8wMEKFX4IgA4hbsCDiWaSqKUBCioIpI8hTLnFFB60EGISVkz5hI8+GuAkChE0AAWUKHypgP8ODhDZ5QI1cAgmExwqGEQDBx5YoIAaFhElpwvyiAKDThBYgYI+oIljDjp6QACBOEZI5QQqbSjFBgdugCGWD+6woAdaGMngE1iWEIYrFjrBoI4FmCjDiRF2yACFBqCwBJFWGsDjgkh6QMWGJHBx9AIbVFABhCIqqaSPIypJ4oAkRMClklfiKCKAODqpFBNKQLDhlQMIeEWBUYoogolXiohDm1FOYWKUV5hgIgkm0KCFBRYU2eqsZp3tqqxnwUqLq0u8gMUUTyr4BBIOIPnEBGCE8IIHI6D4FhITjDCBlnIHCMMIYKAABo0CAihAoT9P2eGGHcLo4YcfYpDghwJqESD/jCWW4CEMYICppYwy9FmNjQ6aueIUT5Twt6snOtAgAhPqmGCIJ06pJRccdMnlkkmUoOATNFj8JIwvaAGGFjTeMuKXhy3R5RYegDECDgdGsGEOBVrQwQEWjuGkD1xQCEGIL4j9oYcAHDjgABEQkGAErglgYgQHBKnjwhUeacQXVAapJA4GYnngjhNqAGIWD3DsZIRKbMAAFAIIEMCEP9Tow4AKQFHgAFQqQKCTUhzBQRNQ5rhDhlLiWFqOOwSRZYtKAsgAgDkcsCEPDErJYwQ2FtgBDUjA7AEDKHoZAQANQJjVgSmSOIWSDgJwogArtNCnhbeaqUIBEAIIY4cPhcTB/5FHujoBx0r0uWKGApgIoN4yRlehB1ygAeGDUWZwApNKoPki4kvR+OKTITRYIAltMAEBrgLKIJYABVjCJ2bwgsHV4gYP2IHDJLCAZoAAEoh4ggBE8IrXfSIUSqBEEkAwi2pIC4QgjFYI0aIWEp4QhWPRhRWAEYD3MEEARohBBmwwATqoYhccWAULQhABwl2CFzgARCEeAQgD9KEPfDDAHS4QAg9IgBaX4EogYmCCrughEGqwwiEwEDYlTcEQZQgDD0Qwgjhg4hUfuEIJJAAETKgAEYGgAQCYYAQhhEARNOABJLxgCgvEYAAm+MEI5iADDACgBSV4wAPKsIMfdKASg/8YwRQOwABbpCENVWCACAJQhh5YwAN80MADOoECG6gRD18oQgmwUYIS6AMGV/hAEepQi1MkAQ8AEN8CYHCAV9jgExl4gAjkwIQ6QAIS2QrELqARASDqYgIlyAAHFJGBJPDmEr9QAQA4YIpQiKIDBAjDJWAhgCRMwAscyFsfGMEVPsThFZxQBShSw4YpOOEGdIDEEriiBln8oBY/qMMBtEEsOGwhAEIQRiYWAQQJBIIriODABEzAART04AmX2IMiZEBRL0xCFLtAQBho0SIWkLQrXoCEJbgSBVmE4RNe0AVXWpGKlvgihTkFywhJSC2d/jSnl7ACijzhBTRkYAYBGID/CvBQAgU4AA94gIMF+NCKQkTiAjMAggVE4AANYEAAaIACiwIBCgxogANeeEJXMOCADkygAQ5gAACEsIlaGEENiuhDHB5gCEGVgUk9EAEMHpABTIxgASBQxAm2EINZZCITfDhBKmwgAkyIoAUtGArAegALWIQCByHowAw0IIAD4OFkeiyDABpQhxmMgBIamAQNHqCAiZjgCYEIBBAKMIMFiCADN+gXLHBgB0X8AAAYkEAfnjCAJeRCD9WIASVQ8EEctKISfNCDH0JxCQtM7g9G2IEsjuALFVwAEDj4Qw/CUAcDOGIIeYDCBBaBA5DUABGToIAaPLEHrgyiAwvo2gFa//ACSlhhCXUowi644ogozGEGQrpEHVpQBlbogiZHcAQnUACFBkwvEBbwghd8EQhYpAwHSujFLFjBFWWgYAIs5coiqsGsKKziEJLgBCoQWgQLWO+6pcAFDWYKVKDyNIQ+NfKSc5oLU8x0Dz8Q3wA+8QRZPEAfujGEA3SgABXw4BObAO0iGqsMCuwgoVwphAFaAYofSIACeejBAE4RAq6sABR90EAAYhAAYEwiFyGQRSUuoIICoBYSt7gFHGBQBX1gIw2/VEAcCGCLLBzAEEu7Vw9qgIITrAIUInhAABQMBCBUwCugaAAkMIAJbIiAD5roQRxOQQE74ICxg9iEejXQA/81gDa9pJAFJUrwgQxkAA9R2EUkQPGAK3SBeTalxCRHEIHpyQIVQyAEDuaYh1sXohCHoIAijtHqUlihpaVYxSxOEIlV8EEUOMiEDTCRCg74ggYS2MEpIKEHNWQCEJxQwiFwQAgNeAAWkLgJKXSRzhWownp9wAAQhICDFZQiCqrAaYoZzJUKQCAEpuiKI1aAiK5kQhWF4MQqioDID2CiE9pwdClQEABK2KAIuOCByZn8UySDUMk9F7qRKwAAfkMiDAMwwg8WoIE/IAAVkeCAAARQjVuEgAaHcEQhGlApIACiD4RG9ySmB4QZRAAWLd7DVgIBBwY8wAgznQQfFsGIVoz/Ii83SEIW4G6JQGjgAwQ4BQAyoIAMDKABpegLAWZwgC5k4BQHoEQMIM6HVMwABq8AwAH08QJD0DuqM8jDCUSwgVgYYvRC/kNLMcGAKSiAEtpIwwwkwIQH2OIKD4DBC8rQjC6E6hRW6EEGNCALWWAiDV5uAChsQIktROEEI8BED1BQikjgwglzaEUjVvCANimtBQDYgghEoI19uODmJegEyLlyjF/mQRWRsMEqQsDzOkQuEsdAhe4ZQIlOvD4S4g8TrkABUGAWKCsOtuAEsEcW6mBCNGELSuEEnmSySkHI4KYM0IADwqAWCkALZMAIDqZmvkAGQm7ofC6Fgu4EV5DJ/yBhBnrH9RSgBFFgECCgASTgDiSgAToAAJ4gEwLBCHYNBxZBEABA1cJAEbqCE0ohFXrAf2ihK0jhMaSqABwgBnogAvIoCgrBA2JAAFBgEvxgFhRJAzSAYHaAFnSBF57ABGKAAPwFAOBgFPAiDfBABb7ACozAEOhkEgagBGagAwQABJLgBrQjC0qgFEDhFQ4jFt4CD8pgCj6AcNBAuD7hyXDgFx7gdzBAFZJEEL6HEm9ABUbgLtIABmAgDTZgOV4gDbaABkBAEETAVW7gO4zlCyZAFphgBk7hBsqgDnrvABSgD1ChFBTAFg4ABF7BFvbhFbYgFSCgFPThA5IgCQDFCf8AgADYYEn8BH8gZgEywH/6ZQfYJA1GgQlkoQiyYAO04RVG4QBgYAO6gAm0wAi8IBfUYAtmAQeCiCt44RZQjAVREIVUMCALMqf+IAx+ABLQ4AAcAAQAYAb+MCLVrxdi4MMiaw5QARUugAFaYK1wgA+4QhNsAPcCwBLsINwW4RDuYAoIABJwwBJG4AKkCAdEoRPkABL6SwKgLwLKQAd+gCYtoBCoBxVGAA68wA8oYAocQAtugAnkoAESgStSwQEMgHI0IAPebAsGYYO0ABgGwBD0YgrYoBkMwQSqzAOS5wlCQBlwABI0oStK4QFoQQhOQQBmgAECwAuCyBT+5gv0DhT/aQF6BEAw4aADClFmTIEFKGECQOsRZCEGJgQHUCEACM4UtEDAnGAGOPALC6AZXqADQMAJMlAh0GAJJsEUKAAChIC4vCAAvgAWboFCCgAILiEXZsoStKAAaOEWLKEOmAAE0AANtOALyAUEBuASpPK6tqAO9MAgh+7npIUgn5M6UegJfuALLuEJ8GcHdJMBsMEBFMAGUqES9kIQQuAWIsBJ+sCX4kAHuKYFeGAIFcDYJGCAaGAPKqAHbEACugIBRuAjCcGMFIEXJsAQkpAr6OAC7sAGKFECMmEVNMAJBCECYoACrKABCiEK+uwHaiB1fmET4AAOJCAEviAA/CsEboAA/wagB2gAFoCAAnDADwbgBz5hntpSAmIABzjhAkqrvjAReiCKKyhABzCADyCBFfZgekJABYbSvlQggKRSD4SpD3DgEUTgADyAK0DBAQCgSESBDgaAB1ghiKyACWygmz7BA/zAORlBAkSA4OTtAgahK5qP53DgDuZAMofwCLaNK35C5MwL3YQhBOysK/IgAAy1OpksOp9lOhcVUkkIFoSAJqHAqV5rBPTyFyygAgphDgShB4ygBWIhCxzACDzBADjAA1RgBpJAA9ILB2QhU59gDzwAEewAAUTgB3guAnQgABhhBS6gA0KSK2JAAToLBzZhBuRgAibBCuQgBtANB2JADv8wANWeQA6AYKYowAHogCsAwQgaAANUwARytAa4YgguoA8gAN0oQBAagCtoQBDuIAB6AAeGsbhKoQZ44FxxYBUo4QbgKgknIQL4IA9iAAVuwuJKIQNioBE0QQIYpgdUQc4g4RAyARU64BMiQCMtgNvijSvkoAusCAfgQBa4IhMQQAMA4Fw1QQVGAQNwQBIi4AdwAS4LYQt2AAMk4U9TQUhxoBcqYds4QRaSkA9wwWPVbAtUwL8idcka1Vke1WmnNoQmARF44Q8i4BQ04AjqAA8cIAO+oEWtoA4CQEiBoGuIi0T+9ABGQEg9IAPgYAKyqAH0gA8uYPAw4AIsYYluTRP/oArF+CALbIArDAAArJIrACAGbg0H6sABUO0QbEAQmrZxHaAUnBMI9NSd8GAQGBcAMIFxcaCpENcSRMADbIBwLaEDIKBH1YADVIBYE+EOROAOcsECIAAH2i4EfiEG7gADkvAP/G8FcIAVECAGPEAqOSAOJIBnP44r7sABZsA5J2AG7gAHCqESoIAVBsAGxs8LaCAChgADPPZRosAGTMAUJgACFkEGgEAyGyESkHQIzxcHVAEDvKArQCEJBKDFqPbIUtCE/FeAcwoSzAgOThcQASAOCG4FUI0GZmAHXpIrNMAGfNcDGiDeFmEEPsBeCw62MIADAoBu/BQI+sAC5iAC/+YWB4agAWygSvvgDjSgaXtAEGggouBAEDRAEORgCGgAcf0gCUpgEobQAeagK6JpeBkBA6YAALrCD3SgE7yCCUpgAhgXqeC1ZEWgSHDAE37JOQ1AbmPAUDO3adVABDoYBzqgA9jqAroiFIBAFAbBBvaADlYBA1KhVkHhDjiAK2ABEwJACbhikPoTB5agE+4AcT2AS2aBcYO1XxdhDqAAEChgAkQOBxghFShBPgdYIE9IajkZlM3CEyxBKgnBCz/B1LgCCOAgArZNDVZvEdwTDpwTAmygAShYAHYNEIDAFEG4B2KgSrkiaeAA1egADrImECggADogBgghBIAgBEZ0E/92sg8kAAO+VgWG+A88wA72YALg4BQMIBGgYATW2F/fowEsIAA0oA46YNv+TgHamCv8oAQCoCuGAAbseYXhQAW2uAemwHpxQA8CoBKmxw8KAItxAAgE4UcVQQEmgCsaYP26YhIC4AKQFwc4ABMQgCuEh3JjoBMkUw2GiVlkoBOmBwfKKJC5QhVkgQXm+Q7qRgZkwDlxwAIqARcoN5RRCGqb5ZN3GqibhXb4ABv5GAcOIQ4CwAISzlAvIAt2YNcIoQgFIAZEgAA8YNtWshVWAANmAAA84hEyQAdUYBNCQA50oA644hBkRUdxYGmYmYLRmBAmoBfkgA/soAAMQQDowAT/ZsAG4OAOPKEBHgAAvBUHJgAV+MAGPGATVOAmDGACAkBLJaEH4OAG7oATeqAHEIHTJIECJEAF8oArEiEDIPp6AQx3uU0EZgAuVyBseoATMGAOGgACGoErwqAF5NkP8CAO+ikO+nUWLqCcuUIUQOABZIArCGEHQOAYLE4DFCCgU+wC+tUOeoESCM2GuQIaAAAS2imoeRqAv1u8QSgQRsAQqkgF5gAI7oAwkhYC8qAGZugjaaAFZsASAOGWf1QPRqAFBOELTIED4EAORCAOZkARDkEDPqEAbFgT4OAD4IArIIABCAAKesAALoEGQBYQRqAE7KwPkkcRAsEGsuAD2hoA/xhAUfFSBFI7Bi7gAkRAt0hLA+DAFExBDjSgASYHEipYAhxBDyagD1RhAghgAjghD+TgDy7hDhDAAwqHBnogDwAACDxgBjohAuzADiQgEjIBCx1g9Xyhzy6gGqJgAiYgCjhhAjAhBjgqD2QgAGgACPLgEWRABZoLAzBABBqgAjhAEwoBClBASNWgF0CgACLgTlUAF+50vEOop8/ipxcd0g2AB6TSCgQhCcLgCWwgDjygBvBgcK1UX1egATj9qC8AAUQbBxCBMBD0DhSADtQgESRAYyFqEnqgDgBgAowAolKhzpl59XBAAjqYBj4gDhJhFqD1wwYBDmwAD7bNA05nKP8zAQg25CNxwBB0oAMgCgr0QQQooJ0qYAaSdloNoQHaaQhKAA9sABI8YAJiAA6SUA1GAMkTlAAAoAIyARcUQIJxQNNRAAISIUvyQAL+wBPiILb2wBQoYap4TgBaYAc8FhE0HQAUwQ/k4PCmBw5w3QgkEwHUuA6IlSsmQAVgFdIZPbxLHuXPwg6GGAf2QBAOIKmYIA7oAANIPKD54A48wAoq4LdxgIbhIL1GMgBA1gYYQMZSWgSEUM8EYIjrIAOU83Qb4A76DFp/YPU+IQ509A/g4BAMQANCoAc0YAXM0AqAAKIQQQLAiCv4hAk6uBDo1Uk5wBDiYIvpAA8OzL4wQQP/POF6gQAAODrVS+AACM4DQGACvFsVdMAQrNIA8gAToEAqB7sObo0DGEBLuWIPoKppPWFs9EAZJgAEstu+bmDvu+I9dmEWEloSCi10U/5ZGt0sHt31XZ8V6kqITMsBTsGrh6ACOqAEpLUB5KAUGoAVnoATNeAJnoBOM0EOHoBY/+AB0DgOCqCmIQxWCUEORuAUTKHiA8BPecAQVk8Pll0DUI0C9nAAuAKwOQEOGgYOjDwAEoEW2ngkN4EGJsARegAAIkACAEKTJg84LFzAgUNCiwk4/FywQgEBwhh4MCiJ0MMPBUU4CmWYAQEhnAAzFuFoUKlDDRx2MjDRhHBXgB8S/zIhpOCkz0k6Vvo4whFIhQqOCO+oyKVnViGEOKBQCsQ0qtSpVKtavYo169QEWqu6SaImrNixZMuaPYs2rdq1bNu6fYvWipF2aq6RIUIAAJk6YeGVyEIh7LgDMdQUs3HnwrN5yYY4c0AsmbFizD4ACOthwYhnYaNF3qSGzwIVYYutKyG2zgENYSk4ECEWhIIATcImcxAAWd0gzNQNU7NpxJkZY9SQGKHgjponIjDYaMJPhbEOHdTQkMLtgoghWEYFMaZm2Bk6Qc5sklGjw5kvAMD1GcWB3ohvKDQwo6bGrw0hYJypATeMOs4MEkBY6nBgTBASPCOdGmdwsQI8E6Aglv8FIxQGV4YabmgWV11N9RWHIo5IYokmptUEGitskwEXJ0xzwAdnyNCHOi2EEFYMDxQGTwY2kHPGNVwE4EwQN4xgzDdckDEMX2o4w0AAxaghQQnVqbECAQrwERYUJXCmRgij4BeWBcRIGdYZRLCwTVjvqENaWFxsFpYQDBzApRodEDGCGkLcYYMNOCITQCfEQKEGMyWcE1YTxMTxmxo2jEIMDWo0oc6QxXhBhCwYLFfCCdkQgKM6g4gTxBPOzNnAlGWcEWgx8ozTAB3qFPcMABTAE1YHQSxzYrAnevhhVG64UWyyyi7LbLPOOmvFDILYMMEnATgQhwpQRKKKJhgooBP/DhHAcQlCl5SAhyWhxFBBHnKEUgEcmZAywQgi2HGIBLXIYROBYTSAkAYMGIAQDTp0wFQjI0iEUBh42IEQLzTEoQdT0jLlhwNQMGUBHivhoEIJNDDVgyAWIBRCDIkghEgccfiBkGoRIGTKDHKsjMMpJfDBUhm49EIBQp9sUUQeONwiCBAIScLBK51AhcMPF6hAB0KDKI2QHVQ/y3XXWBGr7LFej0122WYXOwkQJiDECh0D3IJDHeiaYAEcMfQRwxyMMPUBDCtvYoMGf+BAiA0Q3MEBLDEAAYAHv1DSQA0ZBFJBBkq0MoMCRusBxwxwkIIQBFkwhBAeLTzCVAAlQIwD/yA64MGUInjwjJAHc7AeQwYVI9QAHEx5cAdTjIBwEEJKBLBH6kMwZcIoJuHAwwG9MGXJA3EcgwMvEqzA1C9MAIwQLSPIEkxDEhzC1B69oH92+8uCnazY7s9Pf/1j+4EG1kYcYIgJKsjRClLkgQmGmMMqLvCBHjAFEngAwMoUYQg8wAwIJXiFAkMhB0rAgRaQ0EAhUBEDS3SganYAAAEYVoERPIB2ejBECWCCAyDcYAaEmIgCCIKQETgPIRLAQFTgYIOsyQEAjUBIIubAgdjNAXUIwcDzcEABEewNKIYIGkIm4QDS6UElTMmFCirAFFjEAXyzGERUGqAC1tlvjVtplv/82AjHOMqxKpt4Ag48MQNs7cAUtyiDA2pRhpkhhBAfiIMkcPCHFiAMB6FIgiFY14AsIMwONsDDHGrYARUkpABWuMNSRACEMMQAIQCAgwZQgQNSiCAEGjgBDlYQgADMoYiWOMABPiYC3yHkELhBiKRE4EocKCIOkUidA5KHA0QIgn04UJ1NWII8jMnhYxQgQDEREog5tIIpgdjORHCIgy0abY5whF+x3kjOdKpzjZP4wSmsgBBPeCERnghAuFbBgBIYEAGGICJCbMAEklWBdApJIg5MEIBVUGJ5SYMAHliRC0wsogKG8MQlMKEJFJixB4PIhAYosIk4LMIREjCCHIz/9ocAYAB0OOhAAHoAEw9IoAcS4J0hzIgDNYBABLTrwSg+lokROABnh7DBUnw5gnANwAnjxAENMBEFptBAAcsLhBbUwJQQXAAR67SfOT+Ezq6Kdaz0i8AotlAKEEAhAnhwgAeekAE4HKIPGYyAKKIgAgLA4ZAhwANXw6kCQUCiYSMYwScQooBUSOCwOCCADS5QsU2oAAHB4wUcdjGBAIhLAidAgCXosJKi/oECqODDHYbwhx44wg7OqYRJevAJIaQiewGIwclwQIcJWOCQzcTDbBHCgRJIBBE9AMEdWAoEEVwTB71ogU4sgDWE9CC6ZD3bV7sS1upqd7vP0sINAuCF/3jCApsBMIQDLCCEHYyACRGYhAo60QcJ2EAUTBHBDJjiiQNoNmB4qBpCeOAAgiFEBQAQ8BM6MIO1WQIOcVDgLBhCB6Uh4gKdGGUo8rCCPjRAEXOIxCHqYAdK9oEPGkBEHn5yAUI8QhUdmUEYRuDKR3RABKNsgAc+MQfuIaAHHkABfXGAixH0gBRDEHA467A87pbtulrJrpKfDGWsTGKKU8lFGAaLgydowY44uMQCVgOJPKhiERCI609wwIgR3BYH1TsqI0uwTYQEIANT3AMeVBCKicygXBbYQiQicFQ4MMCgPejEBaAyAADYYJwa0CBB4MCHKPhwD7JwRB4IcoqD0P/ABlYwAQRsQDA4LM8GFDBFB3g2BBUAYQJ5WMVfcVCDO8Asyl1jclacTOtc63pZk/gEK6KmABuEwRIeuMAhG1CGOrC0BwwYpyN64AAM/KQQI1hkQ0QQLiDrkhUMtiIOBmCIweEAEi3Q5SYckIFZbwIEgpgEDgSwBQlglRUiQAVkcfCJC2RiAABThAJEsLJe1EAJGjBJB4oZgwl4IgyvuEMREQKEje3aWbbGCq4njvGMX2USEbBAni/hgDmgAg5PAAAmEAAHQYQBAJ3YwhwAYAX5YiAAGvDAwwEBgI9JwgGCeGYYBFFDhECiAzi7RYPjuQPwIWQCI8OBFwDgXxx0bhb/CNlDAFAQgZXdYgZN/wTwmt4DBHDiAhzpADaaqoc7RFXjyqr4VS7O9rjLfYF4gEPyLJGBDNQCnk84UgzczYoh0gIHIfAhDoZwijos4hEXCBRO6QAAlsZNBLz1wwxwagc5hAQhyhiB5OVAFOgFgMpamAH3khkBQCBEF5M6vSXmEIc6IOQLZUAmDpTQAajNXStutwrcdw98jJsiz/iNSiJMIRVdIMTyEFjFHCygAhHgYQaTAMRjNQEETHzMDgEAAAwjYIgLgK4CgigFUzDwgNPjQA7qD4QgEbKEETCRDrLYHQ5mMAM6tIITls8CDimgAkx0EhigRsFnFb3nFchigAvI/4Ba0QBx4AAzwwpGEAZHdQkzMAosAAQ2gDp0UAc0IAGtoAZw4AGQcAegUAcREANG4wcZMAA4hXNghBA1gAG8RXgtcE0A4ABuNgFQYAE0oAK7UAtM8FdzMApHJQwxsHkNSBUISBW/x4RRCHxWgFVVMQm3JQgaEAgYwDO0IAIdkGQaAB9sFgCocAej1AM18AgBoALZlkkshhB5sACRFwlwQIJMAQU9sDK/IAxLIAE/wQkjgCcI8QdwoH5SyBROCCIKiIiN6IhU4QUZEAAhwBRLQIkRUy4IAQsBAAeq5wk2gAkj4AeKgAqPAH1/4AH0pQkdYAWfsGqXkAs/8DEXYGxMwf8BI4AKs1AJwGACWNMDafSICKGIUgGFwWiMwXcJ49UVdkBliqAFlvBPhmADXDUElbALPWBQl4AzQmADGCAHDTAAu2BEcuAAr/AKpNMBJ8AJuOBtjziMxsKIxyiP81gst/ADRMELAQA5CBEFZ4YQwEAAO4ADv3AB9CUBAWAFVvALzDMKr/B+wfiOTFGM9EiRFckUvACNBfNE5pI6pXAEuBB6TBEKO8AEniCPEYkQE2mRK8mSVgELTFAG8NSSwuhG8TiTN4mTVrGQOImSOKCSOQmUQUmPPfmTQmmURymFRAkWwsKUTemUTwmVUSmVU0mVVTmVSmmVWamVW8mVXemVXwn/lm9BlDaJlGVplo04lmeplmvJhGnJlm8Jl3HnlnFJl3UZZXNpl3mpl2KFl3vpl3/JRn0JmINJmEtWk4WJmIlZa4epmI3pmB8imNWlBsdCmZRJAo+JmQYYmWQ1mcfiA7FgmZkpmnO3mdtFAm8wmqlJmoxJa6epmq+pcaWpXa4Jm7Wpa7JZXbRpm7v5ZLhJVrrJm8FZXb45VsApnMe5TsQpVsaJnM0pR8rZVczpnNPpVawZZdJJndnZPtC5Ttipnd85NtypTt4JnuVJcW60lGdhf9GJmvOjB2EJn/Epn/NJn2KBlWixnt3Znu7znvXpn/8JoAFqIuKJELgQCwkQC1og/xUp8AYN+gZJ0BWu0KBLowVvcJlMQZ7mqaHJQqBqgKAkcKBViBAkkAD70KAQShUkgFXGgRC2kABacEgu6gpRkaEbaqNZQaA5kAAQmgQJkAM0mgC2oKJT8QZBWqJukAA7KglakABTgAMpkAA+IBU1eqNV2oTWiV0JgCxIGo8kmqQ+KhVFqgVIaqEHigOusA8J4Ao9eqEYup9WCqc4iqVNpqU+WadM4QpY5aVhyhUkiixFihA+4KOxEAtTQaVxCqcEigRNKgxTkABI4JMwSgIpgAMkug+8EBWA6qc4AKiV+qVkeaiIWqUEigMuWqS2IIyoiaRfqqCZ2qd12qk4cKAJIP+ibiqqt3qlzFKUCOEKY6oFMxqpktCrx0KpUjGmOeUGl3msI+oGMGqob6pOxlGrY7OsyVKtb+esuDqcc6pkoRqeX+ohgpqkUsqpCXCZJAqtWfGgCJEE6aoVsbqgb9Cq66qt26qrZNmt7ko/SUqZTxqkpZoAlFqk55oAqEkCB3uwUqEGOdCsxQClQuoKKXChk0oCbpACrpADP/qkFyqx5YoQSHAsv4oDOuoD51qsC2uxCCGxC5sDwFqv9UOqc+StXsOvLWunWwqrPkoCOoqa4Ao2JLAPsfAG++AGRZqkp+khJZqk++CiOYsQgNqpBWuqOACuVIuaKRC0LqqgRZqmBfv/stV5r7o2s11jogcaC67ApTdbruC6n4KarXZasmFhtU+btLawpi/qCl7bqVDrISkAsma6qXMrqFhFqOWqBq5gpl+7r9zKXWM7Ni5asXWatkWaAzvrtUv6olIhoaw6tx47t0h6mXrrIXz7pEGbBIB7p6JLt54Lr4prXYxrmvrqPimQBCSgBWmqBg8LsAJrrp6KmkxKrlGBBJDKpD2LqpubqnYauqhJuUhgpoCKpEjgCi7qqUkwo17LpmiKqnvbk67Le7A7m7LbPlDKuTggrlFKtwTbs1XLFDq6tLxrrlGrqr3rtYtaos/LFVi7tFyBpkk6t9P7vqzbvd77NeCbm+Lb/z6ucLAum1NDqrIkMKMKTKkIm7BRYRxtWqmX2bGVSqnGMaOT6ksaLMIhnLsXKsEczBQbvLEPTMDbacC/icAtrJ0xK0eOK8PBScNxZMM3vJs5DEc7zMO16cNsBMRB/Jr3qZ7r1Jlu8JmV6cRPDMVPPK3hJKBVbMVXjMVhgcRmkZ9ytMRRDMZhTJlT3J9ZbMZnjMZcOcRGzMaQ+cJtDMfPssZxTMdtFLZ1jMc0+8Z5zMdXMcdsJLHF2se8+cf246jjOsiEvMdixQtuMLxpKsgNzLKVmrI5xbBXlch/Wchs5KKRjKRda7T7oMBBO7T4mslxucn2g67EiLdBereRG7dTfOTKqLzIY4UETMvAyvu55rq5Sfq2s0yXqTw/OhoLSODAKUm/80sCw4u5MQzMZSnM7uOz8Qi6u2y5AfzMdRnN7UPBx9zAH9zBENzAGJzNtHzH5VzO24zO2qrO63yr7ezOiArP8ZyotUzPRjzP93yjRCm0DurP/wzQAS3QA03QBW3QB43QCa3QC83QDe3QDw3RES3RE03RFW3RAt2TF9zNG83RHe3RHw3SIS3SI03SJW3SJ43SKa3SK83SLe3SLw3TMV3S+kzTNW3TN43TOa3TO83TPe3TPw3UQS3UQ03URW3UR22bAQEAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Responses to a train of 50 stimulations at 50 Hz in a patient with Lambert-Eaton myasthenic syndrome. Note the low initial CMAP amplitude (0.3 mV) and the marked facilitation to 1.5 mV (400 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Howard JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin 1994; 12:305. Copyright &copy; 1994 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32322=[""].join("\n");
var outline_f31_36_32322=null;
var title_f31_36_32323="Sentinel lymph node sampling";
var content_f31_36_32323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Pathologic processing of sentinel lymph node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the selection of tissue sections for processing within a 1 to 2 mm thick sample of a sentinel lymph node performed in our laboratory.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32323=[""].join("\n");
var outline_f31_36_32323=null;
var title_f31_36_32324="Paraneoplastic pemphigus indirect immunofluorescence bladder";
var content_f31_36_32324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic pemphigus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Indirect immunofluorescence microscopy demonstrates deposition of IgG intercellularly and at the basement membrane zone. The substrate is murine bladder. 100X.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32324=[""].join("\n");
var outline_f31_36_32324=null;
var title_f31_36_32325="Oxymorphone: Patient drug information";
var content_f31_36_32325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxymorphone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"     see \"Oxymorphone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Opana&reg;;",
"     </li>",
"     <li>",
"      Opana&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely to make sure you do not misuse, abuse, or become addicted to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Opana&reg; ER is used to treat lasting, long-term pain. It is not for mild pain or pain that comes and goes. Swallow tablets whole. Do not chew, break, melt, or crush. Very bad effects may happen if you take or inject broken, chewed, melted, or crushed tablets. Do not take with alcohol or products that have alcohol. Very bad side effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxymorphone, morphine like drugs, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Liver disease, lung disease, or a slow-moving bowel tract.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use long-acting products for fast pain relief or on an as needed basis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10943 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-E64BEA0BEF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32325=[""].join("\n");
var outline_f31_36_32325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205317\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023433\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023435\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023434\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023439\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023440\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023442\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023437\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023438\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023443\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023444\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=related_link\">",
"      Oxymorphone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_36_32326="Social Security Disability Insurance and workers' compensation in the United States";
var content_f31_36_32326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Social Security Disability Insurance and workers' compensation in the United States",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32326/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32326/contributors\">",
"     Timothy S Carey, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32326/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32326/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32326/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32326/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/36/32326/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disabled may receive benefits through private and public programs in the United States. The main public disability programs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Social Security Disability Insurance (SSDI)",
"     </li>",
"     <li>",
"      Supplemental Social Security Insurance (SSI)",
"     </li>",
"     <li>",
"      Workers' Compensation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review conceptual and administrative issues relative to SSDI and workers' compensation. A discussion of evaluating patients for disability and worker's compensation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/21/22873?source=see_link\">",
"     \"Disability assessment and determination in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOCIAL SECURITY DISABILITY INSURANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social Security Disability Insurance (SSDI) was created in 1954 as Title II of the Social Security Act. It is administered by the Social Security Administration (SSA), which utilizes state and local agencies to process claims. The program is funded through payroll taxes paid by workers.",
"   </p>",
"   <p>",
"    SSDI is the largest disability program of the United States federal government. In 2011, 9.8 million Americans were receiving SSDI benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/1\">",
"     1",
"    </a>",
"    ]. Almost 13 percent of recipients were dependents of disabled workers. Total payments for 2011 were almost $130 billion and are continuing to rise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/2\">",
"     2",
"    </a>",
"    ]. Over 4.6 percent of US adults aged 18 to 64 receive SSDI. The monthly benefit is determined by the number of years worked, can be determined by an online benefit calculator, and is about $1200 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/3\">",
"     3",
"    </a>",
"    ]. Unlike worker's compensation, no provision is made to recognize \"partial disability.\" The clinical characteristics of individuals qualifying for SSDI have changed over time, with rapid growth in the proportion of patients with disability due to musculoskeletal conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Eligibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disability for the SSDI program is defined as the \"inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment&hellip;which can be expected to result in death or which [has] lasted, or can be expected to last, for a continuous period of not less than 12 months\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/4\">",
"     4",
"    </a>",
"    ]. In order to receive benefits an individual must be found disabled and also meet eligibility criteria.",
"   </p>",
"   <p>",
"    Eligibility status is based upon the number of work credits, which are determined by the length of time employed and the amount of wages earned. The number of accumulated work credits needed to qualify for benefits increases with age. Some dependents of disabled workers are also eligible for benefits, including children under age 18 and spouses of disabled workers who are over age 62 or are caring for children (under age 16) of the disabled worker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/5\">",
"     5",
"    </a>",
"    ]. SSA eligibility information for the public can be accessed by phone (1-800-772-1213) or online at",
"    <a class=\"external\" href=\"file://www.ssa.gov/\">",
"     www.ssa.gov",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recipients of SSDI can begin receiving payments after a six month \"grace period\" from when the disability was judged to have begun [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/5\">",
"     5",
"    </a>",
"    ]. Payments continue as long as the recipient meets eligibility requirements (eg, he or she is unable to earn in excess of about $1000 per month). The individual becomes eligible for Medicare benefits once disabled for two years under SSDI. The consequence of this gap is that about 25 percent of individuals who receive SSDI may be completely uninsured for two years prior to Medicare coverage, leading to significant problems with access to care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Disability programs provide a partial safety net for the lack of universal health insurance in the US. A pilot Social Security Administration program to implement health insurance earlier after disability is determined led to substantially improved access to care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A disabled worker whose condition improves is allowed and encouraged to attempt to reenter the workforce and will not lose benefits if the attempt is unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/9\">",
"     9",
"    </a>",
"    ]. Medicare coverage is continued for up to 39 months for those who attempt to return to work. Multiple trials (\"ticket to work\") are underway to add various incentives to encourage return to work for disabled individuals. Although evaluation of these programs is ongoing, early indications are that once disability is established, the vast majority of SSDI beneficiaries remain out of the work force [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/10\">",
"     10",
"    </a>",
"    ]. Over the past decade, SSDI disability awards for musculoskeletal impairments and mental illness have risen, with awards for malignancies and cardiovascular disease stable or dropping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/1\">",
"     1",
"    </a>",
"    ]. Musculoskeletal disease is now the most common reason for permanent disability. More intensive supported employment interventions have shown promise in small trials but have not yet been widely implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/11\">",
"     11",
"    </a>",
"    ]. The increased access to insurance planned through the Affordable Care Act of 2010 (ACA) may take some of the pressure off the SSDI program through availability of subsidized insurance of lower socioeconomic individuals with chronic illness, but many of the insurance changes will not take place until 2014.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Disability determination process",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of disability determination for SSDI begins with the claimant filing at his or her local Social Security office or online. The initial disability determination ideally takes 60 to 90 days. The process is lengthy and complex, and backlogs in applications mean that over a year may pass to reach even an initial determination, so counseling patients at the outset regarding the steps in the application is needed. Application should be made as soon as the worker becomes disabled. Most disability claims are initiated by the patient based upon self-recognition of a potential disabling condition. Physicians can help patients identify disabling conditions and encourage application. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/21/22873?source=see_link\">",
"     \"Disability assessment and determination in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical evidence of impairment is sought once eligibility is confirmed. The state-based Disability Determination Service (DDS) agency gathers the evidence needed to evaluate the claim. Records of previous clinic and hospital visits will be requested. Medical evaluation will either be requested from the treating physician or purchased by the DDS in the form of a consultative examination provided by a physician who contracts with the SSA. A physician&rsquo;s guide is available from the SSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SSA prefers information from the treating physician since it is felt that the data obtained in the context of a longer treatment relationship may be more useful and accurate, although there is no direct evidence to support this supposition. One study surveyed consultative physicians in North Carolina and compared them with a specialty-matched comparison group of practicing physicians who did not contract with SSDI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/13\">",
"     13",
"    </a>",
"    ]. The two groups were demographically similar. Knowledge of the workings of the SSDI system was not different between the groups, although the attitudes toward working with the SSDI program were more positive among the consultative physicians. The practicing physicians had a higher certainty of patients' disability than did physicians employed by SSA.",
"   </p>",
"   <p>",
"    The Social Security disability system defines two categories: \"disabled\" and \"not disabled\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/14\">",
"     14",
"    </a>",
"    ]. Physicians are not required or expected to determine whether the patient is disabled. Instead, they provide a written medical report giving an impairment rating.",
"   </p>",
"   <p>",
"    The DDS uses information about the severity and number of impairments combined with information on functional status to estimate what has been termed the patient's functional residual capacity (FRC), a net measurement of the ability to work. The FRC is then factored together with information about the local economy and the applicant's chances of finding alternative employment to make the determination of disability. FRC has not been fully assessed for validity. The ability of a clinician in an office visit to assess functioning and stamina in a work environment is limited. While this assessment is perhaps better than the ability of an administrative law judge in a hearing to assess stamina, clinicians should recognize the limits of their abilities.",
"   </p>",
"   <p>",
"    The initial disability determination is based upon review by a board consisting of medical and nonmedical agency personnel. Over one-third of applications are approved at this initial stage (",
"    <a class=\"graphic graphic_figure graphicRef67645 \" href=\"mobipreview.htm?9/41/9887\">",
"     figure 1",
"    </a>",
"    ). Applicants have 60 days to appeal the decision. The decision is reconsidered by another administrative panel within the same agency on appeal; few (10 to15 percent) of the appealed claims are reversed at this stage. Patients denied at reconsideration may further appeal the decision to the Administrative Law Judge, who is able to consider additional information regarding the claimed disability, including additional medical information. The applicant can also be represented by legal counsel at this phase. Over half of all claims appealed at this level are reversed in favor of the applicant. If denied, the applicant can appeal decisions through the Social Security Appeals Council and on to Federal court; few appeals (2 percent) are reversed at these levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/15\">",
"     15",
"    </a>",
"    ]. Applications for disability benefits have been rising and the overall rate of successful application has been declining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     WORKERS' COMPENSATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The workers' compensation program is designed to pay the medical expenses of workers who experience an injury or develop an illness arising out of gainful employment. The system also provides cash payments of a portion of the worker's income during the period of disability. Workers who are partially disabled may obtain long-term payments of the appropriate portion of their salary. Three types of disability payments are possible:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temporary total disability",
"     </li>",
"     <li>",
"      Permanent total disability",
"     </li>",
"     <li>",
"      Permanent partial disability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some individuals injured at work may not lose time on the job; the program will pay for medical expenses from the occupational injury or illness in this instance.",
"   </p>",
"   <p>",
"    The workers' compensation system is a twentieth century construct. Prior to that time, American workers injured on the job had to sue their employers through the tort system. This civil litigation was very expensive and perceived as hindering access of workers to both health care and redress for injury on the job. The tort action required the injured worker to prove in court that the employer was negligent in the job situation. Demonstrating cause could be difficult since the employer often claimed that the worker was at least partially responsible for the injury. As an example, if a worker lost a hand during employment as a drill press operator, was the injury related to the workers' lack of attention during the job or to the employers' failure to install a guard on the drill press?",
"   </p>",
"   <p>",
"    The complexity of the tort system and the difficulty and expense of obtaining legal representation for such claims led to the reform movement in the early twentieth century. These reforms were based upon the social democratic movement of Prussia and Western Europe in the late nineteenth century. State-based workers' compensation legislation occurred in all states before 1950.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Determining causality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Workers' compensation is a no-fault system; the early compensation statutes stipulated that workers be indemnified even if they were negligent in their employment duties. Indemnification is contingent upon the work-relatedness of the injury. Causality is in little dispute in the case of obvious, acute trauma occurring at work (eg, the worker falls on the job and sustains a fracture). However, it can be much more difficult to determine causality in those with occupational illness and more subtle musculoskeletal problems which have substantially increased in frequency as a basis for workers' compensation claims.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contact dermatitis may occur as the result of chemical exposure at work, but can also occur due to exposure to cleaning chemicals or cosmetics at home.",
"     </li>",
"     <li>",
"      Back pain may occur as the result of a discrete traumatic precipitant on the job, but may also occur in association with usual daily activities both on the job and at home.",
"     </li>",
"     <li>",
"      No diagnostic test can separate occupationally acquired wrist pain due to carpal tunnel syndrome from that occurring due to idiopathic causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Epidemiology is better adapted to addressing causality in populations than in individuals. In the face of such uncertainty, a structure has been developed to determine whether the injury or illness is related to employment and the extent of the resulting disability, rather than to assess liability. However, even with the issue of liability and negligence removed from the workers' compensation arena, determining the work-relatedness of non-work-specific illnesses may be quite contentious. Case law varies from state to state. \"Cause\" in civil courts is usually interpreted as \"more likely than not,\" or a 51 percent probability. Thus, the worker may still qualify even when the physician is uncertain of the work-relatedness of the illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Whole person concept",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overriding paradigm of workers' compensation is the \"whole person\" concept. An individual may have suffered a permanent loss of function, but is still able to pursue some employment. As an example, the individual with a mangled hand due to a drill-press injury would be able to perform some tasks in the workforce, but would not be able to return to work as a drill-press operator. He would receive compensation commensurate with the severity of his impairment. An individual who is completely unable to perform any gainful activity for pay is rendered 100 percent disabled. Using the whole person concept, partial disability can be apportioned.",
"   </p>",
"   <p>",
"    This availability of partial disability is an advantage in the compensation system and an important difference between workers' compensation and SSDI. The latter is an all or none situation; the patient is either completely disabled or not disabled.",
"   </p>",
"   <p>",
"    The whole person concept has intuitive appeal and some empiric validation when applied to extremity injuries. If a digit is severed or rendered useless, that functional capacity is lost. The amount of functional capacity lost will be proportional to the number of digits lost or the amount of weakness in the extremity. Industrial injuries of the early twentieth century were often associated with amputation or other catastrophic injury; this probably led to the popularity of the whole person concept.",
"   </p>",
"   <p>",
"    Some nonanatomic problems also can be addressed by this paradigm. As an example, occupationally-induced restrictive lung disease can be quantified by the forced vital capacity and diffusion capacity. However, while the results are ordinal (an FVC of 60 percent is worse than an FVC of 80 percent), the impact of such reductions upon functioning is not linear.",
"   </p>",
"   <p>",
"    The whole person concept becomes particularly problematic when applied to clinical conditions such as chronic back pain or dermatitis. The response of the compensation system to these difficult issues is to quantify them as much as possible. However, the type of impairment generated by back problems is qualitatively different from extremity injury. The impairment is global, persistent pain is a prominent characteristic, and quantification of the impairment is quite difficult.",
"   </p>",
"   <p>",
"    Despite these difficulties, the American Medical Association (AMA) impairment rating guide provides a detailed impairment rating for the back [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/16\">",
"     16",
"    </a>",
"    ]. Physicians who are performing impairment rating for workers' compensation boards need to be very familiar with this type of rating system. The focus of the AMA rating guide is upon the measurable. Range of motion is addressed in detail and in multiple axes; reliable measurement of range of motion is possible only with practice and with the use of an inclinometer. Most workers' compensation programs use the AMA guides or very similar systems. The AMA guide may be purchased from the AMA:",
"    <a class=\"external\" href=\"file://www.ama-assn.org/\">",
"     www.ama-assn.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    States vary considerably in the level of patient choice of provider in workers' compensation situations and in the amount of care management involved. In some states the employee has free choice of provider, in others the employer directs the employee to certain providers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Factors affecting workers' compensation claims",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors appear to affect the initiation of a workers' compensation claim and the persistence of work disability:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of job control and fear of layoff [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Monotony and job dissatisfaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unsatisfactory employee appraisal rating by supervisor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Distress and dissatisfaction with coworkers or bosses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Poor coping strategies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Divorce, low income, less education [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Compensation benefits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While job and social stressors may somewhat influence workers' likelihood of claiming that their injury is work-related, clinicians should not assume that patients seeking compensation for work-related injuries are malingering. The vast majority of compensation claims involve no or minimal time off from work and are resolved without litigation.",
"   </p>",
"   <p>",
"    Long-duration compensation claims are associated with high health care costs. In two studies, outcomes were poor for invasive procedures for back pain in the workers&rsquo; compensation population in two states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32326/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early return to employment is helpful in minimizing disability costs. Early return may require that the employer is willing to modify the job situation for the employee and that the physician communicates with the employer. Keeping workers identified with their job so that they remain employees and do not assume the role of claimants also appears to be a key factor in reducing the direct and indirect costs of work disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H672223093\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Social Security Disability Insurance (SSDI) is the largest disability program of the United States federal government. Disability for the SSDI program is defined as the \"inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment&hellip;which can be expected to result in death or which [has] lasted, or can be expected to last, for a continuous period of not less than 12 months.\" Unlike worker's compensation, no provision is made to recognize \"partial disability.\" (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Social Security Disability Insurance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical evidence of impairment is sought once eligibility is confirmed. The Social Security Administration (SSA) prefers information from the treating physician rather than from a physician contracted by the administration. Physicians are not required or expected to determine whether the patient is disabled. Instead, they provide a written medical report giving an impairment rating. Information about the severity and number of impairments combined with information on functional status is used to estimate the patient's functional residual capacity (FRC), a net measurement of the ability to work. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Disability determination process'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The workers' compensation program, managed by state governments, is designed to pay the medical expenses of workers who experience an injury or develop an illness arising out of gainful employment. Disability may be deemed temporary, permanent and total, or permanent and partial. Determining whether an injury resulted from employment can be challenging. AMA guides can be useful in determining an impairment rating for worker&rsquo;s compensation, using quantifiable parameters to determine the extent of disability. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Workers' compensation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early return to work often requires that the employer is willing to modify the job situation for the employee and that the physician communicates with the employer. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Factors affecting workers' compensation claims'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Annual statistical report on the Social Security Disability Insurance Program, 2011. Office of Policy; Office of Research, Evaluation, and Statistics; Social Security Administration.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/2\">",
"      Autor DH, Duggan MG. The growth in the Social Security Disability rolls: a fiscal crisis unfolding. J Econ Perspect 2006; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     Social Security Administration. Social Security Administration Home Page. Available at: www.ssa.gov (Accessed on March 24, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/4\">",
"      Hadler NM. Medical ramifications of the federal regulation of the Social Security Disability Insurance program: Social Security and medicine. Ann Intern Med 1982; 96:665.",
"     </a>",
"    </li>",
"    <li>",
"     Social Security Administration. Social Security Disability Benefits. Social Security Administration, Washington, DC 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/6\">",
"      Short PF, Weaver FM. Transitioning to Medicare before age sixty-five. Health Aff (Millwood) 2008; 27:w175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/7\">",
"      Livermore GA, Stapleton DC, Claypool H. Health care when workers need it most: before and after entry into the Social Security Disability Insurance Program. Inquiry 2010; 47:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/8\">",
"      Michalopoulos C, Wittenburg D, Israel DA, Warren A. The effects of health care benefits on health care use and health: a randomized trial for disability insurance beneficiaries. Med Care 2012; 50:764.",
"     </a>",
"    </li>",
"    <li>",
"     Social Security Administration. How we can help with vocational rehabilitation. Social Security Administration, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/10\">",
"      Livermore GA, Roche A. Longitudinal outcomes of an early cohort of Ticket to Work participants. Soc Secur Bull 2011; 71:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/11\">",
"      Bond GR, Xie H, Drake RE. Can SSDI and SSI beneficiaries with mental illness benefit from evidence-based supported employment? Psychiatr Serv 2007; 58:1412.",
"     </a>",
"    </li>",
"    <li>",
"     Social Security Administration. Disability Evaluation Under Social Security. US Government Printing Office, Washington, DC 2006. Available at: www.socialsecurity.gov/disability/professionals/bluebook (Accessed on March 24, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/13\">",
"      Carey TS, Hadler NM, Gillings D, et al. Medical disability assessment of the back pain patient for the Social Security Administration: the weighting of presenting clinical features. J Clin Epidemiol 1988; 41:691.",
"     </a>",
"    </li>",
"    <li>",
"     Social Security Administration. Disability evaluation under Social Security. US Department of Health and Human Services, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/15\">",
"      Carey TS, Hadler NM. The role of the primary physician in disability determination for Social Security insurance and workers' compensation. Ann Intern Med 1986; 104:706.",
"     </a>",
"    </li>",
"    <li>",
"     Guides to the Evaluation of Permanent Impairment, 6th ed, American Medical Association, Chicago 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/17\">",
"      H&auml;rk&auml;p&auml;&auml; K. Psychosocial factors as predictors for early retirement in patients with chronic low back pain. J Psychosom Res 1992; 36:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/18\">",
"      Bigos SJ, Batti&eacute; MC, Spengler DM, et al. A prospective study of work perceptions and psychosocial factors affecting the report of back injury. Spine (Phila Pa 1976) 1991; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/19\">",
"      Linton SJ, Warg LE. Attributions (beliefs) and job satisfaction associated with back pain in an industrial setting. Percept Mot Skills 1993; 76:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/20\">",
"      Bigos SJ, Batti&eacute; MC, Fisher LD. Methodology for evaluating predictive factors for the report of back injury. Spine (Phila Pa 1976) 1991; 16:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/21\">",
"      Millard RW, Jones RH. Construct validity of practical questionnaires for assessing disability of low-back pain. Spine (Phila Pa 1976) 1991; 16:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/22\">",
"      Swimmer GI, Robinson ME, Geisser ME. Relationship of MMPI cluster type, pain coping strategy, and treatment outcome. Clin J Pain 1992; 8:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/23\">",
"      Deyo RA, Tsui-Wu YJ. Functional disability due to back pain. A population-based study indicating the importance of socioeconomic factors. Arthritis Rheum 1987; 30:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/24\">",
"      Jacobsson L, Lindg&auml;rde F, Manthorpe R, Ohlsson K. Effect of education, occupation and some lifestyle factors on common rheumatic complaints in a Swedish group aged 50-70 years. Ann Rheum Dis 1992; 51:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/25\">",
"      Volinn E, Van Koevering D, Loeser JD. Back sprain in industry. The role of socioeconomic factors in chronicity. Spine (Phila Pa 1976) 1991; 16:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/26\">",
"      Jamison RN, Matt DA, Parris WC. Treatment outcome in low back pain patients: do compensation benefits make a difference? Orthop Rev 1988; 17:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/27\">",
"      Nguyen TH, Randolph DC, Talmage J, et al. Long-term outcomes of lumbar fusion among workers' compensation subjects: a historical cohort study. Spine (Phila Pa 1976) 2011; 36:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32326/abstract/28\">",
"      Turner JA, Hollingworth W, Comstock BA, Deyo RA. Spinal cord stimulation for failed back surgery syndrome: outcomes in a workers' compensation setting. Pain 2010; 148:14.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2748 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-1E93B43961-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32326=[""].join("\n");
var outline_f31_36_32326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H672223093\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOCIAL SECURITY DISABILITY INSURANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Eligibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Disability determination process",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      WORKERS' COMPENSATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Determining causality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Whole person concept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Factors affecting workers' compensation claims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H672223093\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2748|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/41/9887\" title=\"figure 1\">",
"      SSDI application appeal process",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/21/22873?source=related_link\">",
"      Disability assessment and determination in the United States",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_36_32327="Psychotherapy for social anxiety disorder";
var content_f31_36_32327=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychotherapy for social anxiety disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32327/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32327/contributors\">",
"     Stefan G Hofmann, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32327/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32327/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32327/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32327/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/36/32327/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17620086\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social anxiety disorder (SAD) or social phobia is a mental disorder characterized by an intense fear of negative evaluation from others in social",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    performance situations. In severe cases, the disorder can follow a chronic, unremitting course, leading to substantial impairments in the affected individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with SAD who fear most or all social situations are described as having generalized SAD. Some people only experience symptoms in certain social performance situations, such as public speaking. This is given the subtype of nongeneralized SAD in DSM-IV-TR.",
"   </p>",
"   <p>",
"    Cognitive behavioral therapy (CBT) has been found to be an efficacious treatment for SAD. Clinical trials have also tested the efficacy of interpersonal psychotherapy for the disorder.",
"   </p>",
"   <p>",
"    This topic addresses psychotherapy for SAD. The epidemiology, pathogenesis, clinical manifestations, diagnosis, and pharmacotherapy for the disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27416?source=see_link\">",
"     \"Pharmacotherapy for social anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17620093\">",
"    <span class=\"h1\">",
"     THEORETICAL FOUNDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely studied of contemporary psychological theories of social anxiety disorder (SAD) emphasize the role of cognitive processes in the generation and maintenance of social anxiety disorder in vulnerable people upon entry into, or anticipation of, a social situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. These models are the bases for cognitive behavioral therapies (CBT) for SAD.",
"   </p>",
"   <p>",
"    An interpersonal model posits that SAD is primarily maintained by impaired and restricted interpersonal relations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. This model is the basis for interpersonal psychotherapy (IPT) for SAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17620100\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral models",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of cognitive models have been proposed to explain pathologic thought processes in SAD.",
"   </p>",
"   <p>",
"    One widely regarded cognitive-behavioral model assumes that individuals with social anxiety disorder (SAD) believe they are in danger of behaving in an inept and unacceptable fashion, and such behavior would have disastrous consequences in terms of loss of status, loss of worth, and interpersonal rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/4\">",
"     4",
"    </a>",
"    ]. When exposed to situations that might put them in such danger, they become increasingly vigilant for cues that would signal the realization of their fears. They closely attend to sources of potential negative scrutiny and environmental cues. As an example, a person with SAD who is asked to give a speech in front of people might scan the audience members for negative reactions to their speech. They maintain a negative view of how they appear to others and pay close attention to cognitive, behavioral, and affective cues related to the severity of their anxiety in the moment.",
"   </p>",
"   <p>",
"    Another model proposes several psychopathological processes that prevent individuals with SAD from disproving their maladaptive beliefs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When individuals with SAD enter a social situation, they shift their attention to detailed monitoring and observation of themselves. This attentional shift produces an enhanced awareness of feared anxiety responses (eg, increase in heart rate and hot flushes) and interferes with processing their perceptions of other people&rsquo;s behavior. Together with the perception of the physiological anxiety response, this information is then used to construct a negative self impression.",
"     </li>",
"     <li>",
"      Individuals with SAD engage in behaviors to reduce the risk of rejection and provide a sense of safety (eg, wearing dark clothes or a turtle neck to hide facial blushing). Such safety behaviors are subtle avoidance strategies that give the patient a sense of safety in fearful social situations. These behaviors might lead to a short-term decrease in anxiety. However, they contribute to the long-term maintenance of the problem because they prevent individuals with SAD from critically evaluating the outcomes they fear (eg, shaking uncontrollably) and other catastrophic beliefs.",
"     </li>",
"     <li>",
"      They show an anxiety-induced deficit in performance and overestimate how negatively other people evaluate their performance.",
"     </li>",
"     <li>",
"      Before and after a social event, individuals with SAD think about the situation in detail and primarily focus on past failures, negative images of themselves in the situation, and predictions of poor performance and rejection. These anxious feelings and negative self-perceptions are strongly encoded in memory because they are processed in such detail.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third model posits that individuals with SAD are apprehensive in social situations in part because they perceive a high standard or expectations for social performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/9\">",
"     9",
"    </a>",
"    ]. They desire to make a particular impression on others but doubt that they will be able to do so, partly because they are unable to define goals or select specific, achievable behavioral strategies to reach those goals. These thoughts lead to a further increase in social apprehension and increased self-focused attention, which triggers a number of additional cognitive processes, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They exaggerate the probability of a negative outcome of a social situation and overestimate the potential social costs.",
"     </li>",
"     <li>",
"      They perceive little control over their physiologic response to anxiety in social situations.",
"     </li>",
"     <li>",
"      They hold a negative view of themselves as social objects.",
"     </li>",
"     <li>",
"      They view their social skills as very poor or inadequate to master the social task.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, the individual with SAD anticipates social mishaps and engages in avoidance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    safety behaviors followed by rumination after the event. This cycle feeds on itself, ultimately leading to the maintenance and exacerbation of the problem. In general, the three cognitive models of SAD show a considerable overlap. They primarily differ in their emphasis of certain components. Preliminary studies support the notion that changes in cognitions mediate changes in social anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ]. However, the precise mechanism through which CBT acts on symptom change is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H211196353\">",
"    <span class=\"h2\">",
"     Attentional biases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attentional biases have been proposed to contribute significantly to the etiology and maintenance of anxiety disorders, including SAD. Consistent with the cognitive model, researchers have postulated that anxiety disorders are uniquely associated with a bias in the initial stimulus registration phase of cognitive processing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/12\">",
"     12",
"    </a>",
"    ]. In anxiety disorders, attention to threatening information is rapidly and automatically deployed. Although this shift toward threatening information is evolutionarily adaptive, it becomes problematic when it leads to hypervigilance to social and environmental queues, as is proposed to occur in social anxiety",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17620107\">",
"    <span class=\"h2\">",
"     Interpersonal model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially developed as a treatment for depression, interpersonal psychotherapy (IPT) has been adapted for use in SAD and other disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. IPT is based in psychodynamic theories and assumes that SAD is primarily maintained by problems related to role dispute (a prominent conflict within an important relationship) and role transition (a major life change such as marriage, divorce, the birth of a child, graduation, or retirement) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. As a consequence of such insecurity, interpersonal models propose that people with SAD develop a number of self-protective strategies that keep others unaware of the person's wishes and feelings (eg, individuals with SAD may avoid eye contact or avoid asking open-ended questions to limit the degree of social interaction). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some self-protective strategies may make the person with SAD appear uninterested in others, which may lead others to feel rejected and subsequently to withdraw. This is called a self-perpetuating, interactional cycle, in which individuals unwittingly produce the very response they fear. Observation of their fear, avoidance, and failure to perform socially enhances patients&rsquo; role insecurity and sense of defectiveness, leading to maintenance of the problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17620114\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motivated patients with generalized SAD are generally good candidates for psychotherapy. Although SAD frequently co-occurs with other anxiety disorders, depression, and avoidant personality disorder, none of these comorbidities constitute a contraindication to psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link&amp;anchor=H180130#H180130\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Comorbidities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies suggest that different cultures (eg, certain",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    minority groups in the US) may express SAD differently, potentially requiring modification to methods for assessment and psychotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17620142\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAD is a heterogeneous diagnostic category, and individuals differ considerably in the factors that maintain the problem. Therefore, a treatment approach that is tailored to address the principal maintenance factors for each individual is likely to result in the greatest possible treatment benefits. Although it is not standard practice in contemporary therapy to tailor treatment based on the results of specific measures, clinicians are encouraged to carefully explore the core problems of each individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384601228\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384601236\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;More recent cognitive behavioral therapy (CBT) protocols for SAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] are based on earlier protocols on CBT for SAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/18\">",
"     18",
"    </a>",
"    ] and cognitive therapy for anxiety disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/12\">",
"     12",
"    </a>",
"    ]. Specific therapeutic strategies differ slightly, depending on the treatment protocol. However, common elements include psychoeducation, cognitive restructuring, and exposure practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H798361138\">",
"    <span class=\"h3\">",
"     Group and individual CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT has traditionally been administered for SAD by two therapists for a group of four to six patients in 12 weekly 2.5-hour sessions. More recent modifications of this format include individual treatment sessions lasting 60 minutes scheduled weekly for up to 15 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/19\">",
"     19",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Advantages of group CBT include the social support of the group and its utility in conducting exercises involving exposure to social situations. Individual CBT affords more therapeutic time and attention to the individual patient and allows for the targeting of specific cognitive factors that cannot be easily addressed in a group.",
"   </p>",
"   <p>",
"    The only study that has directly compared individual treatment and group therapy format for SAD showed an advantage for the individual format [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/19\">",
"     19",
"    </a>",
"    ]. However, this result may be related to the difference in the direct therapist-patient contact time, which was greater in the individual treatment format than in the group format.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H798361152\">",
"    <span class=\"h3\">",
"     CBT components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is generally designed to encourage patients to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Understand the maladaptive nature of their concerns about social situations",
"     </li>",
"     <li>",
"      Identify specific thoughts and beliefs that are associated with social situations",
"     </li>",
"     <li>",
"      Conduct exposure tasks to challenge the maladaptive thoughts and beliefs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The therapist acts as a coach, setting up the opportunities for learning and guiding accurate interpretations of current performance. As treatment progresses, longer term maintenance is promoted by helping patients become their own therapists by understanding and applying treatment strategies on their own. Such independent application of therapy skills is initiated by the therapist providing a model of the disorder.",
"   </p>",
"   <p>",
"    In the beginning sessions, patients are usually taught the CBT model as applied to SAD, and they are introduced to cognitive restructuring techniques. This includes identifying and challenging negative cognitions (maladaptive beliefs and automatic thoughts), observing the association between anxious mood and automatic thoughts, examining errors of logic, and formulating rational alternatives to these beliefs and thoughts.",
"   </p>",
"   <p>",
"    The newer generation of CBT approaches includes a number of refinements and innovations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Safety behaviors are identified and discouraged. These behaviors lead to a short-term reduction in discomfort in socially threatening situations, but can contribute to the long-term maintenance of the problem. An example is a patient who puts his or her hands in the pocket so that people cannot detect hand shaking. Despite providing a short-term reduction in anxiety, this avoidance strategy does not address underlying cognitions or effective and physiologic responses to the precipitating social situations.",
"     </li>",
"     <li>",
"      Video feedback is employed to correct distorted self-perception. As part of in-session exposure, patients are asked to predict in detail what they will see in the video and form an image of themselves in the social situation. They then watch the video from an observer&rsquo;s point of view following completion of an exposure task.",
"     </li>",
"     <li>",
"      The tendency to focus on anxiety symptoms or negative cognitions in a fearful social situation can be retrained by encouraging individuals to direct their attention toward nonfearful aspects of the situation.",
"     </li>",
"     <li>",
"      Behavioral experiments are created in which the person purposefully creates social mishaps to experience and critically evaluate undesirable consequences (eg, walking around with toilet paper hanging out of the shirt, spilling water in a restaurant, asking a random woman on a street out on a date).",
"     </li>",
"     <li>",
"      People with SAD often ruminate over perceived or actual social mishaps. This post-event rumination can be effectively targeted by helping patients process negative social events more adaptively through guided questions (eg, &ldquo;How will your life change as a result of a particular social mishap?&rdquo;).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H211196363\">",
"    <span class=\"h2\">",
"     Attention retraining",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention retraining is an intervention that modifies this attentional bias by training patients to attend to certain types of stimuli by using dot-probe detection tasks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/20\">",
"     20",
"    </a>",
"    ]. The dot-probe task involves simultaneously presenting two stimuli that vary in emotional content (eg, a threatening word and a neutral word) side-by-side on a computer screen, removing the stimuli, and then replacing one of the stimuli with a probe (ie, a neutral symbol, such as a dot or a line). The viewer is instructed to identify the presence of the probe as quickly as possible. It is assumed that participants will be faster at detecting a probe that replaces the stimulus to which the participant was attending before the probe appeared. As an example, a socially anxious viewer is typically faster at detecting a probe (eg, a dot) that replaces a threatening stimulus (eg, the word &ldquo;speech&rdquo;) than a non-threatening stimulus (eg, the word &ldquo;flower&rdquo;) because the viewer&rsquo;s initial attention is captured by the threatening stimulus.",
"   </p>",
"   <p>",
"    In attention retraining paradigms, the connection between probes and non-threatening stimuli is strengthened, whereas the connection between probes and threatening stimuli is weakened. As an example, if probes are more likely to appear after the non-threatening than after the threatening stimuli, the viewer is encouraged to pay closer attention to the non-threatening than to the threatening stimuli without the viewer&rsquo;s conscious awareness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17620172\">",
"    <span class=\"h2\">",
"     Interpersonal psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal psychotherapy (IPT) is a time-limited psychodynamically-based form of psychotherapy. Originally developed to treat grief and depression, IPT specifically targets interpersonal problems. IPT differs from CBT in several ways. Most importantly, IPT does not conceive of maladaptive cognitions as the primary target of treatment. Instead, conceiving of SAD as a medical illness, IPT focuses more on interpersonal role disputes, interpersonal deficits, and role transitions. A frequently used strategy is to encourage the patient to find ways of enlisting their partner&rsquo;s support in their attempt to overcome social anxiety and to turn them into an ally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/5,21,22\">",
"     5,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The IPT model assumes that early adverse experiences and later peer experiences influence feelings and patterns within adult relationships. The IPT therapist, therefore, addresses past interpersonal difficulties as these inform the patient&rsquo;s understanding of current problems. As an example, the IPT therapist may work with the patient on being more assertive in an upcoming visit with",
"    <span class=\"nowrap\">",
"     her/his",
"    </span>",
"    parents if the IPT therapist views the patient&rsquo;s past relationship with",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    parents to have contributed to the patient&rsquo;s present interpersonal problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17620179\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H211196372\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of randomized trials found CBT to be moderately efficacious for SAD compared to placebo control (OR = 4.21), with considerable variation in effect sizes across studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a randomized trial of 133 patients with SAD compared group CBT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    (a monoamine oxidase inhibitor used to treat SAD), a pill placebo, and an educational-supportive group therapy (serving as a psychological control intervention) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/18\">",
"     18",
"    </a>",
"    ]. After 12 weeks, a higher proportion of patients were assessed as responding to treatment in the groups receiving phenelzine (65 percent) and group CBT (58 percent) than pill placebo (33 percent) or the psychological control (27 percent).",
"   </p>",
"   <p>",
"    A randomized trial of 60 patients randomly assigned to CBT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and self-exposure, or placebo and self-exposure supported the efficacy of newer variations of CBT for SAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/16\">",
"     16",
"    </a>",
"    ]. After 16 weeks of treatment, the group receiving CBT experienced a greater reduction of social anxiety than the groups receiving",
"    <span class=\"nowrap\">",
"     fluoxetine/self-exposure",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     placebo/self-exposure.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H211196379\">",
"    <span class=\"h2\">",
"     Attention retraining",
"    </span>",
"    &nbsp;&mdash;&nbsp;The model underlying attention retraining has been supported by research studies in non-clinical samples. An example is an experiment that manipulated attention by training participants to attend to threatening words using a dot-probe task [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/24\">",
"     24",
"    </a>",
"    ]. One group of participants was trained to attend to threatening words (ie, the probes always replaced the threatening words) while the other group was trained to attend to neutral words (ie, the probe always replaced the neutral words). Post-training, the participants in the threat group exhibited faster reaction times to probes replacing new threatening words. Additionally, post-training those participants in the threat group reported higher levels of negative mood and anxiety during a stressful task than participants in the neutral group, supporting the hypothesis of a causal relationship between attentional biases toward threat and a vulnerability to anxiety.",
"   </p>",
"   <p>",
"    Several randomized trials have found attentional retraining for individuals with SAD resulted in reduced attentional bias toward threat cues and reduced SAD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Although these studies are encouraging, more research is necessary to examine this promising new intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12984674\">",
"    <span class=\"h2\">",
"     Interpersonal psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings from clinical trials of interpersonal therapy (IPT) in SAD, compared to placebo or to another psychotherapy, have been mixed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial randomized 70 patients with SAD to receive 14 weekly, individual sessions of either IPT or supportive therapy (administered as a psychological control intervention) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/8\">",
"       8",
"      </a>",
"      ]. Patients in both groups experienced a reduction in symptoms, but IPT did not result in greater improvement than supportive therapy.",
"     </li>",
"     <li>",
"      117 patients with SAD were randomly assigned to receive 16 individual sessions of either cognitive therapy (CT) or IPT, or to a wait list control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/29\">",
"       29",
"      </a>",
"      ]. After 20 weeks of treatment, the proportion of patients who responded was 65.8 percent for CT, 42.1 percent for IPT, and 7.3 percent for the wait list control. CT performed better than IPT, and both treatments were superior to participation in the control group.",
"     </li>",
"     <li>",
"      Another randomized trial, lacking a placebo control, compared IPT to CBT in 80 residential patients with SAD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/6\">",
"       6",
"      </a>",
"      ]. Patients in both groups improved on the primary outcome measures, however, no differences were observed between therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374822977\">",
"    <span class=\"h1\">",
"     COMPARING CBT AND MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing CBT to pharmacotherapy for SAD have not demonstrated superiority of one treatment over the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27416?source=see_link&amp;anchor=H13590066#H13590066\">",
"     \"Pharmacotherapy for social anxiety disorder\", section on 'Treatment selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362076628\">",
"    <span class=\"h1\">",
"     COMBINING CBT AND MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials comparing the combination of CBT and antidepressant medication for SAD to either treatment individually have shown mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. A promising approach is to enhance the effects of CBT with the partial N-methyl D-aspartate agonist d-cycloserine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27416?source=see_link&amp;anchor=H13590059#H13590059\">",
"     \"Pharmacotherapy for social anxiety disorder\", section on 'Combined psychological and pharmacological treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384601661\">",
"    <span class=\"h1\">",
"     ADDITIONAL PRINCIPLES FOR CLINICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychotherapy for SAD, as for any disorder, can only be effective if the therapeutic context and the therapeutic relationship between clinician and patient are adequate (ie, if the therapist shows the necessary empathy, warmth, and support).",
"     </li>",
"     <li>",
"      As with many other disorders, treatment is negatively affected if patients lack treatment motivation and are deficient in setting appropriate treatment goals. Motivational enhancement strategies can augment CBT techniques [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/38\">",
"       38",
"      </a>",
"      ]. Furthermore, the therapeutic process, including problem identification, goal setting, and treatment planning should be conducted within the general guidelines of CBT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other reasons for nonresponse to CBT include cognitive errors that enhance social anxiety in response to actual or imagined social threat, and avoidance strategies (such as safety behaviors) that lead to the maintenance of social anxiety. Examples of such maladaptive strategies include obvious avoidance and safety behaviors but might also include distraction techniques if they serve the purpose to lessen the anxiety experience.",
"     </li>",
"     <li>",
"      The Liebowitz Social Anxiety Scale, developed for clinical research, can be useful for monitoring the patient&rsquo;s response to treatment. It measures fear and avoidance in a variety of social situations as well as provides information about the type of feared and avoided situations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/40\">",
"       40",
"      </a>",
"      ]. The 24-item, clinician-administered instrument can be used in the development of exposure exercises and homework assignments, and to assess the results. The scale has good psychometric properties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/41\">",
"       41",
"      </a>",
"      ] and has also been administered by patient self-report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32327/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/42/20129?source=see_link\">",
"       \"Patient information: Social anxiety disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47045557\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In cognitive-behavioral models for social anxiety disorder (SAD), maladaptive beliefs are important maintaining factors that are closely associated with anxious feelings, physiologic responses, and avoidance behaviors. (See",
"      <a class=\"local\" href=\"#H17620093\">",
"       'Theoretical foundation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cognitive behavioral therapy (CBT) can vary by treatment protocol but typical components include psychoeducation, cognitive restructuring, and exposure practices. CBT is usually provided in group or individual therapy over approximately 12 weekly sessions. (See",
"      <a class=\"local\" href=\"#H384601228\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cognitive restructuring involves identifying and challenging negative maladaptive beliefs and automatic thoughts, observing the association between anxious mood and automatic thoughts, examining errors of logic, and formulating rational alternatives to these beliefs and thoughts (See",
"      <a class=\"local\" href=\"#H384601228\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In exposure, patients are confronted with feared situations and asked to examine specific expectations that arise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with generalized SAD, we recommend first-line treatment with either pharmacotherapy or CBT (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Randomized trials have found both modalities to be effective treatments for generalized SAD. Trials comparing combined treatment (pharmacotherapy and CBT) to either modality individually have not consistently shown combined treatment to be superior. This may be due to one or more reasons: a small number of trials, differences in effectiveness among the medications studied (SSRIs and MAOIs), or a small margin of benefit. Selection between pharmacotherapy and CBT should be based on patient preference and treatment availability. (See",
"      <a class=\"local\" href=\"#H362076628\">",
"       'Combining CBT and medication'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27416?source=see_link\">",
"       \"Pharmacotherapy for social anxiety disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/1\">",
"      Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. Am J Psychiatry 2000; 157:1606.",
"     </a>",
"    </li>",
"    <li>",
"     Clark, DM, Wells, A. A cognitive model of social phobia. In: Social phobia:  Diagnosis, assessment and treatment, Heimberg, RG, Liebowitz, MR, Hope, DA, &amp; Schneier, FR (Eds), Guilford Press, New York 1995. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/3\">",
"      Hofmann SG. Cognitive mediation of treatment change in social phobia. J Consult Clin Psychol 2004; 72:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/4\">",
"      Rapee RM, Heimberg RG. A cognitive-behavioral model of anxiety in social phobia. Behav Res Ther 1997; 35:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/5\">",
"      Alden LE, Taylor CT. Interpersonal processes in social phobia. Clin Psychol Rev 2004; 24:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/6\">",
"      Borge FM, Hoffart A, Sexton H, et al. Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trial. J Anxiety Disord 2008; 22:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/7\">",
"      Lipsitz JD, Markowitz JC, Cherry S, Fyer AJ. Open trial of interpersonal psychotherapy for the treatment of social phobia. Am J Psychiatry 1999; 156:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/8\">",
"      Lipsitz JD, Gur M, Vermes D, et al. A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. Depress Anxiety 2008; 25:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/9\">",
"      Hofmann SG. Cognitive factors that maintain social anxiety disorder: a comprehensive model and its treatment implications. Cogn Behav Ther 2007; 36:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/10\">",
"      Smits JA, Rosenfield D, McDonald R, Telch MJ. Cognitive mechanisms of social anxiety reduction: an examination of specificity and temporality. J Consult Clin Psychol 2006; 74:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/11\">",
"      V&ouml;gele C, Ehlers A, Meyer AH, et al. Cognitive mediation of clinical improvement after intensive exposure therapy of agoraphobia and social phobia. Depress Anxiety 2010; 27:294.",
"     </a>",
"    </li>",
"    <li>",
"     Beck, AT, Emery, G. Anxiety disorders and phobias: A cognitive perspective, Basic Books, New York 1985.",
"    </li>",
"    <li>",
"     Klerman, GL, Weissman, MM, Rounsaville, BJ, et al. Interpersonal psychotherapy of depression, Basic Books, New York 1984.",
"    </li>",
"    <li>",
"     Weissman, MM, Markowitz, JC, Klerman, GL. Comprehensive guide to interpersonal psychotherapy, Basic Books, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/15\">",
"      Tolin DF, Meunier SA, Frost RO, Steketee G. Course of compulsive hoarding and its relationship to life events. Depress Anxiety 2010; 27:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/16\">",
"      Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71:1058.",
"     </a>",
"    </li>",
"    <li>",
"     Hofmann, SG, Otto, MW. Cognitive-behavior therapy of social phobia: Evidence-based and disorder specific treatment techniques, Routledge, New York 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/18\">",
"      Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/19\">",
"      Stangier U, Heidenreich T, Peitz M, et al. Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther 2003; 41:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/20\">",
"      Posner MI, Snyder CR, Davidson BJ. Attention and the detection of signals. J Exp Psychol 1980; 109:160.",
"     </a>",
"    </li>",
"    <li>",
"     Neal, JA and, Edelmann, RJ. The etiology of social phobia: toward a developmental profile. In: Clinical Psychology Review, 23, 2003. p.761.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/22\">",
"      Davile, J, Beck, JG. Is social anxiety associated with impairment in close relationship? A preliminary investigation. Behav Ther 2002; 33:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/23\">",
"      Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008; 69:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/24\">",
"      MacLeod C, Rutherford E, Campbell L, et al. Selective attention and emotional vulnerability: assessing the causal basis of their association through the experimental manipulation of attentional bias. J Abnorm Psychol 2002; 111:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/25\">",
"      Amir N, Beard C, Taylor CT, et al. Attention training in individuals with generalized social phobia: A randomized controlled trial. J Consult Clin Psychol 2009; 77:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/26\">",
"      Amir N, Weber G, Beard C, et al. The effect of a single-session attention modification program on response to a public-speaking challenge in socially anxious individuals. J Abnorm Psychol 2008; 117:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/27\">",
"      Li S, Tan J, Qian M, Liu X. Continual training of attentional bias in social anxiety. Behav Res Ther 2008; 46:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/28\">",
"      Schmidt NB, Richey JA, Buckner JD, Timpano KR. Attention training for generalized social anxiety disorder. J Abnorm Psychol 2009; 118:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/29\">",
"      Stangier U, Schramm E, Heidenreich T, et al. Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry 2011; 68:692.",
"     </a>",
"    </li>",
"    <li>",
"     Blanco C, Heimberg RG, Schneier FR, et al. (2010) A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 67(3): 286-295.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/31\">",
"      Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/32\">",
"      Blomhoff S, Haug TT, Hellstr&ouml;m K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/33\">",
"      Falloon IR, Lloyd GG, Harpin RE. The treatment of social phobia. Real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis 1981; 169:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/34\">",
"      Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991; 148:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/35\">",
"      Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010; 67:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/36\">",
"      Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/37\">",
"      Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63:298.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, WR, and, Rollnick, S. Motivational interviewing: Preparing people to change addictive behaviors, Guilford Press, New York 1991.",
"    </li>",
"    <li>",
"     Persons, JB. The case-formulation approach to cognitive-behavioral therapy, Guilford Press, New York 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/40\">",
"      Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987; 22:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/41\">",
"      Heimberg RG, Horner KJ, Juster HR, et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999; 29:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32327/abstract/42\">",
"      Baker SL, Heinrichs N, Kim HJ, Hofmann SG. The liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis. Behav Res Ther 2002; 40:701.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14635 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32327=[""].join("\n");
var outline_f31_36_32327=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H47045557\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17620086\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17620093\">",
"      THEORETICAL FOUNDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17620100\">",
"      Cognitive-behavioral models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H211196353\">",
"      Attentional biases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17620107\">",
"      Interpersonal model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17620114\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17620142\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384601228\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H384601236\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H798361138\">",
"      - Group and individual CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H798361152\">",
"      - CBT components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H211196363\">",
"      Attention retraining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17620172\">",
"      Interpersonal psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17620179\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H211196372\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H211196379\">",
"      Attention retraining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12984674\">",
"      Interpersonal psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H374822977\">",
"      COMPARING CBT AND MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362076628\">",
"      COMBINING CBT AND MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384601661\">",
"      ADDITIONAL PRINCIPLES FOR CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47045557\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/42/20129?source=related_link\">",
"      Patient information: Social anxiety disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27416?source=related_link\">",
"      Pharmacotherapy for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_36_32328="Tuberous sclerosis complex: Management";
var content_f31_36_32328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tuberous sclerosis complex: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     Sharon E Plon, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     James Owens, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32328/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/36/32328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H140858474\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberous sclerosis complex (TSC) is an inherited neurocutaneous disorder that is characterized by pleomorphic features involving many organ systems, including developmental delay multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney, and skin. The expression of the disease varies substantially among individuals and within families. Some individuals with TSC may demonstrate only dermatologic features of the disease while others may develop more serious neurologic or systemic manifestations.",
"   </p>",
"   <p>",
"    The management and prognosis of TSC will be reviewed here. Other aspects of TSC are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=see_link\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/1/5142?source=see_link\">",
"     \"Pulmonary involvement in tuberous sclerosis complex\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140859516\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of TSC is directed at its neurologic and systemic manifestations, particularly seizures, cognitive and behavioral problems, brain tumors, skin lesions, renal disease, pulmonary disease, and an increased risk of malignant tumors, primarily in the kidneys, brain, and soft tissues. Ideally, children with TSC should be managed by a multidisciplinary team that may include specialists in genetics, neurology, ophthalmology, nephrology, dermatology, neurosurgery, and plastic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Individual practitioners or the multidisciplinary team should examine the child for treatable complications and provide anticipatory guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140860313\">",
"    <span class=\"h2\">",
"     Seizure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common and difficult aspect of management in TSC is the treatment of seizures (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H25#H25\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Seizures'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Appropriate selection of an anticonvulsant drug depends upon the type of seizure (",
"    <a class=\"graphic graphic_table graphicRef58459 \" href=\"mobipreview.htm?18/1/18460\">",
"     table 1",
"    </a>",
"    ). The treatment of seizures in patients with TSC follows the general principles of epilepsy management for children and adults as reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many children with TSC have infantile spasms, which are hard to control. The treatment of infantile spasms is reviewed here briefly and discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=see_link\">",
"     \"Management and prognosis of infantile spasms\"",
"    </a>",
"    ). The response to corticotropin (ACTH), the mainstay of medical treatment of infantile spasms, is similar to that of patients without TSC, although patients with TSC relapse more often.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     Vigabatrin",
"    </a>",
"    may be more effective than ACTH in treating infantile spasms in patients with TSC. However, all studies of vigabatrin as treatment for infantile spasms suffer from methodologic limitations, the most obvious being small numbers of participants and a paucity of double blind placebo-controlled trials. In addition, there is a risk of possible irreversible retinal toxicity with the use of VGB. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=see_link&amp;anchor=H6#H6\">",
"     \"Management and prognosis of infantile spasms\", section on 'Corticotropin (ACTH)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=see_link&amp;anchor=H143072126#H143072126\">",
"     \"Management and prognosis of infantile spasms\", section on 'Tuberous sclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the available data, we suggest corticotropin (ACTH) for initial treatment of infantile spasms in children with TSC.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     Vigabatrin",
"    </a>",
"    is an alternative. However, other experts prefer vigabatrin as initial therapy in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We usually treat simple partial or complex partial seizures with a narrow spectrum agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    , although some clinicians use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    . For patients who become seizure-free for at least two years with anticonvulsant treatment, tapering off medication is a reasonable consideration, with 30 of 33 such patients remaining seizure free in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although epilepsy can be difficult to manage in TSC, one-third of patients achieve epilepsy remission, including nearly 20 percent of patients with a history of refractory epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/5\">",
"     5",
"    </a>",
"    ]. Unfortunately, approximately 63 percent of patients with TSC and epilepsy develop medically intractable epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/5\">",
"     5",
"    </a>",
"    ]. For such patients, a ketogenic diet or a vagus nerve stimulator can be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery is another treatment option for patients with TSC and drug-resistant epilepsy, especially when a glioneuronal hamartoma or tuber is identified as the primary epileptogenic focus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. A systematic review of 177 published cases reported that epilepsy surgery led to seizure remission in 57 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/15\">",
"     15",
"    </a>",
"    ]. Seizure frequency was reduced in 90 percent of patients. Developmental delay and tonic seizures were potential risk factors for a less favorable outcome after surgery. Concordance between the predominant interictal focus and the site of ictal electrographic onset may predict a better surgical outcome. Increased use of sophisticated neuroimaging techniques may improve the efficacy of surgical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link&amp;anchor=H33#H33\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Epilepsy surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/49/13082?source=see_link\">",
"     \"Neuroimaging in the evaluation of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective review of 70 patients with TSC who had surgery for relief of epilepsy associated poorer surgical outcomes with younger age at seizure onset, infantile spasms, and bilateral interictal EEG discharges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/17\">",
"     17",
"    </a>",
"    ]. Other EEG findings that may predict refractory epilepsy include higher hypsarrhythmia severity scores, background disorganization, and absent normal sleep patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vagus nerve stimulation is a treatment option for patients who are not deemed surgical candidates or who have refractory seizures after epilepsy surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The efficacy of vagus nerve stimulation for patients with TSC and epilepsy appears to be in the same range as that seen for patients with other causes of medically refractory epilepsy which is not surgically amenable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140858567\">",
"    <span class=\"h2\">",
"     Brain tumor treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system abnormalities characteristic of TSC include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H17#H17\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Brain lesions'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cortical glioneuronal hamartomas (also known as cortical tubers) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71505 \" href=\"mobipreview.htm?20/35/21043\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      White matter heterotopia",
"     </li>",
"     <li>",
"      Subependymal nodules (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52792 \" href=\"mobipreview.htm?36/16/37123\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subependymal giant cell tumors (SGCT), also known as subependymal giant cell astrocytomas (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64578 \" href=\"mobipreview.htm?43/4/44100\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The indications for surgical resection vary, but include the presence of hydrocephalus or increased intracranial pressure, interval increase in tumor size, or new focal neurologic deficits attributable to the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A poor surgical outcome was reported in one institutional series for children age 11 and older at the time of resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/21\">",
"     21",
"    </a>",
"    ]. Surgery may also be considered for seizure control. (See",
"    <a class=\"local\" href=\"#H140860313\">",
"     'Seizure control'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite their benign nature, some SGCTs show massive hemorrhage, rapid growth, and local recurrence following resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/22\">",
"     22",
"    </a>",
"    ]. We suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    for patients with TSC and symptomatic subependymal giant cell tumors who are not candidates for surgical resection. (See",
"    <a class=\"local\" href=\"#H140858574\">",
"     'Everolimus and mTOR inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are limited data regarding the outcome of radiation therapy for SGCT. However, at least one case of a high-grade neoplasm was reported eight years after radiation therapy for a giant cell astrocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/23\">",
"     23",
"    </a>",
"    ]. The authors recommended avoiding routine radiation therapy for these lesions. In general, there is growing appreciation that the risk of malignant transformation is increased in patients with related underlying tumor susceptibility syndromes such as the neurofibromatoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This realization has resulted in recommendations to avoid radiation therapy whenever possible in this group of disorders, including TSC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140858574\">",
"    <span class=\"h3\">",
"     Everolimus and mTOR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the actions of the hamartin-tuberin complex is to inhibit cellular signaling that is mediated through the mammalian target of rapamycin (mTOR). These observations led to the evaluation of targeted inhibitors of this pathway as an alternative therapy for brain tumors in patients with TSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H6#H6\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Mechanism of tumor formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most extensive experience with mTOR inhibitors comes from the multicenter EXIST-1 trial of children and adults (median age 9.5 years, range 0.8 to 26.6) with TSC and growing subependymal giant cell tumors (SGCTs) who were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    (n = 78) or placebo (n = 39) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/28\">",
"     28",
"    </a>",
"    ]. At a median follow-up of approximately 10 months, the proportion of patients experiencing a &ge;50 percent reduction in volume of SGCTs was significantly greater for the everolimus group compared with placebo (35 versus 0 percent). In addition, the proportion of subjects with SGCT progression &ndash; defined as increase in SGCT volume, worsening of non-target SGCTs, appearance of new lesions, or new hydrocephalus &ndash; was significantly lower for the everolimus group (0 versus 15 percent). There was no significant change with everolimus treatment in seizure frequency as assessed by 24 hour video electroencephalography (EEG), but this analysis was inconclusive since most patients did not have seizures during the baseline video EEG study. Everolimus was generally well-tolerated; adverse events more common in the everolimus group included mouth ulceration, stomatitis, pyrexia, vomiting, fatigue, cough, diarrhea, rash, otitis media, and pharyngitis.",
"   </p>",
"   <p>",
"    In an earlier open-label study of 28 patients with TSC and SGCTs who were treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , the median patient age was 11 years (range 3 to 34 years) and the median treatment duration was 22 months (range 4 to 34 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/29\">",
"     29",
"    </a>",
"    ]. Some tumor volume decrease was seen in all evaluable patients at 6 and 12 months, and a decrease in tumor volume of &ge;30 percent at one year was observed in 21 patients (75 percent), a result that was clinically meaningful and statistically significant. In addition, there was a statistically significant reduction in seizure frequency.",
"   </p>",
"   <p>",
"    Based upon these results,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    received regulatory approval in a number of countries, including the United States, Canada, and Europe for patients with SGCTs associated with TSC who require therapy but are not candidates for surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/30\">",
"     30",
"    </a>",
"    ]. The starting dose of everolimus for patients with SGCT is based upon body surface area (BSA) as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2.5 mg once daily for BSA of 0.5 to 1.2 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      5 mg once daily for BSA of 1.3 to 2.1 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      7.5 mg once daily for BSA &ge;2.2m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    is then titrated to achieve a serum trough concentration of 5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Additional experience will be required to determine the long-term effectiveness of treatment with this approach. Other studies are underway using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and rapamycin analogs to treat renal angiomyolipomas, pulmonary lymphangioleiomyomatosis, and facial angiofibromas associated with TSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314611330\">",
"    <span class=\"h2\">",
"     Cognitive and behavioral problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patients with TSC may have normal intelligence, cognitive disability is a common and primary feature of TSC. In addition, autism and autistic behaviors, including hyperactivity, inattention, and self-injurious behavior, are common in children with TSC who have seizures and can be a significant source of stress for parents and caregivers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H27#H27\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Cognitive deficits'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H28#H28\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Autism and behavioral problems'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consensus guidelines developed by a European expert panel recommended regular assessment of cognitive development and behavior to identify and treat emerging difficulties and to establish a baseline for evaluating any changes in developmental trajectory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/34\">",
"     34",
"    </a>",
"    ]. They also recommend a comprehensive assessment in response to changes in cognitive development or behavior to identify and treat the underlying causes of neurobehavioral change.",
"   </p>",
"   <p>",
"    Depending on patient age, the following assessments and interventions are recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gross and fine motor skills",
"     </li>",
"     <li>",
"      Social-communication skills",
"     </li>",
"     <li>",
"      Global cognitive ability",
"     </li>",
"     <li>",
"      Receptive and expressive language",
"     </li>",
"     <li>",
"      Attentional-executive skills",
"     </li>",
"     <li>",
"      Visuospatial skills",
"     </li>",
"     <li>",
"      Memory",
"     </li>",
"     <li>",
"      Vocational assessment with knowledge of cognitive strengths and weaknesses",
"     </li>",
"     <li>",
"      Adaptive behavior and daily living skills",
"     </li>",
"     <li>",
"      Social care needs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management should be directed by the findings of the cognitive and behavioral evaluations, and may include early intervention programs, special needs schooling, other scholastic, social and vocational support, and psychiatric evaluation and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise frequency of cognitive and behavioral assessments was not addressed by the European expert panel, but guidelines from the Tuberous Sclerosis Association in the United Kingdom recommend assessing intellectual and cognitive profile at key stages (age two to three and seven to eight years) if developmental delay is suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, screening for psychiatric and behavioral disturbances is recommended at school entry, at age seven years, at the age of transition to secondary school, and during mid-adolescence (eg, age 15 years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314611338\">",
"    <span class=\"h2\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with TSC have one or more of the skin lesions characteristic of the disorder. The most common skin lesions in TSC are hypopigmented macules (",
"    <a class=\"graphic graphic_picture graphicRef61601 \" href=\"mobipreview.htm?26/39/27263\">",
"     picture 1",
"    </a>",
"    ), angiofibromas (",
"    <a class=\"graphic graphic_picture graphicRef54868 \" href=\"mobipreview.htm?27/46/28384\">",
"     picture 2",
"    </a>",
"    ), shagreen patches, and fibrous plaques (",
"    <a class=\"graphic graphic_picture graphicRef78688 \" href=\"mobipreview.htm?6/4/6208\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H11#H11\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Dermatologic features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no significant risk of malignant transformation of skin lesions associated with TSC, which tend to be stable over time. When not prominent, the skin lesions do not require treatment. However, many patients complain about the cosmetic impact of the facial angiofibromas and the lack of effective treatment. Patients, particularly teens, should be counseled that ointments marketed for acne are not effective; their use should be discouraged. Disfiguring lesions (particularly the forehead plaque) may improve with laser therapy and dermabrasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/37\">",
"     37",
"    </a>",
"    ]. There are limited data regarding the use of topical rapamycin to treat facial angiofibromas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314611346\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of renal lesions among patients with TSC ranges from 60 to 80 percent and increases with age. The most common lesion is angiomyolipoma; benign cysts and lymphangiomas also occur, though far less commonly. Patients with tuberous sclerosis and renal lesions may have renin-dependent hypertension, and are at risk of developing chronic kidney disease due to replacement and compression of the renal parenchyma. Renal cell carcinoma occurs in 1 to 2 percent of adult patients with TSC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=see_link\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with TSC should be monitored with serial imaging studies (see",
"    <a class=\"local\" href=\"#H140859778\">",
"     'Surveillance for tumors'",
"    </a>",
"    below). Renal ultrasonography should be performed at the time of diagnosis and every one to three years beginning in childhood to monitor both the growth of lesions and possible signs of malignancy. If malignant transformation or the development of large angiomyolipomas is detected, CT or MRI should be performed although gadolinium-based imaging should be avoided, if possible, in patients with an estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    because of the risk of nephrogenic systemic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=see_link\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary indications for intervention for angiomyolipoma include refractory pain, bleeding, and suspicion of malignancy. Possible indications for intervention include large tumors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large aneurysms, and the treatment of females of childbearing age, and patients in whom follow-up or access to emergency care may be inadequate. Interventions include transcatheter arterial embolization, or less often partial or total nephrectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=see_link\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rare, renal transplantation has been performed successfully in a small number of patients who progressed to end-stage renal disease due to replacement and compression of the renal parenchyma by angiomyolipomas and cysts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=see_link\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314611354\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some adults with TSC develop pulmonary disease that is indistinguishable from the diffuse interstitial fibrosis known as lymphangioleiomyomatosis (LAM). This condition can result in significant limitation in pulmonary function. The most common presenting features are dyspnea and pneumothorax. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/1/5142?source=see_link&amp;anchor=H2#H2\">",
"     \"Pulmonary involvement in tuberous sclerosis complex\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with mild lung impairment, ongoing observation with reassessment of symptoms and pulmonary function once or twice a year is appropriate. No therapy is of proven benefit, although studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    are promising. Lung transplantation may be an option in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/1/5142?source=see_link&amp;anchor=H5#H5\">",
"     \"Pulmonary involvement in tuberous sclerosis complex\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/30/4586?source=see_link&amp;anchor=H7596707#H7596707\">",
"     \"Pulmonary lymphangioleiomyomatosis\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314611362\">",
"    <span class=\"h2\">",
"     Cardiac problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic cardiac feature of TSC is a rhabdomyoma, a benign tumor that often presents as multiple lesions in neonates with TSC and may be visualized antenatally by fetal ultrasound scan. Most regress spontaneously during infancy, and resection is not required unless the child is symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link&amp;anchor=H20#H20\">",
"     \"Cardiac tumors\", section on 'Rhabdomyomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140859778\">",
"    <span class=\"h2\">",
"     Surveillance for tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSC is associated with a variety of benign hamartomatous tumors such as angiofibromas, rhabdomyomas, and angiomyolipomas. In addition, both children and adults with TSC are at risk for malignant tumors, primarily in the kidneys, brain, and soft tissues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H140867129#H140867129\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Risk of invasive malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The periodic surveillance that is recommended for all patients with TSC is predominantly focused on monitoring the development of benign and malignant tumors. Surveillance should follow the guidelines recommended by the Tuberous Sclerosis Consensus Conference published in 1998 and 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is helpful to provide the parents of an affected child with a copy of these guidelines so that they are aware of the recommended surveillance measures.",
"   </p>",
"   <p>",
"    If no potentially serious problems are detected, routine follow-up visits should occur at yearly intervals. Visits should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Skin examination",
"     </li>",
"     <li>",
"      Growth measurements",
"     </li>",
"     <li>",
"      Developmental assessment",
"     </li>",
"     <li>",
"      Review of school progress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Consensus Conference recommended the following surveillance imaging studies for patients with TSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cranial CT or MRI should be performed in children and adolescents every one to three years (see",
"      <a class=\"local\" href=\"#H140859574\">",
"       'Neuroimaging'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Renal ultrasonography should be performed at the time of diagnosis to ascertain the presence or absence of the polycystic variant of TSC or angiomyolipomas. All children with TSC should have screening with renal ultrasonography every one to three years (three years if no prior lesions are seen on imaging). If malignant transformation or the development of large angiomyolipomas (greater than 3 to 4 cm) is detected, abdominal CT or MRI should be performed to evaluate the abnormalities. Interventional radiology can be consulted for treatment of the lesions greater than 3 to 4 cm to prevent hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=see_link\">",
"       \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with cardiac rhabdomyoma should be evaluated and followed by a pediatric cardiologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140859574\">",
"    <span class=\"h3\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain imaging should be performed in children and adolescents every one to three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/2\">",
"     2",
"    </a>",
"    ]. MRI is the test of choice for screening patients with TSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/21\">",
"     21",
"    </a>",
"    ]. Head CT is more sensitive than MRI for detecting calcified subependymal nodules, but this advantage has no clinical utility. In children with syndromes such as TSC that predispose to cancer and require multiple imaging, we recommend neuroimaging with MRI rather than CT to minimize radiation exposure. Contrast enhancement on MRI or CT is seen with a majority of subependymal nodules and subependymal giant cell tumors (SGCTs) but does not appear to provide any significant prognostic information. Therefore, we suggest obtaining screening MRI scans without contrast.",
"   </p>",
"   <p>",
"    Management should progress to either surgery or more aggressive monitoring with MRI every three to six months if a subependymal lesion is identified as a probable or definite SGCT. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    is a treatment option for SGCTs which are not treatable by surgery. (See",
"    <a class=\"local\" href=\"#H140858567\">",
"     'Brain tumor treatment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H140858574\">",
"     'Everolimus and mTOR inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The duration of monitoring for new brain lesions is uncertain. In a series of 134 patients seen at a single center, no patient over the age of 20 required surgical resection of a SGCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, it is atypical for a patient who has been screened every one to three years to present with a new SGCT after the age of 21. As a result, it may be appropriate to diminish the frequency of cranial MRI in young adults without evidence for SGCT. In comparison, a SGCT diagnosed at a younger age may not become symptomatic until many years later, and would require routine monitoring throughout life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140859581\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a child with TSC has a major impact on the family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/38\">",
"     38",
"    </a>",
"    ]. Counseling should be provided for patients and families. It should include information on the inheritance of the disorder, genetic testing results, prognosis, and psychosocial adjustment. The progressive nature of the disease and its clinical manifestations and complications should be addressed.",
"   </p>",
"   <p>",
"    The genetics of TSC, including potential recurrence risk in other offspring, should be explained to the parents of affected children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H2#H2\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific counseling may be warranted for adolescents with TSC who face issues with self-esteem and the psychosocial impact of this condition. Parents of a child newly diagnosed with TSC should also be counseled that the child will need genetic counseling when he or she reaches reproductive age.",
"   </p>",
"   <p>",
"    Organizations such as the",
"    <a class=\"external\" href=\"file://www.tsalliance.org/\">",
"     Tuberous Sclerosis Alliance",
"    </a>",
"    (USA) and the",
"    <a class=\"external\" href=\"file://www.tuberous-sclerosis.org/\">",
"     Tuberous Sclerosis Association",
"    </a>",
"    (UK) provide information about the disorder and general support. Referral of the family to a local chapter can be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140859655\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSC is a progressive disorder, and the individual features tend to emerge at different times. Some individuals with TSC may demonstrate only dermatologic features of the disease while others may develop more serious neurologic or systemic manifestations. The natural history of TSC is described in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H230286827#H230286827\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140859684\">",
"    <span class=\"h2\">",
"     Causes of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications in major organ systems are the predominant source of morbidity in adolescents and young adults with TSC, and they contribute to an increased incidence of early death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/39\">",
"     39",
"    </a>",
"    ]. In one report of 355 patients from the Mayo Clinic, there were 40 deaths that were attributable to TSC, which was more than expected in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/40\">",
"     40",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic disease, including subependymal giant cell tumors (10 patients) and status epilepticus, was the most common cause of death.",
"     </li>",
"     <li>",
"      Renal disease, including renal carcinoma, hemorrhage into angiomyolipoma, and renal failure, was the next most common cause of death (11 patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other causes of mortality included pulmonary disease in four patients, all of whom died at age 40 or older from lymphangioleiomyomatosis, and bronchopneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32328/abstract/40\">",
"     40",
"    </a>",
"    ]. Several children with severe developmental delay and intractable seizures died from pneumonia, and cardiac rhabdomyoma resulted in the death of one infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140859722\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of tuberous sclerosis complex (TSC) is directed at its neurologic and systemic manifestations, particularly seizures, cognitive and behavioral problems, brain tumors, skin lesions, renal disease, and pulmonary disease. (See",
"      <a class=\"local\" href=\"#H140859516\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common and difficult aspect of management in TSC is the control of seizures. The treatment of seizures in patients with TSC follows the general principles of epilepsy management for children and adults (",
"      <a class=\"graphic graphic_table graphicRef58459 \" href=\"mobipreview.htm?18/1/18460\">",
"       table 1",
"      </a>",
"      ). Corticotropin (ACTH) is suggested for initial treatment of most children with infantile spasms.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"       Vigabatrin",
"      </a>",
"      is an alternative. However, there is a risk of possible irreversible retinal toxicity with the use of vigabatrin. We prefer to treat simple-partial or complex-partial seizures with a narrow spectrum agent such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      , although some clinicians use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      . For patients with TSC who develop drug-resistant epilepsy, options include the ketogenic diet, vagus nerve stimulation therapy, and epilepsy surgery. (See",
"      <a class=\"local\" href=\"#H140860313\">",
"       'Seizure control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to seizure control, the indications for surgical resection subependymal giant cell brain tumors in TSC include the presence of hydrocephalus or increased intracranial pressure, interval increase in tumor size, or new focal neurologic deficits attributable to the tumor. For patients with TSC and symptomatic subependymal giant cell tumors who are not candidates for surgical resection, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The starting dose and titration is described above in detail. (See",
"      <a class=\"local\" href=\"#H140858567\">",
"       'Brain tumor treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H140858574\">",
"       'Everolimus and mTOR inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of cognitive and behavioral problems in patients with TSC should be directed by the findings of appropriate evaluations, and may include early intervention programs, special needs schooling, other scholastic, social and vocational support, and psychological and psychiatric treatment. (See",
"      <a class=\"local\" href=\"#H314611330\">",
"       'Cognitive and behavioral problems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disfiguring skin lesions in TSC may improve with laser therapy and dermabrasion. (See",
"      <a class=\"local\" href=\"#H314611338\">",
"       'Skin lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary indications for intervention for renal angiomyolipoma include large size, refractory pain, hemorrhage, and suspicion of malignancy. Interventions include transcatheter arterial embolization, or less often partial or total nephrectomy. (See",
"      <a class=\"local\" href=\"#H314611346\">",
"       'Renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No therapy is of proven benefit for patients with TSC-related lymphangioleiomyomatosis. (See",
"      <a class=\"local\" href=\"#H314611354\">",
"       'Pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The periodic surveillance that is recommended for all patients with TSC is predominantly focused on monitoring the development of benign and malignant tumors. Brain imaging should be performed in children and adolescents every one to three years. In children with syndromes such as TSC that predispose to cancer and require multiple imaging, we recommend neuroimaging with MRI rather than CT to minimize radiation exposure. All children with TSC should have screening with renal ultrasonography every one to three years (three years if no prior lesions are seen on imaging). Children with cardiac rhabdomyomas should be evaluated and followed by a pediatric cardiologist until they regress. (See",
"      <a class=\"local\" href=\"#H140859778\">",
"       'Surveillance for tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some individuals with TSC may demonstrate only dermatologic features of the disease while others may develop more serious neurologic or systemic manifestations. Complications in major organ systems are the predominant source of morbidity in adolescents and young adults with TSC, and they contribute to an increased incidence of early death. (See",
"      <a class=\"local\" href=\"#H140859655\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/1\">",
"      Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/2\">",
"      Roach ES, DiMario FJ, Kandt RS, Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/3\">",
"      Gaily E. Vigabatrin monotherapy for infantile spasms. Expert Rev Neurother 2012; 12:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/4\">",
"      Mytinger JR, Joshi S, Pediatric Epilepsy Research Consortium, Section on Infantile Spasms. The current evaluation and treatment of infantile spasms among members of the Child Neurology Society. J Child Neurol 2012; 27:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/5\">",
"      Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/6\">",
"      Elliott RE, Carlson C, Kalhorn SP, et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav 2009; 16:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/7\">",
"      Major P, Thiele EA. Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex. Epilepsy Behav 2008; 13:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/8\">",
"      Zamponi N, Petrelli C, Passamonti C, et al. Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis. Pediatr Neurol 2010; 43:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/9\">",
"      Parain D, Penniello MJ, Berquen P, et al. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol 2001; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/10\">",
"      Avellino AM, Berger MS, Rostomily RC, et al. Surgical management and seizure outcome in patients with tuberous sclerosis. J Neurosurg 1997; 87:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/11\">",
"      Karenfort M, Kruse B, Freitag H, et al. Epilepsy surgery outcome in children with focal epilepsy due to tuberous sclerosis complex. Neuropediatrics 2002; 33:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/12\">",
"      Lachhwani DK, Pestana E, Gupta A, et al. Identification of candidates for epilepsy surgery in patients with tuberous sclerosis. Neurology 2005; 64:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/13\">",
"      Chandra PS, Salamon N, Huang J, et al. FDG-PET/MRI coregistration and diffusion-tensor imaging distinguish epileptogenic tubers and cortex in patients with tuberous sclerosis complex: a preliminary report. Epilepsia 2006; 47:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/14\">",
"      Jarrar RG, Buchhalter JR, Raffel C. Long-term outcome of epilepsy surgery in patients with tuberous sclerosis. Neurology 2004; 62:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/15\">",
"      Jansen FE, van Huffelen AC, Algra A, van Nieuwenhuizen O. Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia 2007; 48:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/16\">",
"      Wu JY, Salamon N, Kirsch HE, et al. Noninvasive testing, early surgery, and seizure freedom in tuberous sclerosis complex. Neurology 2010; 74:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/17\">",
"      Madhavan D, Schaffer S, Yankovsky A, et al. Surgical outcome in tuberous sclerosis complex: a multicenter survey. Epilepsia 2007; 48:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/18\">",
"      Muzykewicz DA, Costello DJ, Halpern EF, Thiele EA. Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG. Epilepsia 2009; 50:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/19\">",
"      Torres OA, Roach ES, Delgado MR, et al. Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol 1998; 13:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/20\">",
"      Beaumont TL, Limbrick DD, Smyth MD. Advances in the management of subependymal giant cell astrocytoma. Childs Nerv Syst 2012; 28:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/21\">",
"      Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004; 63:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/22\">",
"      Kim SK, Wang KC, Cho BK, et al. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neurooncol 2001; 52:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/23\">",
"      Matsumura H, Takimoto H, Shimada N, et al. Glioblastoma following radiotherapy in a patient with tuberous sclerosis. Neurol Med Chir (Tokyo) 1998; 38:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/24\">",
"      Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol 2009; 39 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/25\">",
"      Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/26\">",
"      Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/27\">",
"      Kohrman MH. Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol 2012; 46:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/28\">",
"      Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/29\">",
"      Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Admnistration. Everolimus (Accelerated Approval). www.fda.gov/AboutFDA/CentersOffices/CDER/ucm231967.htm (Accessed on November 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/31\">",
"      Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/32\">",
"      Haemel AK, O'Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010; 146:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/33\">",
"      Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One 2011; 6:e23379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/34\">",
"      de Vries P, Humphrey A, McCartney D, et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry 2005; 14:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/35\">",
"      Hallett L, Foster T, Liu Z, et al. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr Med Res Opin 2011; 27:1571.",
"     </a>",
"    </li>",
"    <li>",
"     Tuberous Sclerosis Association. Clinical guidelines for the care of patients with TSC: Summary. www.tuberous-sclerosis.org/publications/clinical_guidelines_for_the_care_of_patients_with_TSC.pdf (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/37\">",
"      Papadavid E, Markey A, Bellaney G, Walker NP. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Br J Dermatol 2002; 147:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/38\">",
"      Whitehead LC, Gosling V. Parent's perceptions of interactions with health professionals in the pathway to gaining a diagnosis of tuberous sclerosis (TS) and beyond. Res Dev Disabil 2003; 24:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/39\">",
"      Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol 2002; 168:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32328/abstract/40\">",
"      Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991; 66:792.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16902 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-217.16.9.173-E29AE5AA73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32328=[""].join("\n");
var outline_f31_36_32328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H140859722\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H140858474\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H140859516\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140860313\">",
"      Seizure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140858567\">",
"      Brain tumor treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H140858574\">",
"      - Everolimus and mTOR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H314611330\">",
"      Cognitive and behavioral problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H314611338\">",
"      Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H314611346\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H314611354\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H314611362\">",
"      Cardiac problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140859778\">",
"      Surveillance for tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H140859574\">",
"      - Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140859581\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H140859655\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140859684\">",
"      Causes of death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H140859722\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16902\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16902|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/35/21043\" title=\"diagnostic image 1\">",
"      MRI cortical glioneuronal hamartomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/16/37123\" title=\"diagnostic image 2\">",
"      MRI subependymal nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/4/44100\" title=\"diagnostic image 3\">",
"      MRI subependymal giant cell tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16902|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/39/27263\" title=\"picture 1\">",
"      TSC hypomelanotic macules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/46/28384\" title=\"picture 2\">",
"      TSC angiofibromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/4/6208\" title=\"picture 3\">",
"      TS forehead plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16902|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/1/18460\" title=\"table 1\">",
"      Recommended antiepileptic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=related_link\">",
"      Management and prognosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/49/13082?source=related_link\">",
"      Neuroimaging in the evaluation of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/1/5142?source=related_link\">",
"      Pulmonary involvement in tuberous sclerosis complex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/30/4586?source=related_link\">",
"      Pulmonary lymphangioleiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_36_32329="Sequelae and complications of pneumonectomy";
var content_f31_36_32329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sequelae and complications of pneumonectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32329/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32329/contributors\">",
"     Scott E Kopec, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32329/contributors\">",
"     Richard S Irwin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32329/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32329/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32329/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/36/32329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonectomy, or surgical removal of an entire lung, is performed most frequently for management of bronchogenic carcinoma. In this setting, pneumonectomy is required over lesser resection, such as lobectomy, when the tumor is located in a main stem bronchus or the proximal bronchus intermedius, adjacent to the right upper lobe orifice, or when the tumor extends across a major fissure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/1\">",
"     1",
"    </a>",
"    ]. Pneumonectomy may rarely be performed for pulmonary metastases or for a variety of benign diseases, such as inflammatory lung disease (eg, pulmonary tuberculosis, fungal infections, and bronchiectasis), traumatic lung injury, congenital lung disease, and bronchial obstruction with a destroyed lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumonectomy is associated with a variety of reasonably predictable anatomic changes, significant decrements in pulmonary function, and a number of potential complications that involve the respiratory system, the cardiovascular system, and the pleural space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/3\">",
"     3",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67873 \" href=\"mobipreview.htm?27/10/27820\">",
"     table 1",
"    </a>",
"    ). The preoperative evaluation of the patient being considered for pneumonectomy, and clinical issues relating to the outcome, sequelae, and complications following pneumonectomy will be reviewed here. A general discussion of preoperative evaluation prior to lung resection surgery is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately following pneumonectomy, air fills the space previously occupied by the lung (ie, the postpneumonectomy space, or PPS). Unlike the situation with most other forms of thoracic surgery, a chest tube is not inserted following pneumonectomy, and the air is therefore not evacuated. Over time, a number of changes result in a decrease in the size of the PPS, including elevation of the hemidiaphragm, hyperinflation of the remaining lung, and shifting of the mediastinum towards the PPS. At the same time, there is progressive resorption of air in the PPS and replacement with fluid.",
"   </p>",
"   <p>",
"    Chest radiographic findings immediately after surgery demonstrate the trachea to be midline and the PPS to be filled with air (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72520 graphicRef75963 \" href=\"mobipreview.htm?1/43/1715\">",
"     image 1A-B",
"    </a>",
"    ). Within 24 hours the ipsilateral hemidiaphragm becomes slightly elevated, the mediastinum shifts slightly towards the PPS, and fluid starts accumulating in the PPS. As a general rule, fluid accumulates at a rate of approximately two rib spaces per day. After two weeks, 80 to 90 percent of the PPS is filled with fluid.",
"   </p>",
"   <p>",
"    By chest radiograph, complete opacification of the hemithorax after pneumonectomy takes an average of approximately 4 months, with a range from 3 weeks to 7 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/4\">",
"     4",
"    </a>",
"    ]. Unexpectedly rapid accumulation of fluid into the PPS in the immediate postoperative period should raise concerns for hemorrhage into the PPS, infection of the PPS, or the development of a chylothorax. While the chest radiograph typically demonstrates complete opacification of the hemithorax, chest CT scans demonstrate that only a small fraction of patients have obliteration of their PPS, with most patients having residual fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/5\">",
"     5",
"    </a>",
"    ]. The length of time following pneumonectomy does not correlate with complete obliteration of the space nor the amount of fluid remaining in the space.",
"   </p>",
"   <p>",
"    The location of vital organs (including the heart and great vessels, liver, and spleen) changes significantly following pneumonectomy as a consequence of mediastinal shift and elevation of the hemidiaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/3\">",
"     3",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70082 graphicRef67587 graphicRef81115 \" href=\"mobipreview.htm?24/8/24711\">",
"     image 2A-C",
"    </a>",
"    ). After left pneumonectomy, the heart rotates counterclockwise into the vacant left pleural space. Following right pneumonectomy, the heart shifts into the vacant right pleural space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/6\">",
"     6",
"    </a>",
"    ]. Extreme care must be taken prior to inserting a needle or chest tube into the PPS, due to the risk of injury to vital organs that have shifted position following the surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/7\">",
"     7",
"    </a>",
"    ]. We recommend an imaging study such as ultrasound or CT scan to help locate vital organs prior to any attempt to drain the PPS.",
"   </p>",
"   <p>",
"    Some of the anatomic changes in the thorax following pneumonectomy can result in complications. As an example, postpneumonectomy syndrome &ndash; a rare complication resulting in large airway obstruction due to narrowing and stretching of the main bronchus &ndash; is a direct result of severe shifting of the mediastinum after pneumonectomy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Postpneumonectomy syndrome'",
"    </a>",
"    below.) In addition, residual fluid in the PPS can serve as a nidus for infection and result in the development of a postpneumonectomy space empyema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EARLY MORTALITY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary 30-day mortality rates range from 2.4 to 11.6 percent, based upon both retrospective and prospective studies that have been published since 1990, each containing over 100 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/8-15\">",
"     8-15",
"    </a>",
"    ]. Ten-year survival rates for patients who underwent pneumonectomy for non-small cell lung cancer range from 67 to 85 percent, depending on size and stage of the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/16\">",
"     16",
"    </a>",
"    ]. Several risk factors are associated with an increased 30-day mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right-sided pneumonectomy is associated with a higher mortality rate than left-sided pneumonectomy (10 to 12 versus 1 to 3.5 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. While the reasons are not certain, likely factors include several life-threatening complications that are encountered more frequently after right pneumonectomy; these include postpneumonectomy space empyema, bronchopleural fistula, and postpneumonectomy pulmonary edema.",
"     </li>",
"     <li>",
"      The specific type of surgical resection is an independent risk factor for mortality. As an example, pleuropneumonectomy and pneumonectomy with chest wall resection are associated with a 3-fold increase in mortality compared to a simple or intrapericardial pneumonectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/18\">",
"       18",
"      </a>",
"      ]. In contrast, completion pneumonectomy (ie, a reoperation to remove the remaining portion of a previously, partially resected lung) is associated with lower operative mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Outcome is also affected by the underlying indication for resection. Operative mortality rates for completion pneumonectomy performed for lung cancer are reported to be as low as 3.4 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/20\">",
"       20",
"      </a>",
"      ]; however, when pneumonectomy is performed for benign disease, early mortality may be as high as 26 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pneumonectomy performed emergently for trauma or massive hemoptysis is associated with a mortality rate exceeding 35 percent, likely reflecting the severity of the underlying process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/2,23\">",
"       2,23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link&amp;anchor=H15#H15\">",
"       \"Massive hemoptysis: Initial management\", section on 'Surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several comorbid medical illnesses have been identified as risk factors for increased mortality. These include underlying lung disease, coronary artery disease, heart failure, atrial fibrillation, hypertension, hemiplegia, active cigarette smoking, and weight loss greater than 10 percent within the six months preceding surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/11,12,14,24,25\">",
"       11,12,14,24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While some studies have demonstrated that increased age (eg, &gt;60 to 75 years) is a risk factor for increased mortality with pneumonectomy, others have not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/26-28\">",
"       26-28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The level of experience of the surgeon performing the operation may affect the mortality rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. A lower mortality rate for lung cancer resection has been demonstrated when the surgery is performed by a thoracic surgeon rather than a general surgeon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It remains unclear whether preoperative chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy increase operative mortality and morbidity, as studies have found conflicting results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perioperative blood transfusions do not appear to increase mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE PULMONARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function predictably decreases following pneumonectomy, but many of the changes are less than anticipated for the amount of lung tissue that has been removed. Specific changes include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postpneumonectomy lung volumes fall, but typically less than expected for removal of approximately 50 percent of the original lung tissue. This is especially true for residual volume and is a consequence of overexpansion of the remaining lung. However, despite this overexpansion, there is no pathological evidence of emphysema in the remaining lung.",
"     </li>",
"     <li>",
"      Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) usually decrease by less than 50 percent.",
"     </li>",
"     <li>",
"      Diffusing capacity for carbon monoxide (DLCO) also decreases by less than 50 percent and is usually normal when corrected for lung volume.",
"     </li>",
"     <li>",
"      Lung compliance decreases, airway resistance increases, and dead space may either increase or decrease.",
"     </li>",
"     <li>",
"      Arterial oxygen saturation, PO",
"      <sub>",
"       2",
"      </sub>",
"      , and PCO",
"      <sub>",
"       2",
"      </sub>",
"      at rest do not change in those patients with little or no disease in the remaining lung.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is little subsequent decline in lung function that can be attributed to pneumonectomy beyond one year after the procedure. Long-term studies have demonstrated minimal further change in FEV1 up to 20 years after pneumonectomy, with annual decrements in FEV1 that are 3 to 4 mL per year, which is less than that expected for the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARDIOVASCULAR FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have addressed changes in cardiovascular function after lung resection, with conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/6,35-37\">",
"     6,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Right ventricular ejection fraction decreases, right ventricular end-diastolic volume increases, and left ventricular function does not change, according to one prospective cohort study that evaluated 31 patients before and two days after pneumonectomy using echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, another study used dynamic magnetic resonance imaging to assess the cardiac function of 15 patients five years after pneumonectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/6\">",
"     6",
"    </a>",
"    ]. Right ventricular end-diastolic volume was low and left ventricular function was normal among patients who underwent right pneumonectomy, while right ventricular end-diastolic volume was normal and left ventricular function was low among patients who underwent left pneumonectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/6\">",
"     6",
"    </a>",
"    ]. In all patients, resting heart rate was elevated and stroke volume was low.",
"   </p>",
"   <p>",
"    The reason for the conflicting results is uncertain, but could be due to the different durations since the pneumonectomy or the different imaging techniques used. As long as the remaining lung is relatively normal, there is no significant change in resting values of systolic pulmonary artery pressure, pulmonary vascular resistance index, or central venous pressure after lung resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/36\">",
"     36",
"    </a>",
"    ]. Maximal oxygen consumption decreases between 17 and 28 percent after pneumonectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE QUALITY OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike patients who have had lobectomies and wedge resections, patients who have had pneumonectomies never return to preoperative levels of overall physical function, pain, and dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/40\">",
"     40",
"    </a>",
"    ]. In general, quality of life scores decrease after pneumonectomy. Patients over age 70 and those with low preoperative quality of life appear more likely to have an unacceptable quality of life six months following pneumonectomy than other patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PULMONARY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential pulmonary complications following pneumonectomy include postpneumonectomy pulmonary edema, postpneumonectomy syndrome, and intraoperative spillage of material into the remaining lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpneumonectomy pulmonary edema occurs with an overall frequency of 2 to 5 percent, and it is three times more common following right than left pneumonectomy. Although the pathogenesis is unknown and probably multifactorial, it is thought to represent a form of the acute respiratory distress syndrome (ARDS). It does not appear to be a complication of cardiac dysfunction, sepsis, pneumonia, or aspiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postpneumonectomy pulmonary edema is characterized clinically by respiratory distress and hypoxemia within 72 hours of surgery. A single intraoperative dose of Solu-Medrol (250 mg administered just prior to ligation of the pulmonary artery) may decrease the risk of developing this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/42\">",
"     42",
"    </a>",
"    ]. When it occurs, mortality rates exceed 50 percent. One review of postpneumonectomy pulmonary edema suggests that the underlying mechanism of injury may be due to high inspired oxygen concentrations, associated with single-lung ventilation or ischemic and reperfusion injury to the remaining lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Postpneumonectomy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpneumonectomy syndrome reflects extrinsic compression of the distal trachea and mainstem bronchus due to shifting of the mediastinum and hyperinflation of the remaining lung (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73229 \" href=\"mobipreview.htm?24/35/25151\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. It occurs more than six months following surgery and has even been reported 35 years after surgery. It is more common in patients who undergo surgery in childhood and is almost exclusively seen after right pneumonectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The syndrome is characterized by development of progressive dyspnea, cough, inspiratory stridor, and recurrent pneumonia in patients at least 6 months after surgery. It can be fatal if left untreated. Treatment consists of surgical repositioning of the mediastinum and filling of the PPS with a non-absorbable material; saline breast implants have been used successfully for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/45,47,49\">",
"     45,47,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two rare variants of PPS have been described. One occurs when the esophagus becomes compressed, resulting in dysphagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/50\">",
"     50",
"    </a>",
"    ]. The other occurs due to compression of the remaining pulmonary vein resulting in dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/51\">",
"     51",
"    </a>",
"    ]. Surgical repositioning of the mediastinum improved symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intraoperative spillage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients undergoing pneumonectomy for suppurative lung disease, purulent material can spill into the unoperated lung at the time of surgery. Respiratory failure and death have been reported from this complication. Prevention of intraoperative spillage is therefore critically important, and includes such measures as endobronchial separation with a double-lumen endotracheal tube, prone positioning, and perioperative bronchoscopy to remove secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PLEURAL SPACE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several complications affecting the pleural space, either the postpneumonectomy space or the contralateral pleural space, are considered here. The main categories of pleural space complication include infection, fistula formation, bleeding, chylothorax, and contralateral pneumothorax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Postpneumonectomy empyema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empyema in the postpneumonectomy space complicates approximately 5 percent of pneumonectomies. Early empyema occurs within 10 to 14 days of surgery and is commonly associated with a bronchopleural fistula. Late empyema, in which infection is most often acquired via a hematogenous route, occurs more than three months after pneumonectomy and has been reported up to 40 years following surgery. The most common organisms causing postpneumonectomy empyema are Staphylococcus aureus and Pseudomonas aeruginosa. Almost 50 percent of cases of both early and late empyemas are polymicrobial.",
"   </p>",
"   <p>",
"    Early empyema frequently presents with fever and occasionally expectoration of purulent sputum. The infection may rarely \"necessitate,\" ie, spread directly through the chest wall and drain through the overlying skin. Late empyema frequently presents with nonspecific symptoms such as flu-like symptoms, weight loss, low grade fever, and anorexia.",
"   </p>",
"   <p>",
"    Chest radiographs may be helpful in suggesting the diagnosis. Specific radiographic findings include a shift of the mediastinum away from the PPS, failure of the mediastinum to shift normally in the immediate postoperative period, development of a new air-liquid level, or a sudden change in a preexisting air-liquid level (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80828 \" href=\"mobipreview.htm?28/16/28929\">",
"     image 4",
"    </a>",
"    ). The diagnosis is confirmed by sampling the fluid in the PPS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment includes drainage of the PPS and systemic antibiotics, plus repair of any coexisting bronchopleural or esophagopleural fistula once the PPS is sterilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients with large (&gt;3 mm) bronchopleural fistulae should be treated with aggressive surgical debridement, irrigation of the pleural cavity, and closure of the pneumonectomy stump with an omental patch (Clagett procedure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. A less invasive approach using video-assisted thoracoscopy may be useful in the absence of a bronchopleural fistula, and in those with a small (&lt;3 mm) fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bronchopleural fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopleural fistula occurs with a frequency ranging from 1.5 to 4.5 percent, and is associated with a mortality ranging from 29 to 79 percent. Bronchopleural fistulas occurring within one week of surgery are not necessarily associated with an empyema, whereas those occurring more than two weeks after surgery are associated with an empyema. Risk factors for formation of a bronchopleural fistula include right-sided procedures, a large diameter (&gt;25 mm) bronchial stump, residual tumor, concurrent radiation therapy or chemotherapy, age greater than 60 years, poor wound healing, and prolonged post-operative mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs and symptoms include fever, productive cough, hemoptysis, subcutaneous emphysema, and persistent air leak from a chest tube. Later development of a bronchopleural fistula and empyema may just be associated with nonspecific symptoms, as described earlier for a late PPS empyema. Chest radiographs frequently demonstrate a new air-liquid level in the PPS, multiple air-liquid levels in the PPS, or a change in a preexisting air-liquid level.",
"   </p>",
"   <p>",
"    Treatment of late bronchopleural fistulas as well as early bronchopleural fistulas associated with empyema includes drainage of the pleural space, systemic antibiotics, and then repair of the air leak once the PPS has been sterilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/54\">",
"     54",
"    </a>",
"    ]. Bronchopleural fistulas that occur within one week of surgery and are not associated with an empyema can be surgically closed. The management of bronchopleural fistulas in patients with respiratory failure requiring positive pressure mechanical ventilation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24486?source=see_link\">",
"     \"Management of bronchopleural fistula in patients on mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Esophagopleural fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagopleural fistula formation occurs with a frequency of 0.5 percent, and is more common after right-sided procedures. Most develop at least a year after pneumonectomy and are due to recurrent tumor eroding into the esophagus. Because esophagopleural fistulas are always associated with an empyema, symptoms are identical to those accompanying a late postpneumonectomy empyema. Diagnosis can be confirmed by performing a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow.",
"   </p>",
"   <p>",
"    Treatment is supportive if the fistula is due to recurrent tumor. Otherwise, treatment consists of drainage of the PPS, systemic antibiotics, and surgical repair of the fistula once the PPS is made sterile. Mortality approaches 65 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chylothorax, which occurs with a frequency less than 1 percent, develops within 15 days of surgery, usually in those patients who undergo concurrent lymph node resection. The diagnosis should be considered when there is rapid filling of the PPS in the immediate postoperative period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic patients with slow accumulation of chyle can be treated conservatively with bowel rest, and the chylothorax eventually resolves spontaneously. Patients with signs and symptoms of elevated central venous pressure, tachycardia, dyspnea, and hypotension as well as radiographic evidence of rapid filling of the PPS require drainage and surgical repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute hemothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid filling of the PPS with blood can occur within 24 hours of surgery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80537 \" href=\"mobipreview.htm?40/23/41342\">",
"     image 5",
"    </a>",
"    ). This complication is more common after pleuropneumonectomy or pneumonectomy for suppurative lung disease. The clinical presentation may be with hypotension and shock due to the loss of intravascular blood volume. The mainstay of treatment is surgical reexploration and control of bleeding sources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Contralateral pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contralateral pneumothorax is a rare complication that is usually seen in the immediate postoperative period. Proposed mechanisms have included intraoperative damage to the contralateral mediastinal pleura, or rupture of preexisting blebs or bullae. Signs and symptoms include sudden onset of dyspnea and hypoxemia, and the diagnosis is confirmed by chest radiography. Management includes evacuation of the air in the pleural space in order to achieve reexpansion of the underlying lung. Mortality is approximately 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to cardiovascular complications that can occur in association with any type of surgery, such as arrhythmias, myocardial infarction, and pulmonary embolism, other complications such as intracardiac shunting and cardiac herniation are specifically related to the pneumonectomy procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrhythmias occur in approximately 20 percent of patients following pneumonectomy, with most (80 percent) presenting within 72 hours of surgery. Atrial fibrillation is by far the most common arrhythmia following lung resection. Reported risk factors for development of a postoperative arrhythmia include age greater than 65 years, right pneumonectomy, male gender, clamshell incision, intrapericardial pneumonectomy, preexisting coronary artery disease, and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Extrapleural pneumonectomy appears to further increase the risk of atrial fibrillation, which occurred in 145 of 328 patients (44 percent) in one large series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=see_link\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial fibrillation after lung resection is associated with an increased incidence of other postoperative complications, longer hospitalization, and greater costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/61\">",
"     61",
"    </a>",
"    ]. Mortality rates associated with post-pneumonectomy arrhythmias may be as high as 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/62\">",
"     62",
"    </a>",
"    ]. Risk factors for developing atrial fibrillation after a pneumonectomy may include increasing age, male sex, and resection stage II or higher lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment varies according to the nature of the arrhythmia. Guidelines for treatment of the most common of these arrhythmias, atrial fibrillation, in the setting of pneumonectomy are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef69512 \" href=\"mobipreview.htm?25/62/26603\">",
"     table 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has been shown to be safe and effective for converting patients with postoperative atrial fibrillation back into sinus rhythm after lung resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/65\">",
"     65",
"    </a>",
"    ]. The treatment of new onset atrial fibrillation and the treatment of atrial fibrillation in patients with COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/21/8538?source=see_link&amp;anchor=H1291289#H1291289\">",
"     \"Arrhythmias in COPD\", section on 'Atrial fibrillation and supraventricular tachyarrhythmias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perioperative administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    appears to reduce the incidence of atrial fibrillation in patients undergoing lung resection, including pneumonectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In a randomized trial, 130 patients were randomly assigned to amiodarone or no prophylaxis. Amiodarone significantly reduced the risk of postoperative atrial fibrillation by more than 50 percent. Studies of other prophylactic antiarrhythmic drugs have not demonstrated a benefit with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , although a small study found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    prophylaxis resulted in a 50 percent reduction in the risk of atrial arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/68-71\">",
"     68-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the cardiac surgical literature, beta blockers prescribed preoperatively should not be withdrawn in the perioperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction following pneumonectomy occurs with a frequency of 1.5 to 5 percent. Management follows the usual considerations for management of myocardial infarction in other settings. Mortality from this complication following pneumonectomy is in excess of 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of thromboembolic disease complicating pneumonectomy may be as high as 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/73\">",
"     73",
"    </a>",
"    ]. Pulmonary embolism following pneumonectomy can originate from several sources. In addition to the deep venous system of the lower extremities, thromboembolism can rarely originate from the pulmonary artery stump (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80246 \" href=\"mobipreview.htm?16/50/17184\">",
"     image 6",
"    </a>",
"    ), a complication that is more frequent after right pneumonectomy.",
"   </p>",
"   <p>",
"    In addition, tumor emboli may occur in patients with tumor invading the left atrium or the main pulmonary artery. Air embolism after pneumonectomy is rare and can usually be avoided by using a split-bronchus endotracheal tube and only ventilating the non-operated lung. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23270?source=see_link\">",
"     \"Pulmonary tumor embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of thromboemboli typically includes anticoagulation, but emergency embolectomy may be required. Successful treatment of pulmonary embolism after lung resection with recombinant tissue plasminogen activator (tPA) has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Intracardiac shunting",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unusual complication following pneumonectomy is a right-to-left shunt that develops through a patent foramen ovale or an atrial septal defect. Although such right-to-left shunting can be precipitated by elevation in right heart pressures, it can also occur in the absence of elevated right atrial pressure due to a change in cardiac geometry, directing flow from the inferior vena cava across the interatrial communication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of right-to-left shunting include dyspnea and platypnea, typically developing between two days and one year following surgery. Diagnosis of a right-to-left shunt can be made on a nuclear medicine scan or by performing a shunt study on 100 percent oxygen. The cardiac location of the shunt can be confirmed by contrast echocardiography. Correction of the atrial septal defect or closure of the foramen ovale is curative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cardiac herniation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac herniation, a rare complication following intrapericardial right or left pneumonectomy, involves herniation of the heart through the defect in the pericardium and into the empty pleural (postpneumonectomy) space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. This can result in torsion and twisting of the heart (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54698 \" href=\"mobipreview.htm?6/63/7157\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cardiac herniation is usually seen within three days of surgery, presenting as sudden onset of hypotension and shock, cyanosis, chest pain, and superior vena cava syndrome. The acute event is usually preceded immediately by coughing, moving the patient, vomiting, or extubation.",
"   </p>",
"   <p>",
"    Treatment involves emergent surgery to reposition the heart and close the pericardial defect to prevent recurrence. Cardiac herniation may be prevented by primary closure of the pericardial defect at the time of pneumonectomy, or by suturing the edges of the pericardial defect to the myocardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of miscellaneous complications have also been described following pneumonectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Esophageal motility disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal studies following pneumonectomy have demonstrated abnormalities in esophageal sphincter pressure, esophageal body pressure, and peristalsis. Because these changes have not been extensively studied, their clinical implications are unknown. However, symptoms of dysphagia appear to be infrequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Gastric volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric volvulus is a rare complication that has been seen more than one year following surgery. It probably occurs as a result of anatomic changes after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactation can rarely occur after thoracotomy as a result of irritation of the anterior branches of the thoracic nerves. Treatment options include oral estrogen and progesterone, or nerve block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pneumopericardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumopericardium is a rare complication that occurs as a result of direct communication between a bronchopleural fistula, the bed of the pulmonary artery, and the pericardium. In some cases it may be complicated by development of cardiac tamponade. Diagnosis can be suggested by a pericardial \"crunch\" on physical examination or by a chest radiograph; treatment requires emergent surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Postpneumonectomy paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpneumonectomy paralysis is a rare complication due to intraoperative injury to the left lower intercostal arteries. These vessels feed the arteria magna, which in turn provides much of the blood supply to the thoracolumbar region of the spinal cord. This complication can also result from development of an epidural hematoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Postpneumonectomy scoliosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety percent of patients develop mild thoracic scoliosis after pneumonectomy due to shrinkage of the thoracic cage after surgery. Associated symptoms have not been reported in the postoperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108615060\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumonectomy is associated with a variety of reasonably predictable anatomic changes, significant decrements in pulmonary function, and a number of potential complications that involve the respiratory system, the cardiovascular system, and the pleural space [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32329/abstract/3\">",
"       3",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_table graphicRef67873 \" href=\"mobipreview.htm?27/10/27820\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiographic findings immediately after surgery demonstrate the trachea to be midline and the postpneumonectomy space (PPS) to be filled with air (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72520 graphicRef75963 \" href=\"mobipreview.htm?1/43/1715\">",
"       image 1A-B",
"      </a>",
"      ). Within 24 hours the ipsilateral hemidiaphragm becomes slightly elevated, the mediastinum shifts slightly towards the PPS, and fluid starts accumulating in the PPS. As a general rule, fluid accumulates at a rate of approximately two rib spaces per day. After two weeks, 80 to 90 percent of the PPS is filled with fluid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The location of vital organs (including the heart and great vessels, liver, and spleen) changes significantly following pneumonectomy as a consequence of mediastinal shift and elevation of the hemidiaphragm (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70082 graphicRef67587 graphicRef81115 \" href=\"mobipreview.htm?24/8/24711\">",
"       image 2A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thirty day mortality rates after pneumonectomy range from 2.4 to 11.6 percent, and ten-year survival rates for patients who underwent pneumonectomy for non-small cell lung cancer range from 67 to 85 percent, depending on size and stage of the tumor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Early mortality and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpneumonectomy lung volumes and diffusing capacity for carbon dioxide (DLCO) fall, but typically less than expected for removal of approximately 50 percent of the original lung tissue. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Postoperative pulmonary function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As long as the remaining lung is relatively normal, there is no significant change in resting values of systolic pulmonary artery pressure, pulmonary vascular resistance index, or central venous pressure after lung resection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Postoperative cardiovascular function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike patients who have had lobectomies and wedge resections, patients who have had pneumonectomies have a lower quality of life with regard to of overall physical function, pain, and dyspnea. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Postoperative quality of life'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpneumonectomy pulmonary edema is a form of noncardiogenic pulmonary edema and occurs with an overall frequency of 2 to 5 percent, and it is three times more common following right than left pneumonectomy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpneumonectomy syndrome reflects extrinsic compression of the distal trachea and mainstem bronchus due to shifting of the mediastinum and hyperinflation of the remaining lung (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73229 \" href=\"mobipreview.htm?24/35/25151\">",
"       image 3",
"      </a>",
"      ). It occurs more than six months following surgery and has even been reported 35 years after surgery. It is more common in patients who undergo surgery in childhood and is almost exclusively seen after right pneumonectomy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Postpneumonectomy syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpneumonectomy complications affecting the pleural space include infection, fistula formation, bleeding, chylothorax, and contralateral pneumothorax. Chylothorax develops within 15 days of surgery, usually in those patients who undergo concurrent lymph node resection. The diagnosis should be considered when there is rapid filling of the PPS in the immediate postoperative period. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pleural space complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to cardiovascular complications that can occur in association with any type of surgery (eg, arrhythmias, myocardial infarction, pulmonary embolism), other complications such as intracardiac shunting and cardiac herniation are specifically related to the pneumonectomy procedure. Intracardiac shunting can develop postpneumonectomy with a right-to-left shunt through a patent foramen ovale or an atrial septal defect, due to elevated right atrial pressure or a change in cardiac geometry. Cardiac herniation can result in torsion and twisting of the heart (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54698 \" href=\"mobipreview.htm?6/63/7157\">",
"       image 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cardiovascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other less common complications after pneumonectomy include esophageal dysmotility, gastric volvulus, lactation, pneumopericardium, postpneumonectomy paralysis, and postpneumonectomy scoliosis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/1\">",
"      James TW, Faber LP. Indications for pneumonectomy. Pneumonectomy for malignant disease. Chest Surg Clin N Am 1999; 9:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/2\">",
"      Conlan AA, Kopec SE. Indications for pneumonectomy. Pneumonectomy for benign disease. Chest Surg Clin N Am 1999; 9:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/3\">",
"      Kopec SE, Irwin RS, Umali-Torres CB, et al. The postpneumonectomy state. Chest 1998; 114:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/4\">",
"      CHRISTIANSEN KH, MORGAN SW, KARICH AF, TAKARO T. PLEURAL SPACE FOLLOWING PNEUMONECTOMY. Ann Thorac Surg 1965; 122:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/5\">",
"      Suarez J, Clagett T, Brown AL Jr. The postpneumonectomy space: factors influencing its obliteration. J Thorac Cardiovasc Surg 1969; 57:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/6\">",
"      Smulders SA, Holverda S, Vonk-Noordegraaf A, et al. Cardiac function and position more than 5 years after pneumonectomy. Ann Thorac Surg 2007; 83:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/7\">",
"      Kopec SE, Conlan AA, Irwin RS. Perforation of the right ventricle: a complication of blind placement of a chest tube into the postpneumonectomy space. Chest 1998; 114:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/8\">",
"      Conlan AA, Lukanich JM, Shutz J, Hurwitz SS. Elective pneumonectomy for benign lung disease: modern-day mortality and morbidity. J Thorac Cardiovasc Surg 1995; 110:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/9\">",
"      Miller JI Jr. Physiologic evaluation of pulmonary function in the candidate for lung resection. J Thorac Cardiovasc Surg 1993; 105:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/10\">",
"      Harpole DH, Liptay MJ, DeCamp MM Jr, et al. Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg 1996; 61:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/11\">",
"      Romano PS, Mark DH. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 1992; 101:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/12\">",
"      Harpole DH Jr, DeCamp MM Jr, Daley J, et al. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. J Thorac Cardiovasc Surg 1999; 117:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/13\">",
"      Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Recent results of postoperative mortality for surgical resections in lung cancer. Ann Thorac Surg 2004; 78:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/14\">",
"      Ramnath N, Demmy TL, Antun A, et al. Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting survival. Ann Thorac Surg 2007; 83:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/15\">",
"      Ludwig C, Stoelben E, Olschewski M, Hasse J. Comparison of morbidity, 30-day mortality, and long-term survival after pneumonectomy and sleeve lobectomy for non-small cell lung carcinoma. Ann Thorac Surg 2005; 79:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/16\">",
"      Kim DJ, Lee JG, Lee CY, et al. Long-term survival following pneumonectomy for non-small cell lung cancer: clinical implications for follow-up care. Chest 2007; 132:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/17\">",
"      Harmon H, Fergus S, Cole FH. Pneumonectomy: review of 351 cases. Ann Surg 1976; 183:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/18\">",
"      Wahi R, McMurtrey MJ, DeCaro LF, et al. Determinants of perioperative morbidity and mortality after pneumonectomy. Ann Thorac Surg 1989; 48:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/19\">",
"      Regnard JF, Icard P, Magdeleinat P, et al. Completion pneumonectomy: experience in eighty patients. J Thorac Cardiovasc Surg 1999; 117:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/20\">",
"      Terzi A, Lonardoni A, Falezza G, et al. Completion pneumonectomy for non-small cell lung cancer: experience with 59 cases. Eur J Cardiothorac Surg 2002; 22:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/21\">",
"      Miller DL, Deschamps C, Jenkins GD, et al. Completion pneumonectomy: factors affecting operative mortality and cardiopulmonary morbidity. Ann Thorac Surg 2002; 74:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/22\">",
"      Sherwood JT, Mitchell JD, Pomerantz M. Completion pneumonectomy for chronic mycobacterial disease. J Thorac Cardiovasc Surg 2005; 129:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/23\">",
"      Alfici R, Ashkenazi I, Kounavsky G, Kessel B. Total pulmonectomy in trauma: a still unresolved problem--our experience and review of the literature. Am Surg 2007; 73:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/24\">",
"      Patel RL, Townsend ER, Fountain SW. Elective pneumonectomy: factors associated with morbidity and operative mortality. Ann Thorac Surg 1992; 54:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/25\">",
"      Ferguson MK, Reeder LB, Mick R. Optimizing selection of patients for major lung resection. J Thorac Cardiovasc Surg 1995; 109:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/26\">",
"      Dales RE, Dionne G, Leech JA, et al. Preoperative prediction of pulmonary complications following thoracic surgery. Chest 1993; 104:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/27\">",
"      Leo F, Scanagatta P, Baglio P, et al. The risk of pneumonectomy over the age of 70. A case-control study. Eur J Cardiothorac Surg 2007; 31:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/28\">",
"      Ginsberg RJ, Hill LD, Eagan RT, et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 1983; 86:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/29\">",
"      Silvestri GA, Handy J, Lackland D, et al. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 1998; 114:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/30\">",
"      Krasna MJ. COUNTERPOINT: Pneumonectomy after chemoradiation: the risks of trimodality therapy. J Thorac Cardiovasc Surg 2009; 138:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/31\">",
"      Gaissert HA, Keum DY, Wright CD, et al. POINT: Operative risk of pneumonectomy--influence of preoperative induction therapy. J Thorac Cardiovasc Surg 2009; 138:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/32\">",
"      Thomas P, Michelet P, Barlesi F, et al. Impact of blood transfusions on outcome after pneumonectomy for thoracic malignancies. Eur Respir J 2007; 29:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/33\">",
"      Deslauriers J, Ugalde P, Miro S, et al. Adjustments in cardiorespiratory function after pneumonectomy: results of the pneumonectomy project. J Thorac Cardiovasc Surg 2011; 141:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/34\">",
"      Laros CD, Westermann CJ. Dilatation, compensatory growth, or both after pneumonectomy during childhood and adolescence. A thirty-year follow-up study. J Thorac Cardiovasc Surg 1987; 93:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/35\">",
"      Reed CE, Spinale FG, Crawford FA Jr. Effect of pulmonary resection on right ventricular function. Ann Thorac Surg 1992; 53:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/36\">",
"      Okada M, Ota T, Okada M, et al. Right ventricular dysfunction after major pulmonary resection. J Thorac Cardiovasc Surg 1994; 108:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/37\">",
"      Kowalewski J, Brocki M, Dryja��ski T, et al. Right ventricular morphology and function after pulmonary resection. Eur J Cardiothorac Surg 1999; 15:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/38\">",
"      Bolliger CT, Wyser C, Roser H, et al. Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. Chest 1995; 108:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/39\">",
"      Mossberg B, BJORK O, Holmgren A. Working capacity and cardiopulmonary function after extensive lung resections. Scand J Thorac Cardiovasc Surg 1976; 10:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/40\">",
"      Balduyck B, Hendriks J, Lauwers P, Van Schil P. Quality of life evolution after lung cancer surgery: a prospective study in 100 patients. Lung Cancer 2007; 56:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/41\">",
"      Leo F, Scanagatta P, Vannucci F, et al. Impaired quality of life after pneumonectomy: who is at risk? J Thorac Cardiovasc Surg 2010; 139:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/42\">",
"      Cerfolio RJ, Bryant AS, Thurber JS, et al. Intraoperative solumedrol helps prevent postpneumonectomy pulmonary edema. Ann Thorac Surg 2003; 76:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/43\">",
"      Jordan S, Mitchell JA, Quinlan GJ, et al. The pathogenesis of lung injury following pulmonary resection. Eur Respir J 2000; 15:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/44\">",
"      Mehran RJ, Deslauriers J. Late complications. Postpneumonectomy syndrome. Chest Surg Clin N Am 1999; 9:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/45\">",
"      Valji AM, Maziak DE, Shamji FM, Matzinger FR. Postpneumonectomy syndrome: recognition and management. Chest 1998; 114:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/46\">",
"      Sakiyalak P, Vigneswaran WT. Postpneumonectomy syndrome in single lung transplantation recipient following previous pneumonectomy. Ann Thorac Surg 2003; 75:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/47\">",
"      R&eacute;gnard JF, Pouliquen E, Magdeleinat P, et al. [Postpneumonectomy syndrome in adults: description and therapeutic propositions apropos of 8 cases]. Rev Mal Respir 1999; 16:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/48\">",
"      Kelly RF, Hunter DW, Maddaus MA. Postpneumonectomy syndrome after left pneumonectomy. Ann Thorac Surg 2001; 71:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/49\">",
"      Shen KR, Wain JC, Wright CD, et al. Postpneumonectomy syndrome: surgical management and long-term results. J Thorac Cardiovasc Surg 2008; 135:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/50\">",
"      Y&uuml;ksel M, Yildizeli B, Evman S, Kodalli N. Postpneumonectomy esophageal compression: an unusual complication. Eur J Cardiothorac Surg 2005; 28:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/51\">",
"      Partington SL, Graham A, Weeks SG. Pulmonary vein stenosis following left pneumonectomy: a variant contributor to postpneumonectomy syndrome. Chest 2010; 137:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/52\">",
"      Abbas Ael-S, Deschamps C. Postpneumonectomy empyema. Curr Opin Pulm Med 2002; 8:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/53\">",
"      Schneiter D, Cassina P, Korom S, et al. Accelerated treatment for early and late postpneumonectomy empyema. Ann Thorac Surg 2001; 72:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/54\">",
"      Deschamps C, Allen MS, Miller DL, et al. Management of postpneumonectomy empyema and bronchopleural fistula. Semin Thorac Cardiovasc Surg 2001; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/55\">",
"      Schneiter D, Grodzki T, Lardinois D, et al. Accelerated treatment of postpneumonectomy empyema: a binational long-term study. J Thorac Cardiovasc Surg 2008; 136:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/56\">",
"      Gossot D, Stern JB, Galetta D, et al. Thoracoscopic management of postpneumonectomy empyema. Ann Thorac Surg 2004; 78:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/57\">",
"      Hollaus PH, Lax F, Wurnig PN, et al. Videothoracoscopic debridement of the postpneumonectomy space in empyema. Eur J Cardiothorac Surg 1999; 16:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/58\">",
"      Darling GE, Abdurahman A, Yi QL, et al. Risk of a right pneumonectomy: role of bronchopleural fistula. Ann Thorac Surg 2005; 79:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/59\">",
"      Hollaus PH, Setinek U, Lax F, Pridun NS. Risk factors for bronchopleural fistula after pneumonectomy: stump size does matter. Thorac Cardiovasc Surg 2003; 51:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/60\">",
"      Panagopoulos ND, Apostolakis E, Koletsis E, et al. Low incidence of bronchopleural fistula after pneumonectomy for lung cancer. Interact Cardiovasc Thorac Surg 2009; 9:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/61\">",
"      Roselli EE, Murthy SC, Rice TW, et al. Atrial fibrillation complicating lung cancer resection. J Thorac Cardiovasc Surg 2005; 130:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/62\">",
"      Foroulis CN, Kotoulas C, Lachanas H, et al. Factors associated with cardiac rhythm disturbances in the early post-pneumonectomy period: a study on 259 pneumonectomies. Eur J Cardiothorac Surg 2003; 23:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/63\">",
"      Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/64\">",
"      Onaitis M, D'Amico T, Zhao Y, et al. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg 2010; 90:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/65\">",
"      Ciriaco P, Mazzone P, Canneto B, Zannini P. Supraventricular arrhythmia following lung resection for non-small cell lung cancer and its treatment with amiodarone. Eur J Cardiothorac Surg 2000; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/66\">",
"      Tisdale JE, Wroblewski HA, Wall DS, et al. A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. Ann Thorac Surg 2009; 88:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/67\">",
"      Lanza LA, Visbal AI, DeValeria PA, et al. Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection. Ann Thorac Surg 2003; 75:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/68\">",
"      Ritchie AJ, Bowe P, Gibbons JR. Prophylactic digitalization for thoracotomy: a reassessment. Ann Thorac Surg 1990; 50:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/69\">",
"      Van Mieghem W, Tits G, Demuynck K, et al. Verapamil as prophylactic treatment for atrial fibrillation after lung operations. Ann Thorac Surg 1996; 61:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/70\">",
"      Amar D, Roistacher N, Burt ME, et al. Effects of diltiazem versus digoxin on dysrhythmias and cardiac function after pneumonectomy. Ann Thorac Surg 1997; 63:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/71\">",
"      Borgeat A, Biollaz J, Bayer-Berger M, et al. Prevention of arrhythmias by flecainide after noncardiac thoracic surgery. Ann Thorac Surg 1989; 48:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/72\">",
"      Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997; 336:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/73\">",
"      Mason DP, Quader MA, Blackstone EH, et al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg 2006; 131:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/74\">",
"      Kameyama K, Huang CL, Liu D, et al. Pulmonary embolism after lung resection: diagnosis and treatment. Ann Thorac Surg 2003; 76:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/75\">",
"      Self RJ, Vaughan RS. Acute cardiac herniation after radical pleuropneumonectomy. Anaesthesia 1999; 54:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/76\">",
"      Shimizu J, Ishida Y, Hirano Y, et al. Cardiac herniation following intrapericardial pneumonectomy with partial pericardiectomy for advanced lung cancer. Ann Thorac Cardiovasc Surg 2003; 9:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/77\">",
"      Veronesi G, Spaggiari L, Solli PG, Pastorino U. Cardiac dislocation after extended pneumonectomy with pericardioplasty. Eur J Cardiothorac Surg 2001; 19:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/78\">",
"      Foroulis C, Kotoulas C, Konstantinou M, Lioulias A. The use of pedicled pleural flaps for the repair of pericardial defects, resulting after intrapericardial pneumonectomy. Eur J Cardiothorac Surg 2002; 21:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32329/abstract/79\">",
"      Blum MG, Sundaresan RS. Giant hiatal hernia with gastric volvulus complicating pneumonectomy. Ann Thorac Surg 2006; 81:1491.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1457 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32329=[""].join("\n");
var outline_f31_36_32329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H108615060\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EARLY MORTALITY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      POSTOPERATIVE PULMONARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POSTOPERATIVE CARDIOVASCULAR FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POSTOPERATIVE QUALITY OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PULMONARY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Postpneumonectomy syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intraoperative spillage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PLEURAL SPACE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Postpneumonectomy empyema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bronchopleural fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Esophagopleural fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chylothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute hemothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Contralateral pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CARDIOVASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Intracardiac shunting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cardiac herniation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Esophageal motility disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pneumopericardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Postpneumonectomy paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Postpneumonectomy scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108615060\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1457\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1457|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/41/16031\" title=\"diagnostic image 1A\">",
"      Early postpneumonectomy PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/57/27551\" title=\"diagnostic image 1B\">",
"      48h postpneumonectomy PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/33/13840\" title=\"diagnostic image 2A\">",
"      Postoperative cardiac shift CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/42/5792\" title=\"diagnostic image 2B\">",
"      Postoperative liver shift CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/17/38175\" title=\"diagnostic image 2C\">",
"      Postoperative splenic shift CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/35/25151\" title=\"diagnostic image 3\">",
"      Postop tracheobronchial changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/16/28929\" title=\"diagnostic image 4\">",
"      Postpneumonectomy empyema PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/23/41342\" title=\"diagnostic image 5\">",
"      Tension hemothorax PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/50/17184\" title=\"diagnostic image 6\">",
"      PA stump thrombus CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/63/7157\" title=\"diagnostic image 7\">",
"      Postoperative hypotension PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1457|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/10/27820\" title=\"table 1\">",
"      Pneumonectomy complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/62/26603\" title=\"table 2\">",
"      Tx AF after pneumonectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/21/8538?source=related_link\">",
"      Arrhythmias in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=related_link\">",
"      Identification and assessment of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25610?source=related_link\">",
"      Management of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24486?source=related_link\">",
"      Management of bronchopleural fistula in patients on mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23270?source=related_link\">",
"      Pulmonary tumor embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_36_32330="Overview of hypertension in adults";
var content_f31_36_32330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hypertension in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32330/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32330/contributors\">",
"     Frank J Domino, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32330/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/36/32330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/36/32330/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/36/32330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hypertension is the most common reason for office visits of non-pregnant adults to physicians in the United States and for use of prescription drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/1\">",
"     1",
"    </a>",
"    ]. The national health and nutrition examination survey (NHANES) conducted from 2005 through 2008 estimated that approximately 29 to 31 percent of adults in the United States have hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/1\">",
"     1",
"    </a>",
"    ]. This translates into 58 to 65 million hypertensives in the adult population in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of patients with hypertension is likely to grow as the population ages, since either isolated systolic hypertension or combined systolic and diastolic hypertension occurs in the majority of persons older than 65 years (",
"    <a class=\"graphic graphic_figure graphicRef66935 \" href=\"mobipreview.htm?7/4/7247\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/3\">",
"     3",
"    </a>",
"    ]. The rising incidence of obesity will also increase the number of hypertensive individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the prevalence of hypertension and its associated complications, control of the disease is far from adequate. Data from the 2005-2008 NHANES survey show that only 46 to 51 percent of persons with hypertension have their blood pressure under control, defined as a level below",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg (",
"    <a class=\"graphic graphic_table graphicRef82423 \" href=\"mobipreview.htm?33/26/34219\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are numerous potential reasons for low rates of blood pressure control, including poor access to health care and medications and lack of adherence with long-term therapy for a condition that is usually asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/5\">",
"     5",
"    </a>",
"    ]. The latter may be particularly true when the therapy may interfere with the patient's quality of life and when its immediate benefits may not be obvious to the patient. Thus, hypertension will likely remain the most common risk factor for heart attack and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=see_link\">",
"     \"Patient adherence and the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic provides a broad overview of the definitions, pathogenesis, complications, diagnosis, evaluation, and management of hypertension. Detailed discussions of all of these issues are found separately. The reader is directed, when necessary, to more detailed discussions of these issues in other topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following definitions were suggested in 2003 by the seventh report of the Joint National Committee (JNC 7) based upon the average of two or more properly measured readings at each of",
"    <strong>",
"     two or more visits after an initial screen",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal blood pressure: systolic &lt;120 mmHg and diastolic &lt;80 mmHg",
"     </li>",
"     <li>",
"      Prehypertension: systolic 120 to 139 mmHg or diastolic 80 to 89 mmHg",
"     </li>",
"     <li>",
"      Hypertension:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage 1: systolic 140 to 159 mmHg or diastolic 90 to 99 mmHg",
"     </li>",
"     <li>",
"      Stage 2: systolic &ge;160 or diastolic &ge;100 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolated systolic hypertension is considered to be present when the blood pressure is",
"    <span class=\"nowrap\">",
"     &ge;140/&lt;90",
"    </span>",
"    mmHg and isolated diastolic hypertension is considered to be present when the blood pressure is",
"    <span class=\"nowrap\">",
"     &lt;140/&ge;90",
"    </span>",
"    mmHg.",
"   </p>",
"   <p>",
"    These definitions apply to adults on no antihypertensive medications and who are not acutely ill. If there is a disparity in category between the systolic and diastolic pressures, the higher value determines the severity of the hypertension. The systolic pressure is the greater predictor of risk in patients over the age of 50 to 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar but not identical definitions were suggested in the 2007 European Societies of Hypertension and Cardiology guidelines for the management of arterial hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/8\">",
"     8",
"    </a>",
"    ]. The major difference is that the European guidelines divide blood pressures below",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg into three categories (\"optimal\", \"normal\", and \"high normal\") instead of the two categories (\"normal\" and \"prehypertension\") defined by JNC 7.",
"   </p>",
"   <p>",
"    Clinical significance of blood pressure readings appears age dependant. Over age 50 years, systolic blood pressure &gt;140 mmHg predicts mortality regardless of diastolic readings. Under age 50 years, diastolic blood pressure is a better predictor of mortality than systolic readings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/9\">",
"     9",
"    </a>",
"    ]. Systolic hypertension in older individuals is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7525347\">",
"    <span class=\"h3\">",
"     Definitions based upon ambulatory and home readings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypertension using ambulatory blood pressure monitoring depends upon the time span over which it is interpreted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 24-hour average above",
"      <span class=\"nowrap\">",
"       135/85",
"      </span>",
"      mmHg",
"     </li>",
"     <li>",
"      Daytime (awake) average above",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg",
"     </li>",
"     <li>",
"      Nighttime (asleep) average above",
"      <span class=\"nowrap\">",
"       125/75",
"      </span>",
"      mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Home readings correlate more closely with the results of daytime ambulatory measurements than with blood pressure taken in the physician's office. Thus, the definition of hypertension based upon an average of multiple home readings is the same as for daytime ambulatory blood pressure. The use of ambulatory and home blood pressure monitoring in adults is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malignant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant hypertension refers to marked hypertension with retinal hemorrhages, exudates, or papilledema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/10\">",
"     10",
"    </a>",
"    ]. These findings may be associated with hypertensive encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignant hypertension is usually associated with diastolic pressures above 120 mmHg. However, it can occur at diastolic pressures as low as 100 mmHg in previously normotensive patients with acute hypertension due to preeclampsia or acute glomerulonephritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30698321\">",
"    <span class=\"h2\">",
"     Hypertensive urgency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypertension (as defined by a diastolic blood pressure above 120 mmHg) in asymptomatic patients is referred to as hypertensive urgency. There is no proven benefit from rapid reduction in BP in asymptomatic patients who have no evidence of acute end-organ damage and are at little short-term risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ESSENTIAL (PRIMARY) HYPERTENSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of primary, or essential, hypertension is poorly understood. A variety of factors have been implicated, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased sympathetic neural activity, with enhanced beta-adrenergic responsiveness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44677?source=see_link\">",
"       \"Prehypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased angiotensin II activity and mineralocorticoid excess. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36804?source=see_link\">",
"       \"Low-renin essential (primary) hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension is about twice as common in subjects who have one or two hypertensive parents and multiple epidemiologic studies suggest that genetic factors account for approximately 30 percent of the variation in blood pressure in various populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=see_link\">",
"       \"Genetic factors in the pathogenesis of essential hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduced adult nephron mass may predispose to hypertension, which may be related to genetic factors, intrauterine developmental disturbance (eg, hypoxia, drugs, nutritional deficiency), and post-natal environment (eg, malnutrition, infections). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=see_link\">",
"       \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of primary or essential hypertension and identifiable or secondary hypertension (due to a known cause) differ. A variety of risk factors have been associated with essential hypertension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension tends to be both more common and more severe in blacks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11174?source=see_link\">",
"       \"Hypertensive complications in blacks\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension in maternal, paternal or both parents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excess sodium intake increases the risk for hypertension, and sodium restriction lowers blood pressure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link\">",
"       \"Salt intake, salt restriction, and essential hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excess alcohol intake is associated with the development of hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link&amp;anchor=H8#H8\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obesity and weight gain are major risk factors for hypertension and are also determinants of the rise in blood pressure that is commonly observed with aging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=see_link\">",
"       \"Obesity and weight reduction in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physical inactivity increases the risk for hypertension, and exercise is an effective means of lowering blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/2998?source=see_link&amp;anchor=H2#H2\">",
"       \"Exercise in the treatment and prevention of hypertension\", section on 'Efficacy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dyslipidemia, independent of obesity is associated with hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite well publicized studies suggesting that fructose may increase hypertension risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/20\">",
"       20",
"      </a>",
"      ], the best data suggest that it does not raise blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/21\">",
"       21",
"      </a>",
"      ] or increase the incidence of hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertension may be more common among those with certain personality traits, such as hostile attitudes and time",
"      <span class=\"nowrap\">",
"       urgency/impatience",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/23\">",
"       23",
"      </a>",
"      ], as well as among those with depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin D deficiency is associated with an increased risk of hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SECONDARY OR IDENTIFIABLE HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions may lead to secondary hypertension (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary renal disease &ndash; Both acute and chronic kidney disease, particularly with glomerular or vascular disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link\">",
"       \"Overview of hypertension in acute and chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral contraceptives &ndash; Oral contraceptives often raise the blood pressure within the normal range but can also induce overt hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=see_link\">",
"       \"Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced &ndash; Chronic nonsteroidal antiinflammatory agents and many antidepressants can induce hypertension. Chronic alcohol intake and alcohol abuse can also raise blood pressure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=see_link\">",
"       \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link&amp;anchor=H8#H8\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pheochromocytoma &ndash; About one-half of patients with pheochromocytoma have paroxysmal hypertension, most of the rest have what appears to be primary hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"       \"Clinical presentation and diagnosis of pheochromocytoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link\">",
"       \"Treatment of pheochromocytoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary aldosteronism &ndash; The presence of primary mineralocorticoid excess, primarily aldosterone, should be suspected in any patient with the triad of hypertension, unexplained hypokalemia, and metabolic alkalosis. However, some patients have a normal plasma potassium concentration. The prevalence of primary aldosteronism should also be considered in patients with resistant hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"       \"Clinical features of primary aldosteronism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"       \"Approach to the patient with hypertension and hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renovascular disease &ndash; Renovascular disease is a common disorder, occurring primarily in patients with generalized atherosclerosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=see_link\">",
"       \"Establishing the diagnosis of renovascular hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cushing's syndrome &ndash; Hypertension is a major cause of morbidity and death in patients with Cushing's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other endocrine disorders &ndash; Hypothyroidism, hyperthyroidism, and hyperparathyroidism may also induce hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/62/3046?source=see_link\">",
"       \"Cardiovascular effects of hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23062?source=see_link\">",
"       \"Cardiovascular effects of hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstructive sleep apnea &ndash; Disordered breathing during sleep appears to be an independent risk factor for systemic hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link\">",
"       \"Cardiovascular effects of obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coarctation of the aorta &ndash; Coarctation of the aorta is one of the major causes of secondary hypertension in young children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is associated with a number of serious adverse effects. The likelihood of developing these complications varies with the blood pressure. The increase in risk begins as the blood pressure rises above",
"    <span class=\"nowrap\">",
"     115/75",
"    </span>",
"    mmHg in all age groups (",
"    <a class=\"graphic graphic_figure graphicRef75106 graphicRef66793 \" href=\"mobipreview.htm?33/12/33986\">",
"     figure 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/27\">",
"     27",
"    </a>",
"    ]. However, this relationship does not prove causality, which can only be demonstrated by randomized trials showing benefit from blood pressure reduction.",
"   </p>",
"   <p>",
"    The increase in cardiovascular risk associated with hypertension is importantly affected by the presence or absence of other risk factors (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension is quantitatively the major risk factor for premature cardiovascular disease, being more common than cigarette smoking, dyslipidemia, or diabetes, the other major risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/29\">",
"       29",
"      </a>",
"      ]. In older patients, systolic pressure and pulse pressure are more powerful determinants of risk than diastolic pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of heart failure increases with the degree of blood pressure elevation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15497?source=see_link\">",
"       \"Epidemiology and causes of heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy is a common finding in patients with hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/31\">",
"       31",
"      </a>",
"      ], and is associated with an enhanced incidence of heart failure, ventricular arrhythmias, death following myocardial infarction, and sudden cardiac death (",
"      <a class=\"graphic graphic_figure graphicRef52329 \" href=\"mobipreview.htm?24/36/25165\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=see_link\">",
"       \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension is the most common and most important risk factor for ischemic stroke, the incidence of which can be markedly reduced by effective antihypertensive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical diagnosis of stroke subtypes\", section on 'Ecology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension is the most important risk factor for the development of intracerebral hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"       \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension is a risk factor for chronic kidney disease and end-stage renal disease (",
"      <a class=\"graphic graphic_figure graphicRef69454 \" href=\"mobipreview.htm?38/4/38990\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. It can both directly cause kidney disease, called hypertensive nephrosclerosis, and accelerate the progression of a variety of underlying renal diseases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Marked elevations in blood pressure can cause an acute, life-threatening emergency (",
"      <a class=\"graphic graphic_table graphicRef54145 \" href=\"mobipreview.htm?15/43/16060\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 United States Preventive Services Task Force (USPSTF) guidelines on screening for high blood pressure recommend screening every two years for persons with systolic and diastolic pressures below 120 mmHg and 80 mmHg, respectively (normal BP in JNC 7), and yearly for persons with a systolic pressure of 120 to 139 mmHg or a diastolic pressure of 80 to 89 mmHg (prehypertension in JNC 7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper measurement and interpretation of the blood pressure is essential in the diagnosis and management of hypertension. There are a variety of steps that must be followed to achieve maximum accuracy in this process (",
"    <a class=\"graphic graphic_table graphicRef65136 \" href=\"mobipreview.htm?43/32/44556\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/38\">",
"     38",
"    </a>",
"    ]. The preferred technique is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    .) Out of office blood pressure measurement, which better predicts hypertension related morbidity and mortality, is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of end-organ damage, the diagnosis of mild hypertension should not be made until the blood pressure has been measured on at least",
"    <strong>",
"     three to six visits",
"    </strong>",
"    , spaced over a period of weeks to months. Sequential studies have shown that the blood pressure drops by an average of 10 to 15 mmHg between visits one and three in patients who appear to have mild hypertension on a first visit to a new doctor, with a stable value not being achieved until more than six visits in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Thus, many patients considered to be hypertensive at the initial visit are in fact normotensive.",
"   </p>",
"   <p>",
"    In addition to obtaining multiple blood pressure measurements, blood pressure should be measured in both arms and, in some individuals, postural measurements should be taken:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systolic blood pressure readings in the left and right arms should be roughly equivalent. A discrepancy of more than 15 mmHg may indicate subclavian stenosis and, hence, peripheral arterial disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link\">",
"       \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postural hypotension, defined as a 20 mmHg or greater fall in systolic pressure upon rising from supine to an unassisted upright position, should be pursued in patients over age 65, those experiencing dizziness or weakness upon standing, or those with diabetes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/41/12951?source=see_link\">",
"       \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     White coat hypertension and ambulatory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 25 percent of patients with stage 1 office hypertension have \"white-coat\" or isolated office hypertension in that their blood pressure is repeatedly normal when measured at home, at work, or by ambulatory blood pressure monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/41\">",
"     41",
"    </a>",
"    ]. This problem is more common in the elderly, but is infrequent (less than 5 percent) in patients with office diastolic pressures &ge;105 mmHg. One way to minimize the white coat effect is to have the blood pressure measured while seated after five minutes in a quiet, unobserved setting by an automated device that obtains five repeated blood pressure measurements at one to five minute intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ambulatory blood pressure monitoring (ABPM), which records the blood pressure at preset intervals (usually every 15 to 20 minutes during the day and every 30 to 60 minutes during sleep), can be used to confirm or exclude the presence of white coat hypertension in patients with persistent office hypertension but normal blood pressure readings out of the office [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more detailed discussion of white coat hypertension and ambulatory blood pressure monitoring is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Masked hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;24-hour monitoring of larger populations has revealed a significant number of patients with elevated out-of-office readings despite normal office readings (eg, masked hypertension) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/44\">",
"     44",
"    </a>",
"    ]. Cardiovascular risk appears to be elevated in such patients to a similar extent as patients with sustained hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/45\">",
"     45",
"    </a>",
"    ]. This is consistent with the risk of hypertensive cardiovascular complications being more closely correlated with 24-hour or daytime ambulatory monitoring than with the office pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Indications for ABPM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to patients with suspected white coat hypertension, ambulatory monitoring should be considered in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suspected episodic hypertension (eg, pheochromocytoma)",
"     </li>",
"     <li>",
"      Hypertension resistant to increasing medication",
"     </li>",
"     <li>",
"      Hypotensive symptoms while taking antihypertensive medications",
"     </li>",
"     <li>",
"      Autonomic dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H13#H13\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Indications for ABPM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been determined that the patient has persistent hypertension, an evaluation should be performed to ascertain the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To determine the extent of target organ damage.",
"     </li>",
"     <li>",
"      To assess the patient's overall cardiovascular risk status. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"       \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To rule out identifiable and often curable causes of hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with presumed primary, or essential, hypertension should undergo a relatively limited work-up because extensive laboratory testing is of limited utility and is associated with a high incidence of false positive results. However, it is important to be aware of the clinical clues suggesting the possible presence of one of the causes of secondary hypertension (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"mobipreview.htm?41/38/42604\">",
"     table 4",
"    </a>",
"    ), which indicate the need for a more extensive evaluation. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/422?source=see_link\">",
"     \"Initial evaluation of the hypertensive adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should search for those facts that help determine the presence of precipitating or aggravating factors (including prescription medications, non-prescription nonsteroidal antiinflammatory agents, and alcohol consumption), the natural course of the blood pressure, the extent of target organ damage, and the presence of other risk factors for cardiovascular disease (",
"    <a class=\"graphic graphic_table graphicRef77599 \" href=\"mobipreview.htm?17/8/17549\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main goals on the physical examination are to evaluate for signs of end-organ damage (such as retinopathy) and for evidence of a cause of secondary hypertension (",
"    <a class=\"graphic graphic_table graphicRef69470 \" href=\"mobipreview.htm?13/39/13948\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only tests that should be routinely performed include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematocrit, urinalysis, routine blood chemistries (glucose, creatinine, electrolytes), and estimated glomerular filtration rate",
"     </li>",
"     <li>",
"      Lipid profile (total and HDL-cholesterol, triglycerides)",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional tests",
"    <strong>",
"     may",
"    </strong>",
"    be indicated in certain settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microalbuminuria is increasingly recognized to be an independent risk factor for cardiovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/46\">",
"       46",
"      </a>",
"      ]. A discussion of screening for microalbuminuria among nondiabetics with hypertension is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"       \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/32/521?source=see_link\">",
"       \"Epidemiology of chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Echocardiography is indicated to detect possible end-organ damage in a patient with borderline blood pressure values, thereby identifying some patients who would not be treated based upon clinical criteria alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\", section on 'Indications for echocardiography in hypertensive patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Testing for renovascular hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of this condition varies with the clinical setting. It probably occurs in less than 1 percent of patients with mild hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/48\">",
"     48",
"    </a>",
"    ]. In comparison, between 10 and 45 percent of white patients with severe or malignant hypertension have renal artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic testing for renovascular disease is indicated",
"    <strong>",
"     only",
"    </strong>",
"    in patients in whom there are suggestive clinical clues and",
"    <strong>",
"     only",
"    </strong>",
"    if a corrective procedure will be recommended if significant renal artery stenosis is detected. The clinical clues for renovascular hypertension, screening modalities to detect renovascular disease, and recommendations about whether and in whom corrective interventions should be performed are discussed in detail in other topics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29369?source=see_link\">",
"     \"Treatment of unilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Testing for other causes of identifiable hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of identifiable hypertension also must be excluded in the appropriate settings. Clues to the presence of identifiable causes of hypertension are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Benefits of blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most clinical trials, antihypertensive therapy compared with placebo has been associated with significant 20 to 25 percent relative risk reductions in the incidence of heart failure and myocardial infarction, and a 30 to 40 percent reduction in the incidence of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these relative risk reductions do not tell the absolute benefit. In the aggregate, antihypertensive therapy for four to five years prevented a coronary event in 0.7 percent of patients and a cerebrovascular event in 1.3 percent for a total benefit of approximately",
"    <strong>",
"     2 percent",
"    </strong>",
"    ; this included a reduction in cardiovascular mortality of 0.8 percent (",
"    <a class=\"graphic graphic_figure graphicRef52231 \" href=\"mobipreview.htm?43/29/44509\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, 100 patients must be treated for four to five years to prevent a complication in two patients. It is presumed that these statistics",
"    <strong>",
"     underestimate",
"    </strong>",
"    the true benefit of treating stage 1 hypertension since the trials were of too short duration (five to seven years) to determine efficacy in a longer-term diseases such as atherosclerosis and heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Equal if not greater benefits have been shown with the treatment of elderly hypertensive patients (over age 65), most of whom have isolated systolic hypertension. Because the elderly start at such higher overall cardiovascular risk, short-term reductions in their hypertension provide greater benefits than that observed in younger patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of antihypertensive therapy are less clear or controversial in patients who have mild hypertension (blood pressure less than",
"    <span class=\"nowrap\">",
"     150/90",
"    </span>",
"    mmHg) and no preexisting cardiovascular disease, and in elderly patients who are frail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H2092868#H2092868\">",
"     \"Hypertension: Who should be treated?\", section on 'Low-risk patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link&amp;anchor=H14493503#H14493503\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Problem of frailty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Who should be treated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the above definitions from JNC 7, the following general approach can be used to determine which patients with hypertension require antihypertensive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/4,52,53\">",
"     4,52,53",
"    </a>",
"    ]. This approach largely includes the recommendations of JNC 7 for risk stratification and treatment and assumes accurate measurement of the blood pressure (",
"    <a class=\"graphic graphic_table graphicRef72683 \" href=\"mobipreview.htm?34/41/35484\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/4\">",
"     4",
"    </a>",
"    ]. A review of the potential errors involved with the procedure of blood pressure measurement is available elsewhere. In the absence of end-organ damage, a patient should not be labeled as having hypertension unless: the blood pressure is persistently elevated after",
"    <strong>",
"     three to six visits",
"    </strong>",
"    over a several month period; hypertension is revealed by 24-hour ambulatory monitoring; or the average of home blood pressure readings taken in the morning and evening daily for seven days is elevated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients should undergo appropriate nonpharmacologic (lifestyle) modification (",
"    <a class=\"graphic graphic_table graphicRef62129 \" href=\"mobipreview.htm?42/24/43403\">",
"     table 8",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Nonpharmacologic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following decisions about antihypertensive medications are generally",
"    <strong>",
"     not",
"    </strong>",
"    made until there has been an adequate trial of nonpharmacologic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antihypertensive medications should generally be begun if the systolic pressure is persistently &ge;140 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the diastolic pressure is persistently &ge;90 mmHg in the office and at home despite attempted nonpharmacologic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/4,54,55\">",
"       4,54,55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"       \"Hypertension: Who should be treated?\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Starting with two drugs should be considered in patients with a baseline blood pressure above",
"      <span class=\"nowrap\">",
"       160/100",
"      </span>",
"      mmHg. This strategy may increase the likelihood that target blood pressures are achieved in a reasonable time period, but should be used cautiously in patients at increased risk for orthostatic hypotension (such as diabetics and the elderly). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is some evidence supporting a lower goal for systolic blood pressure in patients with atherosclerotic cardiovascular disease and patients with chronic kidney disease complicated by proteinuria. The supportive data are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"       \"What is goal blood pressure in the treatment of hypertension?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with office hypertension, normal values at home, and no evidence of end-organ damage should undergo ambulatory blood pressure monitoring to see if they are truly hypertensive. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"       \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a number of conditions (eg, atrial fibrillation, heart failure, post-myocardial infarction), certain antihypertensive drugs are given to improve survival or the underlying disease and other drugs are contraindicated, independent of the blood pressure (",
"      <a class=\"graphic graphic_table graphicRef63628 \" href=\"mobipreview.htm?10/53/11101\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, the benefits of antihypertensive therapy are less clear or controversial in patients who have mild hypertension (blood pressure less than",
"    <span class=\"nowrap\">",
"     150/90",
"    </span>",
"    mmHg) and no preexisting cardiovascular disease, and in elderly patients who are frail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H2092868#H2092868\">",
"     \"Hypertension: Who should be treated?\", section on 'Low-risk patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link&amp;anchor=H14493503#H14493503\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Problem of frailty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hypertension should involve nonpharmacologic therapy (also called lifestyle modification) alone or in concert with antihypertensive drug therapy (",
"    <a class=\"graphic graphic_table graphicRef62129 \" href=\"mobipreview.htm?42/24/43403\">",
"     table 8",
"    </a>",
"    ). &ndash;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary salt restriction &ndash; In well-controlled randomized trials, the overall impact of moderate sodium reduction is a fall in blood pressure in hypertensive and normotensive individuals of",
"      <span class=\"nowrap\">",
"       4.8/2.5",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       1.9/1.1",
"      </span>",
"      mmHg, respectively (",
"      <a class=\"graphic graphic_figure graphicRef81634 \" href=\"mobipreview.htm?17/48/18190\">",
"       figure 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/56\">",
"       56",
"      </a>",
"      ]. The effects of sodium restriction on blood pressure, cardiovascular disease and mortality, and specific recommendations for sodium intake are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link\">",
"       \"Salt intake, salt restriction, and essential hypertension\"",
"      </a>",
"      .) In the absence of documented harm from moderate sodium reduction that is advocated in all expert guidelines, the proven ability of sodium reduction to lower blood pressure and to enhance the efficacy of all antihypertensive drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/57\">",
"       57",
"      </a>",
"      ], provides strong justification for the use of moderate sodium reduction.",
"     </li>",
"     <li>",
"      Weight loss &ndash; Weight loss in obese individuals can lead to a significant fall in blood pressure. The decline in blood pressure induced by weight loss can occur in the absence of dietary sodium restriction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/58\">",
"       58",
"      </a>",
"      ], but even modest sodium restriction may produce an additive antihypertensive effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/59\">",
"       59",
"      </a>",
"      ]. The weight loss-induced decline in BP generally ranges from 0.5 to 2 mmHg for every 1 kg of weight lost (",
"      <a class=\"graphic graphic_figure graphicRef60178 \" href=\"mobipreview.htm?24/34/25133\">",
"       figure 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link\">",
"       \"Diet in the treatment and prevention of hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=see_link\">",
"       \"Obesity and weight reduction in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DASH diet &ndash; The DASH diet consists of increased intake of fruits and vegetables and low-fat dairy products and can be combined with salt restriction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link&amp;anchor=H4#H4\">",
"       \"Diet in the treatment and prevention of hypertension\", section on 'DASH trial'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link&amp;anchor=H5#H5\">",
"       \"Diet in the treatment and prevention of hypertension\", section on 'Low sodium DASH'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise &ndash; Aerobic exercise usually has a beneficial effect on the systemic blood pressure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/2998?source=see_link\">",
"       \"Exercise in the treatment and prevention of hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limited alcohol intake &ndash; Women who consume two or more alcoholic beverages per day and men who have three or more drinks per day have a significantly increased incidence of hypertension compared to nondrinkers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/17,61\">",
"       17,61",
"      </a>",
"      ]; this effect is dose-related and is most prominent when intake exceeds five drinks per day. On the other hand, decreasing alcohol intake in individuals who drink excessively significantly lowers blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/62\">",
"       62",
"      </a>",
"      ], and moderate alcohol use appears to reduce the risk of cardiovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin D &ndash; Vitamin D supplementation should be initiated in those with low or low-normal 25-hydroxyvitamin D levels or those at risk for vitamin D deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comprehensive intervention &ndash; The benefits of comprehensive lifestyle modification with all five of the above modalities were examined in the PREMIER trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/65\">",
"       65",
"      </a>",
"      ]. At 18 months, there was a lower prevalence of hypertension (22 versus 32 percent), and less use of antihypertensive medications (10 to 14 versus 19 percent), although the difference was not statistically significant. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link&amp;anchor=H6#H6\">",
"       \"Diet in the treatment and prevention of hypertension\", section on 'PREMIER trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient education &ndash; Patient education has been demonstrated to result in improved blood pressure control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/66\">",
"       66",
"      </a>",
"      ]. In addition to education of patients by their clinicians, blood pressure control may be improved when patients with hypertension hear the personal stories of their peers with hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other &ndash; Other nonpharmacologic therapies that may be beneficial include adequate potassium intake, cessation of smoking, and limiting the use of nonsteroidal antiinflammatory drugs and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13060?source=see_link\">",
"       \"Potassium and hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3395?source=see_link\">",
"       \"Smoking and hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=see_link\">",
"       \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Drug treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     General efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple guidelines and meta-analyses conclude that the amount of blood pressure reduction is the major determinant of reduction in cardiovascular risk in patients with hypertension, not the choice of antihypertensive drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/50,54,55,68\">",
"     50,54,55,68",
"    </a>",
"    ]. Some patients have an indication for a specific drug or drugs that is unrelated to essential hypertension, which will influence the choice of therapy (",
"    <a class=\"graphic graphic_table graphicRef63628 \" href=\"mobipreview.htm?10/53/11101\">",
"     table 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Initial monotherapy in uncomplicated hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a specific indication, there are three main classes of drugs that are used for initial monotherapy: thiazide diuretics, long-acting calcium channel blockers (most often a dihydropyridine such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ), and ACE inhibitors or angiotensin II receptor blockers. It is the attained blood pressure, not the specific drug(s) used, which is the primary determinant of outcome. Beta blockers are not commonly used for initial monotherapy in the absence of a specific indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent therapy may not adequately control the blood pressure, particularly in those whose blood pressure is more than",
"    <span class=\"nowrap\">",
"     20/10",
"    </span>",
"    mmHg above goal. Combination therapy with drugs from different classes has a substantially greater blood pressure lowering effect than doubling the dose of a single agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/70\">",
"     70",
"    </a>",
"    ]. When more than one agent is needed to control the blood pressure, we recommend therapy with a long-acting ACE inhibitor or angiotensin receptor blocker in concert with a long-acting dihydropyridine calcium channel blocker. The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H24#H24\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2528233\">",
"    <span class=\"h3\">",
"     Possible benefit from nocturnal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average nocturnal blood pressure is approximately 15 percent lower than daytime values. Failure of the blood pressure to fall by at least 10 percent during sleep is called \"nondipping,\" and is a stronger predictor of adverse cardiovascular outcomes than daytime blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H10#H10\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Nocturnal blood pressure and nondippers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shifting at least one antihypertensive medication from the morning to the evening both may restore the normal nocturnal blood pressure dip, and reduces 24-hour mean blood pressure. Nocturnal antihypertensive therapy may reduce the incidence of cardiovascular disease. This is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H12238489#H12238489\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Bedtime versus morning dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar observations have been made in patients with chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H3128354#H3128354\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Possible benefit from nocturnal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of antihypertensive therapy in patients with uncomplicated combined systolic and diastolic hypertension is a blood pressure of",
"    <strong>",
"     below",
"     <span class=\"nowrap\">",
"      140/90",
"     </span>",
"     mmHg",
"    </strong>",
"    ; treatment goals are determined by the higher BP category. Similar goals have been recommended for nondiabetic patients with coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link&amp;anchor=H20#H20\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of clinical trials suggest possible benefit from a lower blood pressure goal in two settings: atherosclerotic cardiovascular disease and proteinuric chronic kidney disease. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the rapidly growing population of hypertensive individuals over age 65 with isolated systolic hypertension (eg, a diastolic blood pressure below 90 mmHg), caution is needed not to reduce the diastolic blood pressure to less 60 mmHg to attain a goal systolic pressure less than 150 mmHg, since such low diastolic pressures have been associated with an increased risk of myocardial infarction and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/53,71,72\">",
"     53,71,72",
"    </a>",
"    ]. A more detailed discussion of the treatment of elderly patients with isolated systolic hypertension is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Resistant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have hypertension that is seemingly resistant to conventional medical therapy. Resistance is usually defined as a diastolic blood pressure (BP) above 90 mmHg despite intake of three or more antihypertensive medications including a diuretic.",
"   </p>",
"   <p>",
"    One or more of the following problems may contribute to the inability to adequately lower the blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suboptimal therapy",
"     </li>",
"     <li>",
"      Extracellular volume expansion",
"     </li>",
"     <li>",
"      Poor compliance with medical or dietary therapy",
"     </li>",
"     <li>",
"      Identifiable or secondary hypertension",
"     </li>",
"     <li>",
"      Office or \"white coat\" hypertension",
"     </li>",
"     <li>",
"      Ingestion of substances that can elevate the blood pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed discussions of resistant hypertension are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=see_link\">",
"     \"Definition, risk factors, and evaluation of resistant hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35256?source=see_link\">",
"     \"Treatment of resistant hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Discontinuing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with stage 1 hypertension are well controlled, often on a single medication. After a period of years, the question arises as to whether antihypertensive therapy can be gradually diminished or even discontinued.",
"   </p>",
"   <p>",
"    After discontinuation of treatment, between 5 and 55 percent of patients remain normotensive for at least one to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/74\">",
"     74",
"    </a>",
"    ]; a larger fraction of patients do well with a decrease in the number",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dosage of medications taken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More gradual tapering of drug dosage is indicated in well-controlled patients taking multiple drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/36/32330/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18068?source=see_link\">",
"     \"Can therapy be discontinued in well-controlled hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abrupt cessation of therapy with a short-acting beta-blocker (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ) or the short-acting alpha-2-agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    can lead to a potentially fatal withdrawal syndrome. Gradual discontinuation of these agents over a period of weeks should prevent this problem. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1827?source=see_link\">",
"     \"Withdrawal syndromes with antihypertensive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=see_link\">",
"       \"Patient information: High blood pressure in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/56/40835?source=see_link\">",
"       \"Patient information: Controlling your blood pressure through lifestyle (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=see_link\">",
"       \"Patient information: Medicines for high blood pressure (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=see_link\">",
"       \"Patient information: High blood pressure emergencies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4502595\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following definitions, suggested by JNC 7 in 2003, are based upon the average of two or more properly measured readings at each of two or more clinic visits after an initial screen. These definitions apply to adults on no antihypertensive medications and who are not acutely ill. If there is a disparity in category between the systolic and diastolic pressures, the higher value determines the severity of the blood pressure (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Normal blood pressure: systolic &lt;120 mmHg and diastolic &lt;80 mmHg",
"     </li>",
"     <li>",
"      Prehypertension: systolic 120 to 139 mmHg or diastolic 80 to 89 mmHg",
"     </li>",
"     <li>",
"      Stage 1 hypertension: systolic 140 to 159 mmHg or diastolic 90 to 99 mmHg",
"     </li>",
"     <li>",
"      Stage 2 hypertension: systolic &ge;160 or diastolic &ge;100 mmHg",
"     </li>",
"     <li>",
"      Isolated systolic hypertension: blood pressure of",
"      <span class=\"nowrap\">",
"       &ge;140/&lt;90",
"      </span>",
"      mmHg",
"     </li>",
"     <li>",
"      Isolated diastolic hypertension: blood pressure",
"      <span class=\"nowrap\">",
"       &lt;140/&ge;90",
"      </span>",
"      mmHg",
"     </li>",
"     <li>",
"      Malignant hypertension: severe hypertension with retinal hemorrhages, exudates, or papilledema, with or without hypertensive encephalopathy",
"     </li>",
"     <li>",
"      Hypertensive urgency: severe hypertension (diastolic pressure &gt;120 mmHg) in asymptomatic patients",
"     </li>",
"     <li>",
"      Definitions based upon ambulatory or home BP measurements are somewhat different",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with hypertension have primary, or essential, hypertension. The pathogenesis of primary hypertension is poorly understood. Numerous risk factors for developing hypertension have been identified, including black race, a history of hypertension in one or both parents, a high sodium intake, excess alcohol intake, excess weight, and physical inactivity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Essential (primary) hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identifiable or secondary hypertension, or hypertension due to an identifiable underlying condition, may result from acute or chronic renal disease, renovascular disease, endocrine disorders, or certain drugs.",
"     </li>",
"     <li>",
"      Hypertension is associated with a number of serious adverse effects, including coronary heart disease, heart failure, ischemic and hemorrhagic stroke, chronic kidney disease, and acute hypertensive emergencies such as hypertensive encephalopathy and acute aortic dissection (",
"      <a class=\"graphic graphic_table graphicRef54145 \" href=\"mobipreview.htm?15/43/16060\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The United States Preventive Services Task Force recommend screening every two years for persons with systolic and diastolic pressures below 120 mmHg and 80 mmHg, respectively, and yearly for persons with a systolic pressure of 120 to 139 mmHg or a diastolic pressure of 80 to 89 mmHg. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      White coat hypertension is present if a patient has persistently elevated blood pressure when measured in the office, but repeatedly normal blood pressure when measured at home, at work, or by ambulatory blood pressure monitoring. Ambulatory blood pressure monitoring should be considered in patients with suspected episodic hypertension, hypertension resistant to increasing medication, hypotensive symptoms while taking antihypertensive medications, and in patients with autonomic dysfunction. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'White coat hypertension and ambulatory monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications for ABPM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once hypertension has been diagnosed, an evaluation should be performed to determine the extent of target organ damage, to assess the patient&rsquo;s overall cardiovascular risk status, and to decide whether an evaluation for secondary causes of hypertension is warranted. This evaluation includes a history, physical examination, urinalysis, and measurement of the hematocrit, routine blood chemistries, serum creatinine, lipids (preferably fasting), and an electrocardiogram. In addition, testing for microalbuminuria should be considered (always in patients with diabetes), and echocardiography can be performed in patients with borderline blood pressure values to help determine whether antihypertensive therapy should be initiated. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An evaluation for identifiable or secondary causes of hypertension should be reserved for patients who have clinical clues to the presence of an underlying cause. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Testing for renovascular hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Testing for other causes of identifiable hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients diagnosed with hypertension should undergo appropriate nonpharmacologic (lifestyle) modification (",
"      <a class=\"graphic graphic_table graphicRef62129 \" href=\"mobipreview.htm?42/24/43403\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antihypertensive medications should generally be begun if the systolic pressure is persistently &ge;140 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the diastolic pressure is persistently &ge;90 mmHg in the office and at home despite attempted nonpharmacologic therapy. Starting with two drugs may be considered in patients with a baseline blood pressure above",
"      <span class=\"nowrap\">",
"       160/100",
"      </span>",
"      mmHg. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Who should be treated?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a number of conditions (eg, atrial fibrillation, heart failure, post-myocardial infarction), certain antihypertensive drugs are given to improve survival or the underlying disease and other drugs are contraindicated, independent of the blood pressure (",
"      <a class=\"graphic graphic_table graphicRef63628 \" href=\"mobipreview.htm?10/53/11101\">",
"       table 9",
"      </a>",
"      ). In the absence of a specific indication, there are three main classes of drugs that are used for initial monotherapy: thiazide diuretics, long-acting calcium channel blockers (most often a dihydropyridine), and ACE inhibitors or angiotensin II receptor blockers. It is the attained blood pressure, not the specific drug(s) used, which is the major determinant of outcome. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Initial monotherapy in uncomplicated hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of antihypertensive therapy in patients with uncomplicated combined systolic and diastolic hypertension is a blood pressure of below",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg; treatment goals are determined by the higher blood pressure category. A number of clinical trials suggest possible benefit from a lower blood pressure goal in two settings: atherosclerotic cardiovascular disease and proteinuric chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Goal blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the rapidly growing population of hypertensive individuals over age 65 with isolated systolic hypertension (eg, a diastolic blood pressure below 90 mmHg), caution is needed not to reduce the diastolic blood pressure to less 65 mmHg to attain a goal systolic pressure less than 140 mmHg, since such low diastolic pressures have been associated with an increased risk of stroke. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Goal blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/1\">",
"      Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/2\">",
"      Wright JD, Hughes JP, Ostchega Y, et al. Mean systolic and diastolic blood pressure in adults aged 18 and over in the United States, 2001-2008. Natl Health Stat Report 2011; :1.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan NM, Victor RG. Hypertension in the population at large. In: Kaplan's Clinical Hypertension, 10th ed, Wolter's Kluwer, Philadelphia 2010. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/4\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/5\">",
"      Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005; 112:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/6\">",
"      Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/7\">",
"      Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/8\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/9\">",
"      Taylor BC, Wilt TJ, Welch HG. Impact of diastolic and systolic blood pressure on mortality: implications for the definition of \"normal\". J Gen Intern Med 2011; 26:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/10\">",
"      Ahmed ME, Walker JM, Beevers DG, Beevers M. Lack of difference between malignant and accelerated hypertension. Br Med J (Clin Res Ed) 1986; 292:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/11\">",
"      Severe symptomless hypertension. Lancet 1989; 2:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/12\">",
"      O'Mailia JJ, Sander GE, Giles TD. Nifedipine-associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. Ann Intern Med 1987; 107:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/13\">",
"      Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/14\">",
"      Staessen JA, Wang J, Bianchi G, Birkenh&auml;ger WH. Essential hypertension. Lancet 2003; 361:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/15\">",
"      Wang NY, Young JH, Meoni LA, et al. Blood pressure change and risk of hypertension associated with parental hypertension: the Johns Hopkins Precursors Study. Arch Intern Med 2008; 168:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/16\">",
"      Sonne-Holm S, S&oslash;rensen TI, Jensen G, Schnohr P. Independent effects of weight change and attained body weight on prevalence of arterial hypertension in obese and non-obese men. BMJ 1989; 299:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/17\">",
"      Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009; 302:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/18\">",
"      Carnethon MR, Evans NS, Church TS, et al. Joint associations of physical activity and aerobic fitness on the development of incident hypertension: coronary artery risk development in young adults. Hypertension 2010; 56:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/19\">",
"      de Simone G, Devereux RB, Chinali M, et al. Risk factors for arterial hypertension in adults with initial optimal blood pressure: the Strong Heart Study. Hypertension 2006; 47:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/20\">",
"      Jalal DI, Smits G, Johnson RJ, Chonchol M. Increased fructose associates with elevated blood pressure. J Am Soc Nephrol 2010; 21:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/21\">",
"      Ha V, Sievenpiper JL, de Souza RJ, et al. Effect of fructose on blood pressure: a systematic review and meta-analysis of controlled feeding trials. Hypertension 2012; 59:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/22\">",
"      Forman JP, Choi H, Curhan GC. Fructose and vitamin C intake do not influence risk for developing hypertension. J Am Soc Nephrol 2009; 20:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/23\">",
"      Yan LL, Liu K, Matthews KA, et al. Psychosocial factors and risk of hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA 2003; 290:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/24\">",
"      Meng L, Chen D, Yang Y, et al. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens 2012; 30:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/25\">",
"      Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens 2011; 29:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/26\">",
"      The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/27\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/28\">",
"      Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/29\">",
"      Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/30\">",
"      Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/31\">",
"      Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/32\">",
"      Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/33\">",
"      Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/34\">",
"      Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. Stroke 1996; 27:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/35\">",
"      Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/36\">",
"      Hsu CY, McCulloch CE, Darbinian J, et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/37\">",
"      U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2007; 147:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/38\">",
"      Beevers G, Lip GY, O'Brien E. ABC of hypertension: Blood pressure measurement. Part II-conventional sphygmomanometry: technique of auscultatory blood pressure measurement. BMJ 2001; 322:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/39\">",
"      Hartley RM, Velez R, Morris RW, et al. Confirming the diagnosis of mild hypertension. Br Med J (Clin Res Ed) 1983; 286:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/40\">",
"      Watson RD, Lumb R, Young MA, et al. Variation in cuff blood pressure in untreated outpatients with mild hypertension--implications for initiating antihypertensive treatment. J Hypertens 1987; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/41\">",
"      Pickering TG, James GD, Boddie C, et al. How common is white coat hypertension? JAMA 1988; 259:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/42\">",
"      Myers MG. A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement. J Hypertens 2010; 28:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/43\">",
"      Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 2010; 24:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/44\">",
"      Lurbe E, Torro I, Alvarez V, et al. Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension 2005; 45:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/45\">",
"      Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of \"masked hypertension\" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/46\">",
"      Forman JP, Brenner BM. 'Hypertension' and 'microalbuminuria': the bell tolls for thee. Kidney Int 2006; 69:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/47\">",
"      Cuspidi C, Lonati L, Macca G, et al. Cardiovascular risk stratification in hypertensive patients: impact of echocardiography and carotid ultrasonography. J Hypertens 2001; 19:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/48\">",
"      Lewin A, Blaufox MD, Castle H, et al. Apparent prevalence of curable hypertension in the Hypertension Detection and Follow-up Program. Arch Intern Med 1985; 145:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/49\">",
"      McLaughlin K, Jardine AG, Moss JG. ABC of arterial and venous disease. Renal artery stenosis. BMJ 2000; 320:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/50\">",
"      Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/51\">",
"      Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/52\">",
"      Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/53\">",
"      Vok&oacute; Z, Bots ML, Hofman A, et al. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999; 34:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/54\">",
"      Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/55\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/56\">",
"      Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006; 47:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/57\">",
"      Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/58\">",
"      Tuck ML, Sowers J, Dornfeld L, et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/59\">",
"      Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/60\">",
"      Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/61\">",
"      Ascherio A, Rimm EB, Giovannucci EL, et al. A prospective study of nutritional factors and hypertension among US men. Circulation 1992; 86:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/62\">",
"      Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001; 38:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/63\">",
"      Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342:d671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/64\">",
"      Larsen T, Mose FH, Bech JN, et al. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens 2012; 25:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/65\">",
"      Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/66\">",
"      Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med 2006; 145:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/67\">",
"      Houston TK, Allison JJ, Sussman M, et al. Culturally appropriate storytelling to improve blood pressure: a randomized trial. Ann Intern Med 2011; 154:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/68\">",
"      Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/69\">",
"      Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/70\">",
"      Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/71\">",
"      Bangalore S, Qin J, Sloan S, et al. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010; 122:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/72\">",
"      Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/73\">",
"      de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/74\">",
"      Schmieder RE, Rockstroh JK, Messerli FH. Antihypertensive therapy. To stop or not to stop? JAMA 1991; 265:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/75\">",
"      Nelson MR, Reid CM, Krum H, et al. Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2). Am J Hypertens 2003; 16:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/76\">",
"      Freis ED, Thomas JR, Fisher SG, et al. Effects of reduction in drugs or dosage after long-term control of systemic hypertension. Am J Cardiol 1989; 63:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/36/32330/abstract/77\">",
"      Finnerty FA Jr. Stepped-down therapy versus intermittent therapy in systemic hypertension. Am J Cardiol 1990; 66:1373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3852 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32330=[""].join("\n");
var outline_f31_36_32330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4502595\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7525347\">",
"      - Definitions based upon ambulatory and home readings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malignant hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30698321\">",
"      Hypertensive urgency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ESSENTIAL (PRIMARY) HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SECONDARY OR IDENTIFIABLE HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      White coat hypertension and ambulatory monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Masked hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Indications for ABPM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Testing for renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Testing for other causes of identifiable hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Benefits of blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Drug treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - General efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Initial monotherapy in uncomplicated hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2528233\">",
"      - Possible benefit from nocturnal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Discontinuing therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4502595\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3852\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3852|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/4/7247\" title=\"figure 1\">",
"      Prev htn in men women in US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/61/20447\" title=\"figure 2A\">",
"      CHD mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/18/12591\" title=\"figure 2B\">",
"      Stroke mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25086\" title=\"figure 3\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/36/25165\" title=\"figure 4\">",
"      LVH and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/4/38990\" title=\"figure 5\">",
"      Hypertension and ESRD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/29/44509\" title=\"figure 6\">",
"      Benefit of Rx of mild HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/48/18190\" title=\"figure 7\">",
"      BP change and salt intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/34/25133\" title=\"figure 8\">",
"      Weight loss and fall in BP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3852|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/26/34219\" title=\"table 1\">",
"      Hypertension awareness and Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/43/16060\" title=\"table 2\">",
"      Hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/32/44556\" title=\"table 3\">",
"      Measurement of BP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/38/42604\" title=\"table 4\">",
"      Features of secondary HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/8/17549\" title=\"table 5\">",
"      History in hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/39/13948\" title=\"table 6\">",
"      Physical examination in HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/41/35484\" title=\"table 7\">",
"      Classification and management of blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/24/43403\" title=\"table 8\">",
"      Lifestyle modifications in HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/53/11101\" title=\"table 9\">",
"      Treatment of HTN by underlying disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18068?source=related_link\">",
"      Can therapy be discontinued in well-controlled hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/62/3046?source=related_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=related_link\">",
"      Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=related_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=related_link\">",
"      Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/2998?source=related_link\">",
"      Exercise in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=related_link\">",
"      Genetic factors in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11174?source=related_link\">",
"      Hypertensive complications in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/422?source=related_link\">",
"      Initial evaluation of the hypertensive adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36804?source=related_link\">",
"      Low-renin essential (primary) hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=related_link\">",
"      Patient adherence and the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/56/40835?source=related_link\">",
"      Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=related_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13060?source=related_link\">",
"      Potassium and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44677?source=related_link\">",
"      Prehypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3395?source=related_link\">",
"      Smoking and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35256?source=related_link\">",
"      Treatment of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29369?source=related_link\">",
"      Treatment of unilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1827?source=related_link\">",
"      Withdrawal syndromes with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_36_32331="Symptoms requiring immediate care for sickle cell disease";
var content_f31_36_32331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Illnesses requiring immediate medical care (within four hours of occurrence) for children with sickle cell disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immediate medical care should be sought for any of the following symptoms:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Temperature greater than 101.5&deg;F (38.5&deg;C)",
"         </li>",
"        </ul>",
"        <ul>",
"         <li>",
"          Significant respiratory symptoms (eg, severe cough, shortness of breath, chest pain)",
"         </li>",
"        </ul>",
"        <ul>",
"         <li>",
"          Newly palpable spleen or further enlargement of previously enlarged spleen",
"         </li>",
"        </ul>",
"        <ul>",
"         <li>",
"          Severe abdominal pain, especially right upper quadrant pain&nbsp;or with an&nbsp;increase in jaundice",
"         </li>",
"        </ul>",
"        <ul>",
"         <li>",
"          Any neurologic symptom or sign (even if transient)",
"         </li>",
"        </ul>",
"        <ul>",
"         <li>",
"          Significant increase in pallor, fatigue and/or lethargy",
"         </li>",
"        </ul>",
"        <ul>",
"         <li>",
"          Priapism episode persisting more than four hours",
"         </li>",
"        </ul>",
"        <ul>",
"         <li>",
"          Pain inadequately relieved by home medications",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Lane P, Buchanan G, Hutter J, et al. Sickle cell disease in children and adolescents: Diagnosis, guidelines for comprehensive care, and care paths and protocols for management of acute and chronic complications 2001. Available at:",
"     <a href=\"file://www.dshs.state.tx.us/newborn/sickle.shtm\" target=\"_blank\">",
"      file://www.dshs.state.tx.us/newborn/sickle.shtm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32331=[""].join("\n");
var outline_f31_36_32331=null;
var title_f31_36_32332="Physiologic parameters based on pediatric age";
var content_f31_36_32332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic parameters based on pediatric age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Heart rate, beats/min",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Respiratory rate, breaths/min",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Leukocyte count, leukocytes x 10",
"        <sup>",
"         3",
"        </sup>",
"        /mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Systolic blood pressure, mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Tachycardia",
"       </td>",
"       <td class=\"subtitle2\">",
"        Bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 days to 1 wk",
"       </td>",
"       <td class=\"centered\">",
"        &gt;180",
"       </td>",
"       <td class=\"centered\">",
"        &lt;100",
"       </td>",
"       <td class=\"centered\">",
"        &gt;50",
"       </td>",
"       <td class=\"centered\">",
"        &gt;34",
"       </td>",
"       <td class=\"centered\">",
"        &lt;65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 wk to 1 mo",
"       </td>",
"       <td class=\"centered\">",
"        &gt;180",
"       </td>",
"       <td class=\"centered\">",
"        &lt;100",
"       </td>",
"       <td class=\"centered\">",
"        &gt;40",
"       </td>",
"       <td class=\"centered\">",
"        &gt;19.5 or &lt;5",
"       </td>",
"       <td class=\"centered\">",
"        &lt;75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 mo to 1 yr",
"       </td>",
"       <td class=\"centered\">",
"        &gt;180",
"       </td>",
"       <td class=\"centered\">",
"        &lt;90",
"       </td>",
"       <td class=\"centered\">",
"        &gt;34",
"       </td>",
"       <td class=\"centered\">",
"        &gt;17.5 or &lt;5",
"       </td>",
"       <td class=\"centered\">",
"        &lt;100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-5 yrs",
"       </td>",
"       <td class=\"centered\">",
"        &gt;140",
"       </td>",
"       <td class=\"centered\">",
"        NA",
"       </td>",
"       <td class=\"centered\">",
"        &gt;22",
"       </td>",
"       <td class=\"centered\">",
"        &gt;15.5 or &lt;6",
"       </td>",
"       <td class=\"centered\">",
"        &lt;94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-12 yrs",
"       </td>",
"       <td class=\"centered\">",
"        &gt;130",
"       </td>",
"       <td class=\"centered\">",
"        NA",
"       </td>",
"       <td class=\"centered\">",
"        &gt;18",
"       </td>",
"       <td class=\"centered\">",
"        &gt;13.5 or &lt;4.5",
"       </td>",
"       <td class=\"centered\">",
"        &lt;105",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13 to &lt;18 yrs",
"       </td>",
"       <td class=\"centered\">",
"        &gt;110",
"       </td>",
"       <td class=\"centered\">",
"        NA",
"       </td>",
"       <td class=\"centered\">",
"        &gt;14",
"       </td>",
"       <td class=\"centered\">",
"        &gt;11 or &lt;4.5",
"       </td>",
"       <td class=\"centered\">",
"        &lt;117",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goldstein B, Giroir B, Randolph B, Members of the International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32332=[""].join("\n");
var outline_f31_36_32332=null;
var title_f31_36_32333="Weaver table";
var content_f31_36_32333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Head circumference data of Nellhaus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Males",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Mean (cm)",
"       </td>",
"       <td class=\"subtitle2\">",
"        1 SD",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mean (cm)",
"       </td>",
"       <td class=\"subtitle2\">",
"        1 SD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth",
"       </td>",
"       <td>",
"        34.74",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        34.02",
"       </td>",
"       <td>",
"        1.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 mo",
"       </td>",
"       <td>",
"        37.30",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"       <td>",
"        36.43",
"       </td>",
"       <td>",
"        1.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 mo",
"       </td>",
"       <td>",
"        40.62",
"       </td>",
"       <td>",
"        1.23",
"       </td>",
"       <td>",
"        39.71",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 mo",
"       </td>",
"       <td>",
"        43.76",
"       </td>",
"       <td>",
"        1.29",
"       </td>",
"       <td>",
"        42.68",
"       </td>",
"       <td>",
"        1.38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 mo",
"       </td>",
"       <td>",
"        45.75",
"       </td>",
"       <td>",
"        1.28",
"       </td>",
"       <td>",
"        44.69",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 mo",
"       </td>",
"       <td>",
"        47.00",
"       </td>",
"       <td>",
"        1.31",
"       </td>",
"       <td>",
"        45.81",
"       </td>",
"       <td>",
"        1.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18 mo",
"       </td>",
"       <td>",
"        48.31",
"       </td>",
"       <td>",
"        1.36",
"       </td>",
"       <td>",
"        47.27",
"       </td>",
"       <td>",
"        1.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 yr",
"       </td>",
"       <td>",
"        49.19",
"       </td>",
"       <td>",
"        1.39",
"       </td>",
"       <td>",
"        48.02",
"       </td>",
"       <td>",
"        1.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 yr",
"       </td>",
"       <td>",
"        50.63",
"       </td>",
"       <td>",
"        1.38",
"       </td>",
"       <td>",
"        49.25",
"       </td>",
"       <td>",
"        1.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 yr",
"       </td>",
"       <td>",
"        50.91",
"       </td>",
"       <td>",
"        1.39",
"       </td>",
"       <td>",
"        50.10",
"       </td>",
"       <td>",
"        1.37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 yr",
"       </td>",
"       <td>",
"        51.41",
"       </td>",
"       <td>",
"        1.37",
"       </td>",
"       <td>",
"        50.55",
"       </td>",
"       <td>",
"        1.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 yr",
"       </td>",
"       <td>",
"        51.40",
"       </td>",
"       <td>",
"        1.41",
"       </td>",
"       <td>",
"        50.52",
"       </td>",
"       <td>",
"        1.31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 vr",
"       </td>",
"       <td>",
"        52.24",
"       </td>",
"       <td>",
"        1.52",
"       </td>",
"       <td>",
"        51.46",
"       </td>",
"       <td>",
"        1.35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8 yr",
"       </td>",
"       <td>",
"        52.35",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        51.64",
"       </td>",
"       <td>",
"        1.44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 yr",
"       </td>",
"       <td>",
"        52.58",
"       </td>",
"       <td>",
"        1.44",
"       </td>",
"       <td>",
"        51.87",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 yr",
"       </td>",
"       <td>",
"        53.16",
"       </td>",
"       <td>",
"        1.41",
"       </td>",
"       <td>",
"        52.15",
"       </td>",
"       <td>",
"        1.50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11 yr",
"       </td>",
"       <td>",
"        53.25",
"       </td>",
"       <td>",
"        1.53",
"       </td>",
"       <td>",
"        52.64",
"       </td>",
"       <td>",
"        1.39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 vr",
"       </td>",
"       <td>",
"        53.71",
"       </td>",
"       <td>",
"        1.52",
"       </td>",
"       <td>",
"        53.01",
"       </td>",
"       <td>",
"        1.50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13 yr",
"       </td>",
"       <td>",
"        54.14",
"       </td>",
"       <td>",
"        1.57",
"       </td>",
"       <td>",
"        53.70",
"       </td>",
"       <td>",
"        1.37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14 yr",
"       </td>",
"       <td>",
"        54.59",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"       <td>",
"        54.04",
"       </td>",
"       <td>",
"        1.39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15 yr",
"       </td>",
"       <td>",
"        54.95",
"       </td>",
"       <td>",
"        1.51",
"       </td>",
"       <td>",
"        54.39",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16 yr",
"       </td>",
"       <td>",
"        55.37",
"       </td>",
"       <td>",
"        1.11",
"       </td>",
"       <td>",
"        54.64",
"       </td>",
"       <td>",
"        1.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17 yr",
"       </td>",
"       <td>",
"        55.77",
"       </td>",
"       <td>",
"        1.32",
"       </td>",
"       <td>",
"        54.78",
"       </td>",
"       <td>",
"        1.35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18 yrs and older",
"       </td>",
"       <td>",
"        55.95",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"       <td>",
"        54.94",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This material may not be reproduced, stored in a retrieval system, or transmitted in any form or by any means without the prior written permission of the publisher. Reproduced with permission from: Weaver DD, Christian JC, J Pediatr 1980; 96:990. Copyright &copy; 1980 Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32333=[""].join("\n");
var outline_f31_36_32333=null;
var title_f31_36_32334="Algorithm HIT";
var content_f31_36_32334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Approach to the patient with suspected heparin induced thrombocytopenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 329px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HIT should be suspected when there is thrombocytopenia, thrombosis with thrombocytopenia, a platelet count that has fallen by &ge;50 percent, or necrotic skin lesions at injection sites in a patient started on heparin within the preceding 5 to 10 days. The diagnosis is initially made on clinical grounds, because assays with the highest sensitivity and specificity may not be readily available and have a slow turnaround time.",
"    <div class=\"footnotes\">",
"     HIT: heparin-induced thrombocytopenia; HIPA: heparin-induced platelet aggregation assay; Heparin-PF4 Ab: heparin-platelet factor 4 antibody.",
"     <br/>",
"     * Observation should be chosen only if patient is at high risk for bleeding. Otherwise treatment (anticoagulation with the agents listed) is preferred until the platelet count has returned to normal, at which time treatment with a vitamin K antagonist can be given (see text for details).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32334=[""].join("\n");
var outline_f31_36_32334=null;
var title_f31_36_32335="Lung nodules in nocardiosis";
var content_f31_36_32335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary nodules in nocardiosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple bilateral pulmonary nodules are seen on a chest radiograph in this patient with systemic lupus erythematosus on chronic corticosteroid therapy. The patient had cutaneous lesions as the initial manifestation of this disseminated infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley W Chapman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_36_32335=[""].join("\n");
var outline_f31_36_32335=null;
